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Abstract
High levels of MDM2are associated with poor prognosis in renal cell carcinoma
(RCC) patients. This effect does not seem to be a result of MDM2-mediated
degradation of p53, as those cancers which display high levels of MDM2 usually
also express high levels of p53. Over-expression of p53 and MDM2is associated
with decreased disease free survival in patients with RCC. Since most patients who
die as a consequence of RCC do so as a result of metastatic spread, we therefore
hypothesised that MDM2 maycontribute to cellular processesthat lead to increased
metastatic potential of RCC tumours. In addition, we further hypothesised that
MDM2might accomplish this through promoting somecellular mechanisms, such as
motility and invasiveness, which could contribute to metastasis in RCC patients.
In this study we have foundthatincreased expression levels of the MDM2protein do
drive increased motility and invasiveness of RCC cells. Additionally, we have
demonstrated that MDM2expression is driven by p53 in RCCcell lines expressing
wt p53. Moreover, using FASAY and DNA sequence analysis, we have shownthat
upregulated p53 in clear cell RCC tumour samples is generally wild type which
suggests that the high levels of MDM2in these tumoursarelikely to be promoted by
p53. Therefore, our results suggest that p53 indirectly induces increased motility of
RCCcells, at least in part, through contributing to over-expression of MDM2.
Nearly all of the known functions of MDM2are mediated through protein-protein
interactions. Therefore, one aim additional of this project was the identification of
new proteins that are targeted by MDM2in RCCcells in order to try to explain how
MDM2maycontribute to poor outcome in RCC patients. We performed a yeast two
hybrid screen using MDM2asthebait to identify such MDM2interacting proteins.
In order to maximise the likelihood of identification of interactions that may indeed
provide clues for elucidation of an aggressive phenotype of RCC, an RCC cell line
over-expressing p53 and MDM2(therefore reflecting the situation observed in
tumours) was used as a source of mRNAforlibrary construction. Several (novel)
putative MDM?-interacting proteins were detected and one of these: NME2 was
selected for further analysis for two major reasons. Firstly, NME2 was independently
identified as an MDM2interacting protein in our laboratory using a proteomic
approach and secondly NME2 waspreviously shown to function as a suppressor of
motility and metastasis. Using isogenic cell lines expressing either relatively high or
low levels of MDM2,it was shownthat the motility suppressive function of NME2
was compromised in RCC cells expressing high levels of MDM2.Ourresults suggest
that MDM2 may act to promote motility by opposing or directly blocking NME2-
dependent motility suppression.
Several additional novel functions of NME2 in the regulation of MDM2 and p53
were also revealed. NME2 was shownto negatively regulate the activity of p53 in
the MDM2-independent manner. Moreover, NME2 was demonstrated to reduce the
steady-state level of MDM2 and alter the MDM2-dependent post-translational
modifications of p53, thus showing that NME2 may play a pleiotropic role in
regulation of the p53 and MDM2network.
Altogether the present study identifies a novel function of MDM2 in promoting
motility and invasiveness of RCC cells and provides other clues to understanding of
the processes which potentially contribute to an aggressive phenotype ofrenalcell
carcinoma.
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1 Introduction
1.1 Overview
Over-expression of p53 and MDM?correlates with poor outcome in RCC(renalcell
carcinoma) patients (Haitel et al., 2000). However, over-expression of p53 alone is
not associated with such a highly aggressive phenotype of RCC tumours. It was
therefore speculated that MDM2, rather than p53, is responsible for tumour
progression resulting in the poorest outcome. However, the exact mechanism by
which MDM2functions to accomplish this in RCC remains unknown. Based on the
clinical evidence presented by Haitel et al., two major research strategies were
applied in order to elucidate the mechanism/s by which renal tumours over-
expressing MDM2 become more aggressive. The first strategy aimed at the
identification of novel MDM2interacting proteins in RCC followed by analysis of
phenotypic characteristics of RCC cells in which levels of these molecules were
manipulated. The second strategy involved an investigation of the p53-MDM2
relationship in RCC and in RCC cells. Since over-expression of MDM2 has been
reported to correlate with up-regulation of p53 (Haitel et al., 2000, Mochet al.,
1997), it could be suggested that over-expression of MDM2 may somehow depend
on upregulation of p53.
In order to familiarize the reader with the principles of this project, several issues
related to RCC, suchas association of over-expression of p53 and MDM2 with poor
patient outcomewill be presented in following sections. This will be followed by a
review ofthe literature describing the functions and regulation of p53 and MDM2,
with particular emphasis on the relationship between p53 and MDM2asthisis likely
to be malfunctioning in RCC.
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1.2 Renal cell carcinoma — introduction
1.2.1. Incidence and environmentalrisk factors of RCC
Kidney cancer is diagnosed in around 6,700 people each year in the UK, which is
approximately 2% (3% in men and < 2% in women)of all diagnosed cancer cases.
Every year, over 3,600 patients die as a result of this disease and this numberis
increasing. There are roughly 200,000 new cases of kidney cancer diagnosed
worldwide each year, with various frequencies within different populations ranging
from around 15 per 100,000 population in Czech Republic to around | per 100,000
population in India (Cancer Research UKstatistics, 2002). Similarly to the UK, the
incidence of kidney cancer worldwideis rising (Patel et al., 2006). Although several
factors, such as: cigarette smoking, obesity, hypertension, hormonal therapy as well
as heavy metal ions, asbestos and petroleum products, are knownto increase risk of
developing kidney cancer, it is not clear which (if any) of these contribute and to
whatextentto the increasing incidence (Motzeretal., 1996).
1.2.2 Classification of renal tumours
RCC(renal cell carcinoma) is the most frequent type of kidney cancer and accounts
for 85% of all cases (Cancer Research UKstatistics, 2002). The most common types
of RCCsas well as their most characteristic features are summarised in the Table 1.1.
As the Table shows, there are a plethora of RCC sub-types. However, only the clear
cell, papillary or chromophobe types occur in 5% (or more) of cases. Out of these
three, the clear cell subtype is not only the most common,but appears also to be the
most aggressive one (Lopez-Beltran et al., 2009). Additionally, sarcomatoid RCC (a
histological variation characterised by the presence of tumour cells with morphology
Introduction
 
resembling various
(Delahunt, 1999).
types of mesenchymalcells) may arise from any type of RCC
RCC subtype Incidence Prognosis Genetic Cell/tissue characteristics
Clearcell
Multilocular cystic
Papillary
Chromophobe
Collecting ductsofBellini
Medulary
Xp11 translocation
After neuroblastoma
Mucinous tubular and spindle
cell
Unclassified
Renalcell neoplasms in
end-stage renal disease
Thyroid follicular
carcinoma-like tumor of
kidney
Tubulocystic carcinoma
75%
10%
5%
Rare
Rare
4% to 6%
Rare
Rare
Rare
Aggressiveness according to
grade, stage and
sarcomatoid change
No progression or metastases
Aggressiveness according to
grade, stage and
sarcomatoid change
10% mortality
Ageressive, 2/3 of patients die
within 2 years
Mean survival of 15 weeks
after diagnosis
Indolent
Related to grade and stage
Rare metastases,
High mortality
Unknown
Unknown
Unknown
-3p, +5q22, —6q, —8p, —9p,
—14q
VHL gene mutation
+3q, +7, +8, +12, +16, +17,
+20, -Y
-1,-2,-6,-10,-17, -21,
hypodiploidy
-1q, -6p, -8p, -13q, -21q,
—3p (rare)
Rare loss of chromosome 22
t\;1}(p11.2;q21),
t(X;17}(p11.2;q25), Other
Allelic imbalance at 20q13
-1,-4, -6, -8,-13, -14 +7,
+11, +16, +17
Unknown
Variable gains chromosomes
7 and 17
Gains 7936, 8q24, 12, 16,
17p11-q11, 17424, 19q,
20q13, 21q22.3, and Xp.
Losses of 1p36, 3, 9q21-3
Variable trisomy of
chromosome 17
Clear cytoplasm; cells with
eosinophilic cytoplasm
occasionally)
Clear cytoplasm, small dark
nuclei
Type 1 (basophilic) or type 2
(eosinophilic)
Pale or eosinophilic granular
cytoplasm
Eosinophilic cytoplasm
Eosinophilic cytoplasm
Clear and eosinophilic cells
Eosinophilic cells with
oncocytoid features
Tubules, extracellular mucin
and spindle cells
Variable, sarcomatoid
Clear cells or eosinophilic
cells
Clear cells
Eosinophilic cells
 
Table 1.1 Types of RCC. The Table summarises selected features characteristic to
the most commontypes of RCC. Reproduced from (Lopez-Beltranet al., 2009).
There are several criteria according to which RCC tumours can beclassified. The
TNMstaging system is based on the TNM (Tumour Node Metastasis) classification
and is presented in Table 1.2. TNM staging is the most commonly used system for
classification of tumours and prediction of the outcome in patients (Ficarra et al.,
2007). Based on this system, the five-year disease specific survival for stagesI, II, III
and IV has beenreported as 89.6%, 82.7%, 57.7%, and 18.3%, respectively (Elmore
et al., 2003). In addition to the TNM classification, other systems are used to classify
RCC tumours and evaluate prognosis.
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T — primary tumour
TO there is no evidence of a primary tumourin the kidney
T1_ the tumouris no more than 7cm across and is completely inside the kidney
T2 the tumouris more than 7cm across, butis still completely inside the kidney
T3 the cancer has spread through the kidney capsule, to a major vein, the adrenal
glandor othertissues immediately surrounding the kidney
T4 the cancer has spread further than the tissues immediately surrounding the
kidney
N — regional lymph node
NO No cancer in any lymph nodes
NI Cancer spread to one nearby lymph nodeonly
N2 Cancer spread to more than one nearby lymph node
M — distant metastasis
MO Absenceof distant metastasis
M1 | Presence of distant metastasis
Staging criteria
StageI Tl NO MO
Stage II T2 NO MO
Stage III T1,T2 Nl MO
T3 NO, N1 MO
Stage IV T4 NO, N1 MO
Any T N2 MO
Any T Any N Ml     
Table 1.2 Tumour stages based on the TNM (Tumour Node Metastasis)
classification (Cancer Research UK,classification of RCC tumours).
For example, the Fuhrman nuclear grading system, which is based on evaluation of
the shape of nuclei (see Table 1.3), is widely used for classification of renal tumours.
This classification scheme has been shownto be a valuable tool for prediction of
metastatic disease (Fuhrmanet al., 1982).
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Grade Characteristics of nuclei
I Small, regular, homogeneous, nucleoli invisible
z Larger than in grade 1, variable size, occasionally irregular, nucleoli
visible at high microscopic power
3 Large, irregular, with large nucleoli,
4 Large, very irregular and multi-lobed, with very distinct nucleoli and
chromatin clumps
Table 1.3 Fuhrman’s nuclear grading system (Fuhrmanetal., 1982).
1.2.3 Management of RCC
RCC is well known for its unpredictability as the aggressiveness of similarly staged
or graded tumours using conventional histological techniques, even within the same
type of RCC(e.g. clear cell RCC), appears to be highly variable (Rouviere etal.,
2006, Beisland 2004). Additionally, RCC tends to be asymptomatic; however, if the
symptomsare present (typical symptoms associated with RCC include hematuria,
flank mass and flank pain), they often occurlate in the disease course and are rarely
present together. In many cases the disease remains undetected until it reaches an
advanced stage. In fact, 40-60% of diagnoses are made incidentally in developed
countries, when patients undergo abdominal CT scanning for other complaints
(Jayson, 1998). Additionally, various kinds of treatment, such as radiotherapy and
conventional chemotherapy, are ineffective, especially in case of metastatic disease
(Motzeret al., 1996, NICE Technology Appraisal Guidance 178). Therefore, the lack
of reliable disease course prediction markers, late detection and resistance to
conventional therapies, contribute to the RCC mortality rate and make the disease
very difficult to manage. Surgery is a basic treatment for RCC which often cures
early stage kidney cancers (20-30% relapse rate in stages 1 and 2) (NICE Guidance
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on Cancer Services). Nephron sparing (for small tumours) and radical nephrectomy
(for more advanced disease) is a standard treatment not only for patients with
localised disease; prolonged survival has also been observed in patients with
metastatic disease undergoing radical nephrectomy (Motzeret al., 1996). Surgery is
also performed as a part of palliative treatment and is usually offered to all patients
whoare fit enough to survive the operation (NICE Guidance on CancerServices).
Postoperative treatment for advanced RCC hashistorically included IL-2 and IFN-a,
but the overall response rate to these drugs is only around 15% (Reeves and Liu,
2009). IL-2-based therapy has been shownto result in complete remissions, though,
at a low rate and accompanied by severe side effects restricting the number of
patients eligible for this treatment (Reeves and Liu, 2009). Additionally, these
therapies have also been shown to be ineffective for treatment of the early-stage
tumours (NICE Guidance on CancerServices).
Several new therapeutic strategies to treat advanced RCC are based on a new
generation of drugs. These include Sunitinib, an inhibitor of RTK (receptor tyrosine
kinase); Bevacizumab, a monoclonal antibody which inhibits VEGF (vascular
endothelial growth factor); or Sorafenib, which inhibits Raf kinase function.
Additionally, drugs targeting the mTOR pathway were recently introduced to the
clinic. mTOR inhibitors, such as Temsirolimus in 2007, significantly increase the
overall survival, progression free survival and the objective response rate
(measurable response such as changes in tumour size) in patients with metastatic
disease (Rini, 2008). The drugs mentioned above have recently been approved NICE
(NICE Technology Appraisal Guidance 178). However, clinical effectiveness as a
first-line treatment for patients with advanced and/or metastatic RCC (Bevacizumab,
Sorafenib and Temsirolimus) and second-line treatment for patients with advanced
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and/or metastatic RCC (Sorafenib and Sunitinib) is limited (Motzer et al., 2006,
Yang et al., 2003, FDA, NICE Technology Appraisal Guidance 178). The overall
response to these drugs measured according to RECIST (Response Evaluation
Criteria in Solid Tumours, see Table 1.4) (Padhani and Ollivier, 2001), reaches up to
40% and extend the progression free survival to up to 11 months compared with
IFN-a alone (median time to progression to 5.4 months). However, among the
targeted therapies for advanced RCC (specific inhibitors or monoclonal antibodies)
presented above, only Temsirolimus and Sunitinib appeared to increase overall
survival compared to IFN-a. Application of targeted therapies often results in high
initial response; however, the tumours eventually adapt and becomeresistant (Patel
et al., 2006). Therefore, there is a need for methods allowing early detection and
therapies which will cure RCC rather than just delay disease progression. Various
approaches, such as proteomic methods, are used to search for disease-specific
targets for new therapies as well as disease prognostic markers. Two-dimensionalgel
electrophoresis combined with mass spectrometry has been applied to the
identification of proteins aberrantly expressed in tumours; whereas antibody arrays
have been used to identify tumour associated antigens (Craven and Banks, 2008).
Identified proteins could be used as biomarkers or, potentially serve as therapeutic
targets. Alternatively, high throughput methods such as DNA microarray analysis,
not only allow measurement of expression of single genes, but also analysis of
patterns of gene expression specific for the type and character of a disease.
Recognition of these specific patterns could have prognostic value and could help to
define which signalling pathwaysare altered in aggressive RCC. This would help to
predict the disease course, and aid in planning of therapeutic strategies (Tan etal.,
2004).
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Type of response RECISTchangein sum longest diameter
Complete response (CR) Disappearance of all target lesions; confirmed at 4
weeks
Partial response (PR) At least 30% reduction in the sum of the longest
diameter of target lesions, taking as reference the
baseline study; confirmed at 4 weeks
 Stable disease (SD) Neither PR nor PD criteria are met, taking as reference
the smallest sum of the longest diameter recorded since
treatment started
Progressive disease (PD) At least 20% increase in the sum of the longest
diameter of target lesions, taking as reference the
smallest sum longest diameter recorded since treatment  started or appearance of new lesions  
Table 1.4 Definition of response according to RECIST criteria. Adapted from
(Padhani and Ollivier, 2001).
1.3 Molecularbiology of renal cell carcinoma
As mentioned previously, RCC is a heterogeneous disease due to a large number of
tumourtypes (see Table 1.1). This diversity is also manifested at a molecular level;
there are a number of factors knownto be associated with the pathogenesis of RCC.
As Table 1 shows, the number of chromosomal aberrations typically observed in
RCCislarge and distinct for particular subtypes; certain abnormalities appear to be
tumour-type specific, such as 3p loss in the clear cell subtype. One explanation for
loss of the chromosome3pin clear cell carcinomasis presence of the VHL gene (see
the next section) on the short arm of the chromosome3 (3p25.3) and therefore loss of
heterozygosity of this tumour suppressor. The role of VHL in tumour suppression is
described in the following section.
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1.3.1. The VHL tumoursuppressorin renal cell carcinoma
VHL (von Hippel-Lindau protein) is thought to be a critically important tumour
suppressor in the kidney. Germline mutations in the VHL gene cause von Hippel-
Lindau disease, often leading to development of tumours of which RCC,
haemangioblastoma and pheochromocytomaare the most typical (Duanet al., 1995).
The importance of the role of VHL in tumoursuppression is further supported by the
observation that this protein is mutated in over 50% of sporadic clear cell RCC cases,
whereas hypermethylation of the VHZ promoter has been found in a further 10-20%
of cases (Gnarra et al., 1994). Mutations of VHL have also been observed in
haemangioblastomas and pheochromocytomas (Kim and Kaelin, 2004). The tumour
suppressor function of VHL is dependentonits ability to regulate the level of HIF-1
(hypoxia-inducible factor-1), a transcription factor that up-regulates a range of genes
involved in angiogenesis; thus preventing a key step in tumour formation. VHL is
composed of two functional domains, aand B (Iliopoulos et al., 1998). The
a domain is responsible for organisation of the E3 ubiquitin ligase complex called
ECV (Elongin-Cullin-VHL), which is essential for mediating the tumour suppressor
function of VHL. This domain binds to elongin C, which interacts with CUL2
(cullin-2). CUL2, in turn, recruits RBX1 (RING-box 1), a protein mediating
interaction with the E2 ubiquitin-conjugating enzyme. The B domain of VHLis
responsible for recognition and interaction with a target protein to which ubiquitin is
transferred by the ECV complex (Ohh, 2006). The ECV acts as an ubiquitin ligase
for HIFla. The process of ubiquitylation of HIFla is regulated by presence of
oxygen in the cellular environment. In the presence of oxygen, the proline residues
402 and 564 of HIFla are hydroxylated, allowing for ECV-dependent ubiquitylation
of HIFla. This leads to its subsequent degradation by 26S proteasomes. Under
7
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hypoxic conditions, however, the proline residues are not hydroxylated; as a result
HIF la is not degraded and mayfunction to promote angiogenesis (Ohh, 2006).
Mutations of VAL result in loss of tumour suppressor function and, as previously
mentioned, are common in RCC,particularly the clear cell sub-type (Duanet al.,
1995). Inherited mutation in one allele of the VHL gene andloss of the secondallele
during life is typical of patients with von Hippel-Lindau disease. Loss of the second
allele of a TSG is a phenomenonfrequently observed in cancers, called LOH(loss of
heterozygosity) (Singh et al., 2001). Penetrance of von Hippel-Lindau disease
reaches 97% by the age of 60 with a median survival of 49 years (Maheretal.,
1990). Although RCC is not the most common type of tumour in VHL patients
(occurring in only 28%), it is the major cause of death in VHL disease.Interestingly,
the most common VHLdisease-associated tumours are heamangioblastomas which
occur in around 65% ofcases.
It has been suggested that the VHL mutation in humanrenalepithelial cells may be
an early event in the evolution of RCC (Linehanetal., 1995). As shown in Figure
1.1, loss of VHL heterozygosity seemsto trigger cytological changes. Depending on
the type of VHL mutation (as several types of VHL mutations are known,see table
1.5), the renal epithelial cells begin to form cysts and over-express HIF 1a.
Further genetic changes result in the formation of carcinomas (Kim and Kaelin,
2004). It appears, that VHL inactivation may bea critical event in the development
of RCC,as restitution of wt VHL in RCC cell lines decreases their tumourigenic
potential (Iliopoulos et al., 1995). However, it is important to establish what other
genetic alterations may be responsible for carcinoma formation and for promoting
the further progression into aggressive metastatic disease. Interestingly, analysis of
mice with heterozygous VAl knockout (VhI"') that were generated in order to mimic
10
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the von Hippel-Lindau disease, revealed some rather unexpected results. The VAl-
animals did not develop tumours characteristic of VHL disease, suggesting a human-
specific mechanism of RCC development associated with loss of VHL function
(Kleymenovaetal., 2004).
Recent studies have revealed new functions of VHL. The VHL protein was found to
interact with p53 and protect it from MDM2 mediated inhibition and degradation
(Roe et al., 2006). Moreover, VHL also seems to have the ability to increase
transactivation activity of p53 by promoting acetylation of the carboxy-terminal
residues K373 and K382 of p53 through stabilisation of a complex containing p300,
pCAFand p53. This suggests that VHL has more anti-tumouractivities than just
degradation of HIF1 a,and its loss may have a wide spectrum of effects contributing
to tumourigenesis.
 VHL mutation HIF binding Risk for RCC
Type I None High
Type HA Moderate Low
Type UB Weak High
Type IIC Strong None     
Table 1.5 Types of VHL gene mutations. The table shows types of mutations of the
VHL gene(left column) together with their effect on HIF binding (right column) and
risk for RCC associated with this mutation. Type I mutations — deletions, nonsense
and missense mutations resulting in a total loss of function. Type IA, B and C —
usually point mutations which modulate the ability of VHL to bind to HIFla.
Adapted from (Iliopoulos, 2006).
11
Introduction
 
Renal Cyst Renal Cell Carcinoma
Renal Tubular
—Cell 7&)
ue osJy
*Oncogene activation
or tumor suppressor
gene loss   xHit 1 * Hit 3
Figure 1.1 The 3-hit model of RCC progression. Thefirst two mutational hits lead
to loss of VHL function, the third involves inactivation of another TSG oractivation
of an oncogene. The second andthird hits are associated with changes in behaviour
of affected cells. Reproduced from (Kim and Kaelin, 2004).
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1.3.2 Biomarkers implicated in RCC
Since loss of VHL activity/function occurs in the majority of RCC cases (Gnarra et
al., 1994), analysis of VHL as a prognostic marker does not have any significant
value. Therefore considerable effort has been focused on the identification of novel,
more informative biomarkers.
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), markers of
systemic inflammation have also been shownto have a relevant prognostic value in
RCC.Elevated ESR has been shownto be associated with decreased disease specific
survival (p=0.0086) and shorter progression free survival (p=0.002) in a study of 110
Japanese patients with a localised CCRCC (Senguptaet al., 2006).
CRP hasalso been shownto be an adverse indicator of survival (Lambet al., 2006).
The study has shownthat patients with the levels of CRP (n=45) higher than 6mg/I
had substantially reduced survival following the surgery than patients with the levels
of CRP (n=26) lower than 6mg/I (p=0.0046).
Carbonic anhydrase IX (CAIX), an enzyme producedbyrenal cells, has been shown
to be a predictor of poor outcome (Buiet al., 2003); reduced expression of CAIX is
associated with markedly decreased survival of RCC patients.
Although several biomarkers such as these mentioned above have been identified,
none of them are appropriate for diagnosis and evaluation of treatment outcome in
RCC reviewed by Tunuguntla et al. Since, as mentioned before, the standard
classification schemes often fail to predict the disease course, there is a need for
more definitive biomarkers that will allow more accurate prognostication and thus
enable stratification of patient treatment.
13
Introduction
 
1.4 p53 and MDM2in RCC
As mentioned above, renal cell carcinoma is an unpredictable disease, as neither the
tumourstage nor the nuclear grading system and currently available biomarkers have
proven to be sufficiently informative in many RCCcases. Therefore, there is a need
for new waysof predicting tumour behaviour.
It has been observed that p53 is often over-expressed in high-grade renal tumours
and there are a numberof studies that investigated expression and mutational status
of p53 in RCC. Several factors, however, constitute a source of variation between
these studies. For instance, differences in tumour grade, stage and proportions of sub-
types investigated in particular studies make it difficult to compare the data from
different papers (Munro et al., 2005). Additionally, several different fixation
techniques and antibodies were used for detection of p53 in these studies (reviewed
in Noonetal., 2010 and shownin Table 1.6). It has been suggested, that the DO-7
antibody is more sensitive that the antibody 240 (Olumiet al., 2001). This might lead
to generation ofdifferent results in studies using different reagents. However, despite
these differences, it has been demonstrated, that p53 is over-expressed in about a
quarter of all RCC tumours, including also other histological subtypes, such as
papillary renal cell carcinoma (reviewed in Noonet al., 2010). It has been calculated
that p53 is more often over-expressed in metastatic (51.8%) vs non-metastatic (22%)
cancers (Zigeuneret al., 2004). Moreover, the majority of studies (presented in the
Table 1.6) reported correlation of p53 over-expression with decreased survival
(reviewed in Noonet al., 2010 and presented in Table 1.6).
Mutational analyses have also been performed in several studies; SSCP (single-
strand conformation polymorphism) was usually used for screening of samples to
detect mutated alleles which was followed by direct sequencing. The frequencies of
14
Introduction
 
mutations appear to vary from 0 to 79% andasis the case in other cancers, missense
mutations are the most common (Gadet al., 2007, Oda et al., 1995). However, the
majority of studies reported the mutation frequency below 10% which is
substantially lower than in other carcinomas such ascolorectal, breast or lung. This
might be due to heterogeneity of tumour sub-types among different studies and
difficulty in detection of mutations in tumoursrich in stromal components (reviewed
in Noonet al., 2010). Since the screening process using SSCPis very laborious, the
majority of studies investigated the sequence of exons 5-8 or 4-8 which encode the
DNA-binding domain of p53. Although the majority of mutations (around 85%)
occur within the DNA-binding domain of p53, significant number (around 15%) of
mutations are found also outside of exons 5-8 (Hollstein et al., 1991). Therefore, the
real number of mutations may be higher than reported in the studies reviewed by
Noonetal.
As MDM2over-expression is well knownto be associated with poor outcome in
various types of tumours such as: breast, gastric, non- Hodgkin’s and Hodgkin’s
lymphomaand leukeamias (Yanget al., 2006, Ohmiyaet al., 2006, Maestro etal.,
1995, Chilosi et al., 1994, Lu et al., 2002, Bueso-Ramoset al., 1993), expression of
MDM2wasalso investigated in RCC. A study of 97 CCRCC specimensby Haitelet
al. showed that over-expression of MDM2,present in 19% of cases, was associated
with high tumour grade (p=0.0149) and decreased disease free survival (p=0.001 13)
(Haitel et al., 2000). The study also evaluated expression of p53, which appeared to
be upregulated in 36% of tumour samples and correlated with decreased disease-free
survival (p=0.00291). Interestingly, the study also showed that a subset of tumours
co-over-expressed MDM2and p53 and this was associated with the worst prognosis
(disease free survival shorter than 1 year). In cases where only p53 was over-
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expressed, this figure increased to around two years, whereas patients with normal
p53 and MDM2levels were likely to live more than five years without progression
of the disease (p=0.00179).
 
 
 
      
Study No. of Specimens Antibody p53 Comments
(% CCRCC), prognostic
value
Klatte 2009 170(100), AS NP Yes Decreased DFS
Perret 2008 50(0) all PRCC DO-7 Yes Decreased OS
In type II PRCC
Phuoc 2007 119(100), AS DO-7 Yes Decreased DSS
Kankuri 2000 117(80), AS DO-7 Yes Decreased OSin
patients with
metastases
Kramer 2005 117(89), AS DO-7 Yes
Langner 2005 95(75), stage pT 1 DO-7 No
Cho 2005 92(100), AS NP Not evaluated Decreased DSS
Shvarts 2005 193(85), AS DO-7 Yes 20% cutoff predicted
recurrance
Uzunlar 2005 57(77,1), AS NP Yes Decreased DSS
Zigeuner 2004 184(70.7), AS, DO-7 Yes Decreased MFSin
56(94.8)" CCRCC
Kim 2004 318, AS DO-7 Yes Decreased DSS
Uchida 2002 112(78), AS DO-7 Yes
Olumi2001 43(100), AS DO-7/ No Decreased DSS
PAB240/
both
Ljungberg 2002 99(74), AS DO-7 Yes Decreased survival in
non-CCRCC
Girgin 2001 50(62) DO-1 Yes Decreased DSD
Haitel 2000 97(100) DO-1 Yes Decreased DSS
Rioux 2000 66(?), AS DO-7 Yes Decreased DSS
Sejima 1999 53(?), AS RSP53 No
Vasavada 1998 38(71), Tl and T2 DO-7 No
Silik 1997 39(100), AS DO-7 No
Papadopoulos 1997 90(?), Tl and T2 DO-1 No
Zhang 1997 70(?), AS Ab-6 Not evaluated
Gelb 1997 52(100), Tl and T2_ DO-7 No
Shiina 1997 72(?), AS DO-7 Yes Decreased OS
Moch 1997 50(100), T3 DO-7 Yes Decreased OS
Hofmockel 1996 31(?), T1-T3 DO-7 No
Chemeris 1995 82(40) DO-1 Notevaluated
Lipponen 1994 123(?) CM1 Yes Increased RFS
Kamel 1994 56(?), AS CM1 No
Bot 1994 100(74), T1-T3 DO-7 No
Uhlmen 1994 175(?), AS NP Yes Decreased DSS  
Table 1.6 Prognostic significance of p53 over-expression in RCC tumours. The
Table shows the results of studies investigating the prognostic significance of p53
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over-expression in RCC tumours. Note that the Table also shows the percentage of
clear cell RCC (CCRCC) analysed vs other RCC sub-types and antibodies used for
IHC analysis. DFS, disease-free survival; OS, overall survival; DSS, disease-specific
survival; MFS, metastasis-free survival; DSD, disease-specific death; RFS,
recurrence-free survival; AS, all stages; NP, information not provided; “in addition to
184 renal cancers, 56 surgically removed metastatic tissues were analyzed. Adapted
from Noonet al.
This suggests that over-expression of MDM2(in addition to p53) may further
increase the aggressiveness of RCC. Haitel et al. also show that p53/MDM2 double
positivity is associated with presence of distant metastasis (p=0.003) and high
tumour grade (grade 3 and 4, p=0.007) which suggest that p53 and MDM2 mayserve
as indicators of tumourprogression. Intriguingly, high levels of MDM2appeared to
be highly associated with the presence of high levels of p53 (p=0.00004). This
observation was also made by another study (p=0.0006) (Moch et al., 1997) and
suggested that over-expression of p53 and MDM2 may be somehow connected
(Noonet al., 2010).
Very little is known aboutthe biological properties of RCC cells over-expressing p53
and MDM2. Aswill be discussed later (see Chapter 4), co-over-expression of p53
and MDM2is not a commonsituation; it is not observed in normalcells or in most
types of cancercells (other than RCC). Therefore, several questions arise:
- Is MDM2 involved in tumour progression-promoting mechanisms in RCC? As
cancer patients usually die due to expansion of distant metastasis (not due to
growth of the primary tumour), it is not unreasonable to suggest that MDM2
17
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could play a role in promoting this process, however, the exact (putative) role of
MDM2in RCCprogression remains unknown.
How does MDM2 become upregulated in RCC and what role does p53 play in
this upregulation? As high levels of MDM2 in RCCare highly associated with
the presence of high levels of p53, it could be suggested that expression of
MDM2 may somehow depend on p53. However, as it is unclear if p53 is usually
wt or mutated in high grade RCC tumours,it is not obvious if over-expression of
MDM2is dueto increased p53-dependenttranscription (reviewed in Noonet al.,
2010). An alternative possible explanation is provided by studies of SNP at
position 309 (SNP309) in the MDM2 promoter (a more detailed description of
SNP309 will be presented in the next section). It has been observed, that the G/G
variant of the 309 polymorphicsite in the promoter of MDM2is responsible for
increased transcription of MDM2 in RCC tumours (Hirata et al., 2007).
However, this study did not provide any information regarding survival and
therefore whether the SNP309 haplotype is associated with altered survival is a
question that has to be addressed in future studies.
Why is p53 elevated in some RCCs and why is MDM2 not degrading p53 in
these tumours? Several mechanismsleading to stabilisation of p53 exist. These
are usually parts of stress responsive pathways (reviewed in Vousden, 2000). As
there are a number ofstresses present in cancer cells (such as DNA damage,
oncogene activation), the possibility exists that these mechanismsalso lead to
p53 stabilisation in RCC. Alternatively, the ability of MDM2 to degrade p53
could be inhibited by some yet unknown mechanisms (reviewed in Noonet al.,
2010).
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As the key questions asked above remain generally unanswered, there is a need for a
better understanding of the molecular biology of RCC tumours over-expressing p53
and MDM2. Analysis of the p53-MDM2pathway, whichis clearly altered in these
tumours, may provide clues leading to the identification of components of the
pathwaythat are not functioning normally in RCC.
The following part of the Introduction will therefore focus on the p53-MDM2
network, in order to highlight basic aspects of the normal regulation and
pathophysiological deregulation of this complicated system.
1.5 The p53 tumour suppressor
1.5.1 Introduction to the p53 network
p53 wasfirst identified as a transformation-related protein in (SV40) transformed
cells in vitro, as well as in cancer cells. Since its expression wasinitially detected
only in tumourtissues, it was concluded that p53 might be an oncogene (DeLeo et
al., 1979, Lane and Crawford, 1979, Linzer and Levine, 1979). This view was further
supported by the observation that high levels of p53 correlated with increased cell
proliferation in culture (Dippold et al., 1981). However, it has subsequently been
demonstrated that the p53 studied in cancer cells, was in fact mutated and that the
wild type form of p53 did not have any transforming potential in vitro (Hindset al.,
1989). Moreover, it has been shownthat mutated p53 could inhibit the activity of wt
p53 molecules which made the cells more susceptible to transformation with H-RAS;
thus providing an explanation for the confusing data obtained previously by DeLeo
et al., Laneet al. and others (Eliyahu et al., 1988). Finally, nearly ten years after p53
was first identified, its role as a tumour suppressor gene was firmly established
(Bakeret al., 1989). Intensive research carried out in subsequentyears, has led to a
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massive increase in our understanding of various aspects of p53 including how it
functions and how it is regulated. A brief summary ofthis will be presented below.
p53 is a 393 AA (aminoacid) protein which, has 5 major functional domains (Toledo
et al., 2007, Levine, 1997): an amino-terminal transactivation domain (AA 1-42), a
proline rich regulatory domain (AA 58-98), a DNA binding domain (DBD AA 102-
292), a tetramerization domain (AA 324-355) and a carboxy-terminal regulatory
domain (AA 367-393).
p53 functions as a sequence-specific DNA binding protein that can regulate the
transcription of target genes (reviewed in Levine, 1997). It has the ability to
specifically recognize and bind DNA through a DBD (DNA-binding domain), which
coordinates Zn** ions (Choet al., 1994). This region recognises and binds to DNA
consensus sequences composed of two copies (half-sites) of a palindromic DNA
sequence: 5’-PuPuPuC(A/T)(T/A)GPyPyPy 3° (where Pu = purine and Py =
pyrimidine) separated with a spacer up to 13bp long (el-Deiryet al., 1992). A more
recent, genome-wide search for p53 binding sites, comprehensively describes the p53
binding sequences present in the human genome (Weiet al., 2006). This study
quantitatively evaluated representation of each nucleotide in each position of the p53
binding site (see Figure 1.2). In addition, several novel p53 binding sites were
identified in promoters of genes which have not previously been reported to be
regulated by p53. Interestingly, the study also showsthat there are usually no spaces
between the half-sites (occasionally, there was one base present in between the half
sites). This contradicts the results published by el-Deiry et al. and accords with
observations made by (Jordan et al., 2008) who have demonstrated that introduction
of the spacer between twohalf-sites and increasing its length results in dramatically
reduced p53-dependenttransactivation both in yeast- and human- reporter systems.
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Therefore it appears that the presence/length of the spacer between the half-sites
determinestheir functionality (responsiveness to p53). However, the authors showed
that half-sites separated by very long spacers or even single half-sites, retain the
ability to (weakly) bind p53 and induce transactivation at low levels.
Interestingly, non-canonical p53 binding sites composed of % and % of the consensus
site (1 or 1% of the half-site) have also been found to constitute a target for p53
(Jordan et al., 2008); a single % consensus site appeared to induce substantially
stronger p53-dependenttransactivation than a single half-site.
Since the non-canonical p53-consensus sequences are very abundantin the genome,
this finding reveals a possibility, that complexity of the network regulated by p53
may be muchhigher than previously expected.
The p53 protein acts as a tetramer and all 4 subunits need to be wt for maximal
transcriptional activity (reviewed in Joerger and Fersht, 2008). The presence of even
one mutant p53 subunit may compromise the activity of the tetramer and this
phenomenoniscalled the dominant negative effect. Mutations of the DBD (exons 5-
8) are the most detrimental to the activity of p53 (Hollstein et al., 1991).
p53 is the most frequently mutated tumour suppressor in human cancers and most
p53 mutationsare situated within its DBD at a frequency exceeding 50% ofall cases
(reviewed in Vousden and Lu, 2002). Inactivating mutations of the p53 protein
results in inability to induce cellular programs such as apoptosis, cell cycle arrest,
senescence or DNArepair (see the next section) in response to various types of
stresses such as DNA damageor oncogeneactivation.
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Figure 1.2 The p53 consensus sequence. The Figure illustrates two half-sites of the
p53 consensus sequence. The letter size in a particular position indicates the
frequency with whichit is found in p53 binding sites. Reproduced from (Weietal.,
2006).
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1.5.2 Functions of p53
p53 functions primarily as a major regulator of apoptosis (reviewed in Vousden and
Lu, 2002). When unopposed, p53 acts very potently as it has been shownin mice in
which the major negative regulator of p53, Mdm2, has been deleted (Jonesetal.,
1995); these mice died early in embryonic development due to massive apoptosis.
The effect of embryonic lethality appears to be fully rescued by deletion of p53
(Montes de Oca Luna etal., 1995). This observation further supports a critically
important role of MDM2in regulation of p53 and provides additional evidence that
p53 plays a majorrole in induction of apoptosis.
The strong pro-apoptotic activity of p53 makes it a key player in the anti-tumour
defence. This has clearly been shown in mice with homozygousdeletion ofp53 gene
in which it has been demonstrated that as much as 74% of 6 month old p53”animals
develop tumoursandall animals died by the age of 10 monthsas a result of tumour
formation (Donehower et al., 1992, Harvey et al., 1993). For comparison, no wt
control animals developed any tumours by the age of 10 months in these studies.
Hence, the absence of p53 activity, inevitably results in tumour formation. These
results support data obtained from studies of human cancers. Although p53" tumours
are infrequent, the importance of the intact p53 function is well illustrated by the
fact, that mutations of this TSG are present in at least 50% of tumours and the p53
pathwayis likely to be compromisedin all cancers (Vousden and Lu, 2002).
p53 is a stress-responsive protein; in response to various typesof cellular stress such
as: DNA damage, oncogeneactivation, the abnormalpresence or absence of survival
signals, depletion of ribonucleotides, hypoxia or telomere degradation, p53 becomes
stabilised and activated. p53 is then able to mediate a range ofcellular processes such
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as: apoptosis, senescence, cell cycle arrest or DNA repair (Vousden, 2000). A
summaryofeach of the most important functions of p53 is given below.
1.5.2.1 The role of p53 in apoptosis
Apoptosis is a process of programmed cell death that leads to organized
disintegration of the cell in such a way that remaining cellular components may be
easily and safely utilised by surrounding cells or phagocytes. Apoptosis is an
essential part of development, and is crucial in suppression of tumourigenesis
(reviewed in Elmore, 2007). There are several apoptotic pathwaysinthecell:
- extrinsic (mitochondrial) pathway
- perforin/granzyme pathway
- intrinsic pathway
Despite completely different means of activation, the three apoptotic pathways
mentioned above rely on the same mechanism to execute the apoptotic process
(Elmore, 2007). Figure 1.3 shows howall apoptotic pathways lead to the activation
of caspases (cysteine-aspartic acid proteases) which are responsible for
fragmentation of cellular componentsresulting in cell death.
It has been demonstrated, that p53 has the ability to induce apoptosis by several
different mechanisms:
- Activation of the mitochondrial apoptotic pathway by inducing expression of
proteins such as BAX, PUMA and NOXA.Theseproteins increase permeability
of the mitochondrial membraneandlead to translocation of cytochromec to the
cytoplasm. This event triggers activation of APAFI (apoptotic protease
activating factor 1) resulting in initiation of the caspase (cysteine aspartate
protease) cascaderesulting in apoptosis (Cecconi and Gruss, 2001). p53 has also
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been shownto induce the mitochondrial apoptotic pathwayin a different manner
(Chipuk et al., 2005). The process appears to be regulated by two opposing
proteins, BCL-xL and PUMA.Sequestered in the cytoplasm by BCL-xL, p53 is
inactive. In response to genotoxic stress, nuclear p53 induces PUMA which
releases p53 from the complex with BCL-xL. Liberated cytoplasmic p53 may
then be translocated to the nucleus or interact with BAX and other members of
the BCL-2 family in the cytoplasm to trigger the mitochondrial apoptotic
pathwayresulting in activation of caspases.
Enhancing expression of death receptors such as: FAS, PIDD and KILLER/DR5
which could sensitize the cells to death signals and lead to activation of caspases
through the extrinsic apoptotic pathway (Vousden and Lu, 2002).
Activation of FAS and subsequently caspases in a transactivation-independent
manner. In a poorly understood way, activated p53 promotestrafficking of FAS
to the cell membrane. Once translocated to the outer side of the plasma
membrane, FAS can bind FasL (Fas ligand). Ligand binding triggers activation
of FAS molecules and transmission of the death signal to the cytoplasm (Bennett
et al., 1998).
Transcriptional activation of the PTEN gene by p53 (Stambolic et al., 2001).
PTEN functions as a PIP3 phosphatase and, even though dephosphorylation of
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Figure 1.3 Different mechanisms of apoptosis induction. The diagram shows three
different apoptosis initiating pathways which lead to activation of apoptosis-related
processes, such as DNA degradation, that result in death of the cell. Reproduced
from (Elmore, 2007).
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PIP3 does not directly lead to apoptosis, it switches off the most important survival
pathway which is mediated by AKT, and therefore renders the cell more sensitive to
apoptosis induced by the other “conventional” actions of p53 (Mayo and Donner,
2002).
1.5.2.2. The role of p53 in cell cycle arrest
p53 can also inducecell cycle arrest (which is a reversible pause in the cell cycle) in
responseto cellular stress such as DNA damage. Cell cycle arrest serves to pause the
cell during the cell cycle and may allow the cell to repair damage before DNA
undergoesreplication or before the cell begins to divide. p53 is capable of arresting
cells in two main stages during the cell cycle: G1 and G2 (Levine, 1997).
The main transcriptional target of p53 that induces G1 and G2cell cycle arrest is
p21 VAFCIPKCDENIA) 591 mediates its effect by inhibiting cyclinD1-CDK4, cyclinE-
CDk2, cyclinA-CDK2 and cyclinA-CDC2 complexeshalting cell cycle progression.
On the other hand, however, it has been suggested that p21 functions as an adaptor
protein promoting association of cyclinD1-CDK4 complex and thus p21 displays a
complex interaction with the cell cycle regulatory machinery. It has been shownthat,
although high levels of p21 inhibit the kinase activity of cyclinD-CDK4 complexes,
low levels promote cyclinD-CDK4 complex formation and do not inhibit the kinase
activity (LaBaer et al., 1997). Additionally, p21 interacts with PCNA, a DNA
polymerase processivity factor, which acts as a cofactor for DNA polymerase delta
(Agarwal et al., 1995, Waga et al., 1994). Binding of p21 to PCNAresults in a
decrease in DNA polymerase processivity thus inhibiting DNA replication and, as a
result, also cell division (Levine, 1997). Interestingly this also appears to promote
increased DNArepair activity and this is discussed below.
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1.5.2.3 The role of p53 in DNA repair
p53 has been shown to induce DNA repair through several different mechanisms,
including:
- Binding of the p53-induced p21 to PCNA (mentioned in the previous section)
whichresults in inhibition of DNAreplication, however, it does not inhibit DNA
repair mediated by this enzyme. This way the cell gains not only a chance to
repair damaged DNA,butalso an enhanced capacity to do so while the cell cycle
is arrested due to action of p21.
- Activation of the GADD45 (growth arrest and DNA damage 45) gene. It has been
shown that GADD45proteins are essential in maintaining genomicstability, since
cells from Gadd45a-null mice developed chromosomal rearrangements,
amplification of genes and centrosomes and were aneuploid (Hollanderetal.,
1999). GADD45 takes part in the global genomic repair (GGR), a subtype of
nucleotide excision repair (NER) responsible for bases repair, damaged due to
action of various environmental factors, such as UV (Friedberg, 2001).
1.5.2.4 The role of p53 in senescence
Senescence is a process in which cells irreversibly enter into a non-proliferating
state, their metabolism is decreased and they acquire characteristic morphological
changes (Hemann and Narita, 2007). Senescent cells appear large and flat in culture,
and therefore this phenotype has been described as resembling a “fried egg”
(Wynford-Thomas, 1996). Senescence maybe inducedin different ways:
- Oncogenic signalling (such as Ras) has been shownto induce senescence through
activation of p53 and p16**,
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- DNA damageandothertypes of stress have been shownto trigger p53-dependent
cellular senescence,
- Telomere erosion results in replicative senescence, which is also dependent on
p53 (Wynford-Thomas, 1996, Mooi and Peeper, 2006).
The ability of the cell to induce senescence in response to stimuli mentioned above
has several advantages for the host organism, reviewed in (Campisi, 2005, Lowe et
al., 2004).
- Protection from cancer, when cells carrying an active oncogene are forced to exit
the proliferation cycle,
- Cells with damaged DNA donotreplicate which prevents further deterioration of
this state (further accumulation of mutations),
- Cells that have reached their replicative limit may still function in the body
without posing threat of carcinogenesis.
The description of senescence, presented here, is a simplified one, as it is not
essential to discuss it further from the perspective of this project. However, it is
worth mentioning thatit is still unclear what mechanisms determine which response
path is followed for example undergoing senescence instead of, for instance,
apoptosis in response to oncogene activation. Senescence appears to be a multi-
purpose and multi-factorial process conserved from yeast and worms to humans
(Isobe, 2003). As these primitive organisms do not develop cancer, it seemslikely
that senescenceis not only a protection from tumourigenesis, but it remains unclear
whatthe other roles of senescence might be.
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1.5.3 Regulation of the p53-MDM2 network
Extreme outcomes of either lack of p53 activity (resulting in tumourigenesis) or
unrestrained activity (resulting in death), described in Section 1.5.2 suggests, that
p53 must be very tightly regulated in order to provide protection from cancer and
allow cell growth and proliferation and sustainable development of the whole
organism. Indeed, the process of p53 regulation is complex and precise; any
deregulation of this sensitive system may result in unwanted apoptosis or in cancer,
(reviewed in Levine, 1997). For instance, a few-fold increase in MDM2levels
caused by SNP T309G wasshownto decrease the activity of p53 (Bondet al., 2005)
and enhances tumour formation in humans (Bondet al., 2004), also see Section
1.5.3.2.1). On the other hand, it has been demonstrated that animals which express
markedly decreased levels of Mdm2 (the mice lack one allele and retain the second,
hypomorphic Mdm2 allele - Mdm?“"°") are smaller, radiosensitive and display
increased apoptotic rate in several different tissues due to increased activity of p53
(Mendrysaet al., 2003).
p53 is very unstable in unstressed cells and its low level is maintained due to the
activity of MDM2. However, in response to various types of stress, p53 becomes
stabilized and/or activated. Stabilization and activation of p53 is a very complex,
multifactorial process and may be achieved by different means, depending on the
type of stimuli andthe cellular context (Toledo and Wahl, 2006).
DNA damage signals are key inducers of p53. They are transduced to p53 by
members of PI3K family which modify both p53 and MDM2.Phosphorylation of
p53 results in stabilization and subsequent activation and may be mediated by ATM
(Ataxia - telangiectasia mutated), ATM-activated CHK2 in response to IR (ionizing
radiation) and ATR (ATM-related polypeptide) in response to UV mediated DNA
30
Introduction
 
damage. Another kinase, DNA-PK (DNA-dependent protein kinase) is capable of
detecting DNAbreaks and phosphorylation of p53 (Lakin and Jackson, 1999).
Hypoxiais another type ofstress resulting in activation of p53. Prolonged, low levels
of oxygen (which often occur in the tumour environment) lead to phosphorylation,
stabilisation and accumulation of p53 mediated by ATM and ATR kinases
(Hammond et al., 2007). Under hypoxic conditions, p53 is capable of inducing
apoptosis (Hammondetal., 2003). To accomplishthis, p53 activity has to overcome
HIF-1 mediated survival promoting signals which include VEGF (vascular
endothelial growth factor) induction and signalling downstream from its receptor
(VEGFR) (Schmid et al., 2004). It has been shown that p53 decreases HIF-1a (an
unstable subunit of the HIF-1 transcription factor) stability by enhancing MDM2-
mediated ubiquitylation of HIF-la, thereby having an indirect effect on VEGF-
mediated vascularisation (Raviet al., 2000).
Perturbations that occur during DNAreplication, such as nucleotide depletion can
also lead to induction of p53 (Halazonetiset al., 2008). Interestingly, it has recently
been shown that oncogenic activation (activation of p53 in response to activation of
oncogenes such as RAS or MYCoccurring via E2F-ARF pathwaywill be described
in Section 1.5.3.5) can also result in the same type of cellular response as occurs
following nucleotide depletion. Both nucleotide depletion and the activation of
certain oncogenes maylead to the division of the cell with incompletely replicated
DNA,since either the cell does not have enough substrate to replicate the whole
DNA,orthecell cycle progression is too strongly stimulated by an active oncogene.
As a result, double-strand breaks (DSB) form which are subsequently detected by
CHK2 and ATM, ultimately leading to phosphorylation and activation of p53
(Halazonetis et al., 2008).
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Heat-shock is another type of stress that can induce p53 activation, and has been
relatively poorly studied. Results from one study, for example, have suggested that it
might induce p53 through ATM kinase (Miyakodaet al., 2002), but another study
has demonstrated that ATM is not essential for p53 stabilization in response to heat-
shock and that the mechanism of p53 activation involves interaction of p53 with the
HSP90 chaperone (Wang and Chen, 2003). Other members of the HSP family,
HSP70 and HSP27, have also been shownto regulate p53 in response to heat-shock
(Hindset al., 1987, Gao et al., 2000). Interestingly, the expression of both HSP70
and HSP27seemsto be regulated by p53 suggesting the existence of a feedback loop
between p53 and HSPproteins (Gaoet al., 2000, Agoffet al., 1993).
Oxidative stress has also been shown to modulate functions of p53. The p53 protein
undergoespost-translational modifications such as phosphorylation by p38 (Bragado
et al., 2007), ERK (Persons et al., 2000) or ATM (Kurz and Lees-Miller, 2004) in
response to elevated ROS,resulting in activation of p53. Interestingly, the thiol (-SH)
groups of p53 which are present in the DNA binding site, have been shown to
constitute direct targets of ROS (Hainaut and Mann, 2001) and appeared to modulate
the DNA binding ability of p53 and this also contributes to the direct regulation of
p53 by oxidative stress (reviewedin Liu et al., 2008).
1.5.3.1 Post-translational modifications of p53
The p53 protein undergoes various post-translational modifications that may affect
its stability and function (reviewed in Prives, 1998). Figure 1.4 illustrates most of the
known post-translational modifications of p53 occurring in response to stress.
Several residues of p53 have been shown to be modified upon stress by
phosphorylation, acetylation, ubiquitylation, SUMOylation or NEDDylation.
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Figure 1.4 Modifications of p53. The Diagram shows most of the known
modifications of p53 within its transactivation domain (TAD), DNA binding domain
(DBD), nuclear localization sequence (L), tetramerization domain (TD) and the
carboxy-terminal regulatory domain (CTD). The letter “E” denotes the nuclear
export signal sequence. Each phosphorylationsite constitutes a target for at least one
kinase, which is indicated above. Modifications of lysines of the carboxy-terminal
domain are showsat the bottom of Figure and are presented as: Ac (acetylation), Ub
(ubiquitylation), N (NEDDylation) and S (SUMOylation) (Toledo and Wahl, 2006,
Bode and Dong, 2004).
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Several lines of evidence (mostly in vitro studies) suggest that post-translational
modifications (excluding ubiquitylation which plays a critical role in p53 turnover
and will be described in the following section) play important roles in regulation of
the activity and stability. For instance, phosphorylation of S15 has been shownto
result in stabilisation of p53 resulting in apoptosis, reviewed in (Bode and Dong,
2004). Interestingly, however, S18A mutant of p53 expressed in mice (S18 of murine
p53 is an equivalent of S15 in human p53) appeared to have normalstability and
ability to induce cell cycle arrest and only partially defective apoptotic response to
DNA damage (Sluss et al., 2004). This appears to be true also for other types
modifications studied in vivo these modifications, reviewed in (Toledo and Wahl,
2006). Therefore, unlike the major regulators of p53 such as MDM2, MDMXand
ARF (described below), post-translational modifications have been suggested to play
a role in fine-tuning the activity of p53.
1.5.3.2, MDM72as a majornegative regulator of p53
Mdm2 (murine double minute 2) wasidentified as one of three genes foundin extra-
chromosomalnuclear bodies called “double minutes” of a spontaneously transformed
murine cell line — 3T3-DM (Cahilly-Snyder et al., 1987). Since only Mdm2
manifested oncogenic activity by inducing tumourigenicity of transfected cells
(Fakharzadeh et al., 1991), it became a target of extensive investigation. It has
subsequently been discovered that MDM2functions as a majornegative regulator of
p53. The following sub-sections will summarise the current knowledge regarding
how MDM2executesits p53-suppressive functions.
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1.5.3.2.1 Clinical evidence for the MDM2-dependentinhibition of p53
MDM2wasfirst identified as a p53-binding protein in co-precipitation experiments
(Momandetal., 1992). This study also showed, for the first time, that MDM2 was
capable of reducing the transcriptional activity of p53. Subsequently, several
different studies have shown that amplification of the MDM2 gene(leading to over-
expression of the MDM2protein) was present in a subset of soft tissue sarcomas
sustaining wt p53.
Failure to detect p53 mutations in an MDM)2-over-expressing group of tumours
suggests that over-expression of MDM2itself may be sufficient to compromise the
p53 pathway (Leachet al., 1993, Oliner et al., 1993, Cordon-Cardo et al., 1994).
Several lines of evidence suggest that over-expression of MDM2 mayresult in
tumourigenesis due to inhibition of p53-mediated tumour suppression. Increased
expression of MDM2,similarly to soft tissue sarcomas, has been observed in various
other types of cancers, carrying wt p53, such as: gastric, kidney, non- Hodgkin’s and
Hodgkin’s lymphoma and leukeamias (Ohmiya et al., 2006, Haitel et al., 2000,
Maestro et al., 1995, Chilosi et al., 1994, Lu et al., 2002, Bueso-Ramoset al., 1993).
Additionally, the contribution of increased levels of MDM2 to tumour development
has been demonstrated in Li-Fraumeni patients carrying a SNP309 (309T>G
polymorphism) in the MDM2 gene where thymidine in the position 309 of MDM2
geneis substituted by guanosine. The T>G nucleotide substitution has been shown to
result in increased expression of MDM2asit creates an enhanced SPI transcription
factor binding site in the promoter of the gene (Bondet al., 2004). Li-Fraumeni
patients who carried SNP309 displayed muchearlier onset of tumours, with a mean
of 29.7 years of age compared with 45.5 years in the group ofpatients who had T in
position 309 (Ruijs et al., 2007). Since it is unlikely that the frequency of
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mutation/loss of the second allele was higher in the SNP309 group of patients (even
if the cells growing in the tumour eventually lose the second p53 allele), it is
suggested that elevated levels of MDM2 inhibit the ability of p53 to suppress
tumourigenesis more efficiently, which results in significantly earlier onset of
tumours.
1.5.3.2.2 How does MDM2antagonize p53?
There are three major ways in which MDM2can inhibit p53: by promoting p53
degradation through ubiquitin-mediated proteolysis, promoting p53 nuclear export by
mono-ubiquitylation and by inhibiting p53 transcriptional activity through direct
binding, reviewed in (Freedmanet al., 1999). These antagonistic activities of MDM2
towards p53 are described in more detail below.
MDM2functions as a homodimeror a heterodimer with its homolog, MDMX (Stad
et al., 2001) and section 1.5.3.4. MDM2 has been found to possess E3 ubiquitin
ligase activity within its RING-finger domain that catalyses covalent attachment of
ubiquitin (Ub) molecules with the result that the ubiquitylated p53 substrate can be
targeted for proteasomal degradation. This p53 degradation may occurin the nucleus
or in the cytoplasm (Josephet al., 2003). p53 has been shownto be one of the major
targets for the E3 ligase activity of MDM2 and therefore MDM2 functions as a
negative regulator of stability of the p53 protein (Hondaetal., 1997) and Section
1.4.4. The ability of Mdm2 to promote degradation of p53 appears to be essential for
mouse development, as mice that express only the Mdm2-RING-finger mutant,
lacking the E3 ubiquitin ligase activity (Mdm2-C462A knockin mice), die before day
E7.5 of embryonic development and this phenotype can be rescued by deletion of
p53 (Itahanaet al., 2007).
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MDM2 can mediate both mono- and poly-ubiquitylation of p53. Whilst poly-
ubiquitylation usually results in degradation of the target protein, mono-
ubiquitylation does not lead to degradation, but can modulate the activity of proteins
(Maguire et al., 2008) or their ability to interact with other proteins (Brooksetal.,
2004). Mono-ubiquitylation of p53 by MDMz2has been shown to promote nuclear
export of p53 which prevents p53 from playingits role as a transcription factor(Li et
al., 2003). More interestingly, it has recently been demonstrated that mono-
ubiquitylation of p53 uncovers the NES andalso facilitates the carboxy-terminal
SUMOylation of p53 resulting in decreased MDM2-pS53interaction and enhanced
nuclear export of p53 (Carter et al., 2007). The mechanisms that mediate the process
of p53 translocation to the cytoplasm remain unknown.It is also unclear what might
be the function of the cytoplasmic p53. It has been speculated that cytoplasmic p53
might be involved in some transactivation-independent activities such as FAS
activation (Sigal and Rotter, 2000), translocation to the mitochondria and alternative
p53 pathways leading to the induction of apoptosis (Zhao et al., 2005, Miharaetal.,
2003) or even more enigmatically the process of binding to ribosomes (Fontoura et
al., 1997). Another possibility is that mono-ubiquitylation may serve as a means of
creating the energy-saving reservoir of a transcriptionally inactive p53(it is inactive
because it is localized in the cytoplasm), that can be quickly reactivated by
transporting it back into the nucleusif stress signals appear (Brookset al., 2004).
Anotherinhibitory effect of MDM2 on p53 is mediated by direct interaction between
the two proteins. MDM2 has been shown to bind strongly to the transactivation
domain of p53 and to form a complex with p53 in cells resulting in potent inhibition
of transcriptional activity of p53 (Oliner et al., 1993, Momandetal., 1992). It has
been demonstrated that this interaction is independent of the RING finger of MDM2
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as the RING finger mutant of MDM2 appeared to be as potent an inhibitor of
transcriptional activity of p53 as wt MDM2protein in p53 reporter assays and has
also been shownto havestimulatory effect on cell cycle progression (Argentini etal.,
2000). However, as mentioned previously, mice expressing only the Mdm2-RING-
finger mutant (instead of the wt protein) die during early embryonic development
and this lethal phenotype can be rescued by concomitant deletion of p53. This result
suggests that binding and repression of p53 transcriptional activity in the absence of
E3 ubiquitin ligase activity of Mdm2 is not sufficient to inhibit the proapoptotic
activity of p53 in developing embryos(Itahanaet al., 2007).
A numberofcellular factors have been shown to modulate the efficiency of MDM2-
mediated ubiquitylation of p53 and binding of MDM2to p53. Post-translational
modifications of p53 and MDM2, as well as interactions with other proteins
(described later in this section), allow multi-step control of the p53-MDM2network,
whichiscritical for maintenance ofcellular homeostasis.
Similarly to p53, also MDM2 undergoes post-translational modifications which
modulate its ability to ubiquitylate target proteins. Apart from ubiquitylating p53,
MDM2also has the ability to ubiquitylate itself in vitro, thus regulating its own
turnover (Fang et al., 2000). The E3 ligase activity of MDM2is encoded by the
RING finger domain and it has been demonstrated that the RING finger mutants of
MDM2were more stabile, most likely due to the absence of auto-ubiquitylation
(Hondaet al., 1997, Fang et al., 2000). Interestingly, although the ability of MDM2
to auto-ubiquitylate ex vivo is well documented and appears to play a majorrole in
regulation of MDM2protein levels, in vivo studies have revealed that the E3
ubiquitin ligase activity of Mdm2is not essential for Mdm2 degradation. A RING-
finger mutant of Mdm2 expressed in early passage MEFs derived from Mdm2-
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C462A knock-in animals, appeared to display a steady state level and turnover
indistinguishable (half-life around 20 min.) from that of the endogenously expressed
wt protein. Moreover, the half-life of Mdm2 appeared to decrease equally in MEFs
expressing wt and RING-finger mutant Mdm2 after exposure to IR (Itahanaet al.,
2007 437). It has therefore been proposed that auto-ubiquitylation is not required for
Mdm2degradation under physiological conditions, suggesting the existence of some,
yet unidentified factors regulating ubiquitylation and level of the Mdm2protein.
As stated earlier MDM2 has also been shown to be phosphorylated by several
kinases such as DNA-PK (Mayoet al., 1997), ATM (Maya et al., 2001) or ATR
(Shinozakiet al., 2003) which appeared to impair the ability of MDM2 to promote
p53 turnover. However, MDM2hasalso been shownto be phosphorylated by AKT,
which was shown to promote stabilization and nuclear localisation of MDM2and,
subsequently, enhanced inhibition of p53 (Mayo and Donner, 2001, Ogawaraet al.,
2002, Zhouetal., 2001).
It has also been demonstrated that MDM2 undergoes acetylation which has been
shown to be mediated by CBP and to a lesser extent also p300 histone acetyl
transferases (Wanget al., 2004). Acetylation of MDM2appeared to occur withinits
RING-finger domain and was shownto inhibit the MDM2-dependent degradation of
p53. On the other hand, other types of post-translational modifications such as
SUMOylation (Buschmannetal., 2000) or NEDDylation (Watsonet al.) have been
shownto stabilise MDM2and promote the MDM2-dependentinhibition of MDM2.
However, these types of modifications of MDM2 andtheir functional consequences
are still not comprehensively described; therefore they will not be discussedfurther.
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1.5.3.3 The p53-MDM2auto-regulatory feedback loop
There are several ways in which the levels and activity of both p53 and MDM2 can
be regulated, as described in previous sections. However, the discovery of the p53-
responsive element in the MDM2 promoter shed new light on their regulation. It has
been demonstrated that p53 can regulate its own degradation by enhancing the
expression of MDM2, thus creating a negative feedback loop between these two
molecules (Wuetal., 1993).
In the absenceofstress stimuli or in the presence of growth/proliferation signals, p53
levels are maintained low due to MDM2-dependent degradation. The stress
responses disturb the auto-regulatory feedback loop by induction of the post-
translational modifications of p53 and MDM2. Most of these prevent the protein-
protein interaction and protect p53 from the MDM2-mediated degradation
(Freedmanetal., 1999).
The ability of MDM2 to negatively regulate p53 makes it a potent oncogene. As
described earlier, MDM2 promotes degradation, cytoplasmic shuttling and inhibition
of p53-dependent transactivation, reviewed in (Vogelstein et al., 2000). Several
different mechanisms govern the MDM2-p53interplay, with profound effects on the
functions of both proteins. Several types of post-translational modifications
(mentioned in the present section) in response to different internal and external
stimuli (existence or absence of growth signals, DNA damage, hypoxia, oncogene
activation etc.) modulate the activity of this sensitive and multifactorial system and
allow the cell to grow andproliferate, but also maintain control over the cell cycle
and genetic stability. The following sections will focus on other components of the
p53-MDM2networkplaying importantroles in its regulation.
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1.5.3.4 The role of MDMX in regulation of p53 and MDM2
Mdmx(also known as Mdm4)protein wasinitially discovered in a screen of a mouse
expression library with radioactively labelled p53 used as a bait protein (Shvarts et
al., 1996). Subsequently, the human homologue (HDMX), exhibiting 90% amino
acid identity with its murine counterpart, has been identified and described (Shvarts
et al., 1997). The amino acid sequence of MDMXwasalso found to be similar to the
sequence of MDM2, hence the name. The highest degree of homology, present
within the p53 binding domain, suggests an important functional role for this region
(Shvarts et al., 1997). A high degree of homology has also been found between the
RING domains of MDM2 and MDMxXthrough which the proteins can
heterodimerize, reviewed in (Marineet al., 2006), however, it has been shownthat
MDMxXdoes not possess E3 ubiquitin ligase activity, reviewed in (Marine and
Jochemsen, 2005). Extensive studies have revealed that, although MDMX does not
directly promote p53 degradation,it reducesthe activity of p53 through bindingtoits
transactivation domain (Shvarts etal., 1996, Jackson and Berberich, 2000, Little and
Jochemsen, 2001). In addition, MDMX has also been proposed to regulate p53
activity through inhibition of p53 acetylation by p300/CBP (both in presence and
absence of MDM2) (Danoviet al., 2004, Sabbatini and McCormick, 2002). The
ability to regulate acetylation of p53 has been shown to be dependent on the p53-
binding domain of MDMXwhichsuggests that binding of MDMXtop53is essential
for inhibition of the p300/CBP-mediated acetylation of p53 (Danoviet al., 2004).
This provides therefore an obvious explanation for the apparently greater ability of
MDM<xXto act as an inhibitor of p53 transcriptional activity.
In contrast with the well established role of MDMXasa suppressorof p53 activity,it
remains unclear, what is the involvement of MDMxXin regulation of the levels of
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p53 and MDM2.Several studies have revealed a potential significance of MDMX
expression levels and the relative levels between the level of MDMX and MDM2in
regulation of p53. High levels of MDMX appear to compete with MDM2 and
MDM2-MDMxdimers for binding and degradation of p53; as a result, p53 becomes
upregulated (Sharp et al., 1999, Stad et al., 2000, Stad et al., 2001). On the other
hand, depletion of MDMX hasbeen observed to result in increased levels of p53
(Linares et al., 2003) as heterodimerization of MDM2 and MDMxXhas been shown
to be vital for stabilization of MDM2 which enhances degradation of p53 (Guetal.,
2002). It is therefore likely that the ratio between the MDMX and MDM2expression
levels is critical for precise regulation of the levels of both p53 and MDM2.
Analysis of MEFs from either Mdm2 or Mdmx knockout mice, conditionally
expressing of p53 (a non-conditional knockout of Mdm2 or Mdmxis lethal) revealed
that, unlike the loss of Mdm2, loss of Mdmx does not seem to significantly alter the
levels of p53, as deletion of both Mdm2 and Mdmx resulted in expression of similar
p53 levels as in the Mdm2" MEFs (Francoz et al., 2006). Analysis of the
transcriptional activity of p53 in this system has revealed that restoration of p53 in
the Mdmx" MEFsincreasedactivity of p53 only slightly (compared to the Mdmx*"*
background) which contrasted with deletion of Mdm2 which resulted in a very
dramatic increase of p53 activity (compared to the Mdm2*" background). This
phenomenon has been explained by the activation of p53-MDM2 feedback loop in
the absence of negative regulation of p53 by Mdmx.Asa result, increased levels of
Mdm2would partially compensate for the absence of Mdmxleading to a decrease of
the activity of p53. Further clues supporting the idea that Mdm2 and Mdmxplay
different roles in the regulation of p53, came from in vitro studies performed on
Mdm2/Mdmx-null MEFs expressing a temperature sensitive mutant of p53 (the wt
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activity of the temperature sensitive mutant of p53-A135V is switched on by
increasing the temperature to 39°C in the absence of either Mdm2 or Mdmx).It has
been demonstrated that deletion of Mdmx results in increased, p53-mediated
expression of cell cycle arrest genes such as p21, as well as Mdm2. In contrast,
deletion of Mdm2 has been shownto increase expression of apoptosis-mediating
genes, such as Bax and Noxa (Barbozaet al., 2008) strongly suggesting that Mdm2
and Mdmxregulate the transcriptional repertoire of p53 in different ways and may
provide distinct modes of inactivation of p53 function.
It has been proven that Mdmxis essential for embryonic development; depending on
the type of mouse model, deletion of both Mdmx alleles led to early embryonic
lethality around day E10.5 (Migliorini et al., 2002, Finch et al., 2002). This
phenotype could be rescued by concomitant knockout of p53 (Parant et al., 2001)
thus proving the importance of Mdmxin regulation of p53 activity.
In contrast, investigation of the tissue-specific p53-suppressive functions of Mdmx
revealed a striking difference in regulation of p53 by Mdm2 and Mdmx.
Homozygous deletion of Mdmx in individual tissues did not result in embryonic
lethality. It has been demonstrated that conditional deletion of Mdmx, in smooth
muscle cells of the gastrointestinal tract, had no apparent effect in this tissue
(Boesten et al., 2006). Similar results have been obtained when the Mdmx gene has
been conditionally knocked out in cardiomyocytes. However, the animals that had
the MDMxXgeneknockedoutin their cardiomyocytes, died prematurely later on due
to unknown condition/s (Grier et al., 2006). Both studies show a strong discrepancy
between the actions of Mdmx and Mdm2, as deletion of the Mdm2 in the same
tissues resulted in lethality of the animal. Similarly to the conclusions drawn by
Francoz et al. based on in vitro studies, it has been suggested that loss of Mdmx can
43
Introduction
 
be compensated by increased levels of Mdm2 in these tissues, especially as the
knockout of Mdmx has been shownto increase p53-driven expression of Mdm2. On
the other hand, knockout of Mdm2 has been shown to result in a massive
accumulation of p53 whose activity could not be efficiently controlled by the
remaining Mdmx (reviewed in Marineet al., 2006).
Similarly to MDM2, over-expression or amplification of MDMX has been shownto
mediate oncogenic effects and it this has been observed in several types of
malignancies such as gliomas (Riemenschneideret al., 2003) or breast cancers (Ried
et al., 1995). Moreover, reduction of the MDMXprotein levels using RNAi in the
MCF-7cell line (which over-expresses MDMX), has been demonstrated to reduce
the numberof clones obtained in a colony formation assay (Danoviet al., 2004). The
same study has shownthat over-expression of MDMXcan cooperate with oncogenic
RasV12 in transformation of MEFswhich,as a result, acquire oncogenic properties .
To sum up, MDMXpresentsitself as an essential for life, negative regulator of p53.
Both laboratory and clinical data suggest that increased levels of MDMX mediate
tumourigenesis. At the molecular level, MDMX has been shown to bind to, and
inhibit the activity of p53 both in vitro and in vivo.It is still unclear whatis the role
of MDMxXin regulating the levels of p53 and MDM2.Although studies on animal
models suggest that Mdmx rather inhibits the p53-Mdm2 feedback loop by
decreasing the activity of p53, more studies addressing these issues are needed to
unravel features of the p53-MDM2-MDMxXnetwork.
1.5.3.5 The role of ARF in regulation of p53 and MDM2
The pl4AkF tumour suppressor is encoded in an alternate reading frame (hence the
name) of the JNK4a locus which also encodes the tumour suppressor protein,
44
Introduction
 
6'NS2 (reviewed in Sherr, 2000). Expression of ARF has been shownto bepl
differentially regulated in response to oncogenic/mitogenic signalling and appears to
be dependent on the E2F transcription factor. Oncogenic activation of proteins such
as RAS and MYC, which stimulate the activity of E2F, or presence of someviral
oncogeneshasbeen reported to increase expression of ARF (Sherr, 2000).
ARF has been shown to bind MDM2 which led to inhibition of MDM2-mediated
ubiquitylation of p53 resulting in stabilization of the latter one, reviewed in (Sherr
and Weber, 2000, Vousden, 2000). However, as will be discussed below, Arf has
also been shownto alter cellular localization of MDM2 in sometypes of cells and
several different mechanisms of this phenomenon have been proposed, see Figure
1.5. In cells unaffected by oncogenic stress the level of Arf is usually low, both p53
and MDM2localize in the nucleoplasm and p53 turnoveris very rapid. In model one,
depicted in Figure 1.5 (a) it has been proposed that binding of Arf to MDM2leads to
nucleolar sequestration of MDM2andactivation of p53, at least in somecells. It has
been demonstrated that up-regulated Arf (but not Arf mutant which fails to localize
to the nucleolus) relocalizes MDM2, but not p53, to the nucleolus. It has also been
shown that mutant of Arf unable to bind MDM2,fails to relocalize MDM2 to the
nucleolus and to trigger p53 response suggesting a potential role of MDM2shuttling
between nucleus and nucleolus in regulation of p53 (Weberet al., 1999). This model
also suggests that blocking the nuclear export of p53 might also contribute to Arf-
mediated activation of p53.
Another model depicted in Figure 1.5 (b) predicts that cytoplasmic shuttling of
MDM2occurs,at least in part, via the nucleolus. Using heterokaryon assays, it has
been demonstrated that MDM2 gradually accumulates in the nucleolus whereit co-
localizes with Arf (Tao and Levine, 1999). The model suggests that the nuclear
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export of MDM2 through the nucleolus could constitute a barrier for the nuclear
export of p53 when Arf becomes induced.Interestingly, the models (a) and (b) were
created based on the results obtained in different types of cells. Weber et al. used
MEFs whereas Tao et al. used MEFs-derivative cells fused with human cervical
cancer HeLa cells. This creates a potential source of variations, such as presence of
oncogenic stress or DNA damage signals in HeLa cells, and could potentially
contribute to the differences in observations in the two studies and differences
between these two models.
In contrast with the two previous models, which examined murine ARF protein, the
model shown in Figure 1.5 (c) has been proposed based on research carried out on
human ARF. It has been shown that p53, MDM2 and ARF accumulate in the
nucleoplasm in nuclear bodies resulting in inhibition of the nuclear export of both
p53 and MDM2, accompaniedbystabilization of p53. Interestingly, human ARF has
been shown to localize predominantly in the nucleoli of cells expressing low levels
of MDM2. However, over-expression of MDM2 results in nucleoplasmic
localization of ARF in several different cell lines. Moreover, it has been
demonstrated that relocalization of ARF from the nucleolus to the nucleoplasm
(where it co-localizes with MDM2in the nuclear bodies) was induced by oncogenic
signalling. (Zhang and Xiong, 1999). This has been observed in both cancer and
fibroblast-derived human cell lines and contrasts with the results obtained in murine
cells using murine Arf. This suggests a potentially different mode of ARF-mediated
inhibition of MDM2in mice and humans.
Apart from the mechanisms of ARF-dependent regulation of p53 and MDM2,
presented above, described in (Sherr and Weber, 2000), other possible ways of
MDM2 and p53 regulation by ARF have also been proposed. ARF has been
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suggested to prevent inhibition of the transactivation domain of p53 by MDM2.In
support of this idea, it has been shown that binding of ARF to MDM2resulted in
increased transcriptional activity of p53 (Pomerantz et al., 1998). It has also been
shown that ARF decreases the E3 ubiquitin ligase activity of MDM2 towards p53
(Honda and Yasuda, 1999) and as a consequence of this, ARF appears to inhibit the
MDM2-dependent degradation of p53. This way of action of ARF seems to be a
generally accepted paradigm (reviewed in Sherr, 2006) and is not mutually exclusive
with other possible or putative mechanisms of ARF-dependent regulation of p53
presented above.
The ability of ARF to rescue p53 from MDM2-mediated inhibition in response to
oncogenic signalling has been shown to be an important anti-tumourigenic
mechanism. The role of ARF as a tumour suppressor gene has been supported by the
fact that inactivating mutations in the ARF gene have been found in various types of
tumours (Pollock et al., 1996). In addition, 80% of Arf null mice developed tumours
(predominantly lymphomasand sarcomas) with a meanlatency of 38 weeks (Kamijo
et al., 1999). Although the tumoursretained wt p53, suggesting that deletion ofArfis
sufficient to compromise the response of p53 to oncogenic stress (hence, tumours
developed), different tumour spectrum as well as delayed tumour latency compared
with p53-null mice (mean latency 18-20 weeks) has been observed. It has been
suggested that the ability of p53 to respond to other types of stress (such as DNA
damage) could contribute to a residual p53 activity in Arf-null cells resulting in
developmentof tumourslater than in p53-null animals (Lozano and Zambetti, 2005).
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Nucleolus ARF, Mcm2,and p53levels ara lowARFis nucleolar
Nucleus p53 and Mcm2 are nucleoolasmic
Cy:oplasm ¢53 turnover is rapidy
 
a
ARFinduction: p53is induced, active, mostly nucleoplasmic, and stable
(a) Nucleolar sequestration (b) Nucleolarexit (c) Nuclear bodies
Figure 1.5 ARF-mediated activation of p53. Reproduced from (Sherr and Weber,
2000).
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The importance of Arf in activation of the p53 pathway has been further
demonstrated by analysis of lymphomagenesis model mice (in which over-
expression of the c-Myc oncogene is driven by the immunoglobulin heavy chain
enhancer). Thess studies have revealed that 28% of lymphomas that arise had
sustained loss of function of p53, 24% loss of function of Arf and the rest of the
tumours over-expressed Mdm2. This suggests that all three situations lead to a
similar outcome- inactivation of the p53 pathway. Moreover, c-Myc over-expressing
Arf” animals appeared to have markedly reduced survival compared to the 4r, fe
mice and 80% of lymphomas developed in these mice appeared to have lost the
second Arf allele. The c-Myc over-expressing, Arf’ animals died of lymphomas a
few weeksafter birth, further supporting the importance of Arf in providing defence
against oncogenicactivation (Eischenet al., 1999).
1.6 MDM2has p53 independentfunctions andinteractions
The data described in previous sections strongly suggest that MDM2 functions as an
oncogene,asit leads to suppression ofthe activity of p53. However, MDM2 appears
to have also p53-independent interactions which may contribute to oncogenesis.
Someofthese are shownin the Figure 1.6.
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p53 independentfunctions and interactions of MDM2
E2F1 Ribosomal Numb DNA B-arrestin DHFR
Rb proteins: L5, polymerase ¢
MTBP L11,L26, S7
regulation of the -ribosome biogenesis -differentiaton -DNA synthesis -trafficking of -folate metabolism
cell cycle -protein biosynthesis _-p53 repression the B-AR -DNA methylation?
-p53 regulation receptor
Figure 1.6 p53-independent targets of MDM2. The Diagram presents various
proteins that are bound by MDM2 and target proteins/mechanisms which are
regulated by these interactions, adapted from (Iwakumaand Lozano, 2003).
MDM2is knownto be involved in various cellular processes.
- MDM2 has been shown to interact with cell cycle regulators. Inhibition and
ubiquitylation of the tumour suppressor Rb by MDM2hasbeen showntoresult in
E2F-dependentcell cycle progression and loss of Rb dependent G1 arrest (Uchida
et al., 2005). Interaction of MDM2 with E2F1 heterodimeryzation partner, DP1,
has been demonstrated to increase activity of the E2F1-DP1 heterodimer
promoting transactivation of the S-phase genes (Martin et al., 1995). MDM2 has
also been shownto inhibit the Gl cycle arrest mediated by MTBP (Boydetal.,
2000).
- MDM2has been implicated in regulation of protein synthesis and ribosome
biogenesis through binding of several ribosomal proteins. Moreover, it has been
reported that interaction with several ribosomal proteins, such as L11 (Zhang et
al., 2003) or S7 (Chenet al., 2007) has leads to stabilization of p53 and increase
p53 activity.
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- MDM2z2hasbeen shownto have an effect on differentiation through interaction
with Numb, a negative regulator of Notch signalling. This interaction results in
ubiquitylation and proteasomal degradation ofNumb (Yogosawaetal., 2003).
- MDM2is also known to be involved in regulation of DNA synthesis due to
interaction with carboxy-terminus of the DNA polymerase ¢ which results in
increased activity of the enzyme (Vlatkovicet al., 2000, Asaharaet al., 2003).
- MDM2has been found to regulate trafficking and turnover of the B2AR. By
ubiquitylation and degradation of B-arrestin, a key negative regulator of the B2-
adrenergic receptor (B2AR) responsible for regulation of its internalization,
MDM2leads to internalization and sequestration of the B2AR (Ganguli and
Wasylyk, 2003).
- MDM2hasalso been implicated in folate metabolism through interaction with
and mono-ubiquitylation of dihydrofolate reductase DHFR (an enzymecatalysing
regeneration of tetrahydrofolate, essential for thymidine synthesis, and therefore
also for DNAreplication). Inhibition of DHFR by MDM2has been shownto
result in decreased activity (but not stability) of DHFR.It has been suggested that
apart from compromising the ability to regenerate tetrahydrofolate, inhibition of
DHFR by MDM2 mayalso play role in epigenetic regulation by methylation,
thus potentially contributing to tumourigenesis (Maguire et al., 2008).
In spite of extensive studies addressing the issue of p53-independent functions of
MDM2andtheir potential contributions to cancer, very little is known about the
molecular basis of these MDM2-mediated processes. However, there is a
considerable body of evidence, such as clinical and animal model data, suggesting
that in addition to inhibiting p53, MDM2also possesses p53-independent oncogenic
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activities. For example, it has been shownthat increased levels of MDM2expression
in addition to mutation of p53, correlate with decreased survival of bladder cancer
patients (Lu et al., 2002). Analysis of the p53" mice over-expressing Mdm2 has
demonstrated a different spectrum and incidence of tumours in these mice compared
with p53 animals. For example, p53” mice over-expressing Mdm2 suffered from
increased incidence of sarcomas (38%) compared with p53 null animals (9%). This
suggests a p53-independent role for Mdm2in pathogenesisofthis particular group of
tumours (Joneset al., 1998). Another study, in which Mdm2 has been over-expressed
in the mammary gland during gestation and lactation showed poor development of
the gland and perturbationsofthe cell cycle in mammaryepithelial cells in both p53
wt and p53” mice. Thecells from both p53" and wt animals appeared to undergo
multiple S-phases without mitotic divisions. Moreover, 16% ofp53 wt, Mdm2-over-
expressing mice developed mammary adenocarcinomas due to over-expression of
Mdm2after a long (14-18 months) period of latency. However, it remains unclear
whether this is due to p53-independent activity of Mdm2, or by Mdm2-mediated
inhibition of p53 (Lundgren et al., 1997). Additional evidence for the p53-
independent role of Mdm2 in tumourigenesis has come from studies of Mdm2
deletion mutants (Fridman et al., 2003). Mutants of Mdm2 used in this study
represented the splice variants of Mdm2 expressed in human lymphomas. This study
has revealed that mutants of Mdm2, which are unable to bind p53, also contribute to
development of lymphomas(similarly to the wt Mdm2protein) in mice. In addition,
a different study has demonstrated that splice variants of Mdm2that do not have the
ability to bind p53 still retain the transforming potential (in combination with
oncogenic Ras) (Sigalas et al., 1996).
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1.7 Aim of the project
Several lines of evidence suggest the existence of p53-independent oncogenic
activities of MDM2(see Section 1.6). In renal cell carcinoma, concomitant over-
expression of both p53 and MDM2appearsto be associated with a worse outcome
than over-expression of p53 alone (see Section 1.4). This suggests a possible
functional role for MDM2 in promoting aggressiveness of RCC tumours and makes
RCC an excellent model to study p53-independent oncogenic functions of MDM2.
Therefore, we decided to search for novel oncogenic functions of MDM2 in RCC
cells.
Since MDM2 executes essentially all of its known functions via protein-protein
interactions, this project aimed to identify novel protein targets of MDM2.
Identification of novel MDM2-binding proteins specific for RCC was hypothesised
to be likely to explain the role of MDM2in mediating the aggressive phenotype of
this type of cancer.
An additional aim was to characterize RCC cells over-expressing both p53 and
MDM2with respect to their p53 status and functionality as this might contribute to
our understanding of the regulation of p53 and MDM2levels in RCC. Finally, since
increased cell motility and invasiveness contribute to the metastatic process (motile
cells can actively disseminate from the primary tumour and migrate to othertissues),
the role of MDM2in promoting these cellular activities will also be investigated in
the present study.
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2 Materials and methods
2.1 List of reagents
 
 
 
 
Reagent Manufacturer
3-amino-1,2,3-triazole Fluka
Acrylogel 2,6 (40%) solution Electran
Adenine hemisulfate salt Sigma
Agar Oxoid
Agarose Flowgen bioscience
Agarose Seakem GTG Cambrex
Albumin, bovine Sigma
Amonniumperoxodisulfate BDH
Ampicillin sodium salt Sigma
Aprotinin Roche
Bio-rad protein assay reagent Bio-rad
Blotting grade blocker, non-fat dry milk Bio-rad
Bromophenolblue Sigma
BSA (bovine serum albumin) Sigma
Chloroform BDH
D(+)-glucose solution Sigma
Dimethylformamide BDH
DMSO(dimethyl sulfoxide) Sigma
Dulbecco’s modified eagle’s medium Sigma  
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Dulbrcco’s phosphate buffered saline Sigma
EDTA(ethylenediaminetetraacetic acid) Sigma
Ethanol absolute for molecular biology Sigma
Ethidium bromide solution Sigma
Fetal Bovine Serum Sigma
Formaldehyde solution 37% BDH
Genejuice Novagen
Glass beads Sigma
D-(+)-glucose Formedium
Glycerol form molecular biology Sigma
Glycine BDH
HEPES(4-(2-hydroxyethyl)-1- Calbiochem
piperazineethanesulfonic acid)
Hybond ECLnitrocellulose membrane Amersham Biosciences
 
  Isopropanol for molecular biology SigmaKanamycin sulphate SigmaLeupeptin RocheLipofectamine 2000 InvitrogenL-leucine FormediumLuria Broth SigmaMEM Non-essential aminoacid solution 100x SigmaMinimum essential medium eagle balancedsalt SigmasolutionMcCoy’s 5a Medium Sigma 
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Nutlin-3 Sigma
Opti-MEM medium Gibco
Pepstatin Roche
Phenol (equilibrated), pH = 8 Sigma
Phenylmethanesulfonyl fluoride Fluka
RNA-bee Biogenesis
RPMI-1640 medium Sigma
SDS(sodium dodecy] sulfate) Fluka
Sodium bicarbonate solution Sigma
Sodium chloride GPR
Sodium dihydrogen phosphate dihydrate Fluka
Sodium phosphate dibasic dihydrate Reidel-de Haen
 
 
Sodium pyruvate Sigma
Soybean Trypsin Inhibitor Roche
TEMED(N,N,N',N'Tetramethylethylene-diamine) VWR
Tris base (2-Amino-2-(hydroxymethyl)-1,3- Calbiochem
propanediol)
Triton X-100 Fluka
Trypsin — EDTAsolution Sigma
Tween 20 USB
Western lightning chemiluminescence reagent
plus
Perkin Elmer Life
Sciences X-beta-galactosidase (5-bromo-4-chloro-3-indolylB-D-galactopyranoside)  Apollo Scientific
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X-alpha-galactosidase (5-bromo-4-chloro-3-
indolyl a-D-galactopyranoside)
Apollo Scientific
  
Xylene cyanol Sigma
Yeast nitrogen base without amino acids Formedium
YEP broth Formedium
YPD Agar Formedium  
Table 2.1 List of reagents.
2.2 Buffers and solutions
Electrophoresis running buffer
25mM Tris base
250mM glycine
0.1% w/v SDS
Electrophoresis transfer buffer
25mM Tris
192mM glycine
20% v/v methanol
4x protein sample buffer
0.25M Tris (pH 6.8)
8% w/v SDS
40% v/v B-mercaptoethanol
0.4% w/v bromophenol blue
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10x DNA/RNAnative loading buffer
50% v/v glycerol
ImM EDTA
0.1% w/v bromophenolblue
0.1% w/v xylene cyanol
5x denaturing RNAloading buffer
50% v/v formamide
40% v/v glycerol
0.1% w/v bromophenolblue
0.1% w/v xylene cyanol
Buffer E (10x)
0.18M NaHPO,
0.02M NaH»PO,
RNA denaturing sample buffer
9.25 % v/v formaldehyde
75% v/v formamide
Sample preparation for the denaturing agarose gel electrophoresis
18ul of 10x E buffer was added to 9,2u1 of the RNA denaturing sample buffer, 2411
(10ug) of RNA,and 6ul of the denaturing RNA loading buffer.
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PBS/Tween
0.065M
0.015M
0.075M
0.1% v/v
NaHPO,
NaHPO,
NaCl
Tween 20
SLIP (Stuart Linn immuno-precipitation) buffer (per 100ml)
0.05M
1% v/v
0.1% v/v
150mM
0.05% w/v
TAE buffer (50x)
2M
2M
50mM
2.3 Media
HEPES pH=7.5
glycerol
Triton X-100
NaCl
BSA
Tris base
glacial acetic acid
EDTA
Luria broth (1L) liquid medium
25g of powdered LB dissolved in 1L of water and autoclaved.
Luria broth agar (1L)
25g powdered LB
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ISg agar
Wateradded to 1L and autoclaved.
YPDAliquid medium (1L)
30g of YEP broth dissolved in 885 ml of water, autoclaved;
Following autoclaving 100 ml of 20% w/v sterile glucose and 15 mlofsterile 0.2%
w/v adenine hemisulphate salt was added.
YPDA+liquid medium (for yIG397 FASAYyeast)
30g of YEP broth dissolved in 885 ml of water, autoclaved; following autoclaving
100 ml of 20% w/v sterile glucose and 20ml of 1% w/v adenine hemisulphate salt
was added.
DOliquid media (1L)
6.9 g of yeast nitrogen base without amino acids was dissolved in 850 ml of water
and autoclaved. The following supplements were dissolved in 50 ml of water:
- Leu DO liquid medium:0.69g of—Leu DO supplement;
- Trp DO liquid medium: 0.64g of—Leu/-Leu DO supplement and 0.1g of leucine;
- Leu/Trp DO liquid medium: 0.64g of —Leu/-Leu DO supplement
- Leu/Trp/His/Ade DO (quadruple, QDO)liquid medium: 0.60g of —Leu/-Trp/-His/-
Ade DO supplement,
filter sterilised and added to the yeast nitrogen base solution as required. 100 ml of
20% w/v glucose was subsequently added. All media, except of QDO, were
supplemented with 15 ml ofsterile 0.2% w/v adenine hemisulphate.
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YPDAagar medium (1L)
70 g of YPD agar was added to 985ml, autoclaved and supplemented with 15 ml of
sterile 0.2% w/v adenine hemisulphatesalt.
YPDA+¢agar medium (1L) (for yIG397 FASAYyeast)
70 g of YPD agar was dissolved in 985ml, autoclaved and supplemented with 20ml
of 1% w/v of adenine hemisulphatesalt.
DO agar media (1L)
6.9 g of yeast nitrogen base without amino acids was dissolved in 850 ml of water,
20g of agar was subsequently added and autoclaved. The following supplements
were dissolved in 50 ml of water:
- Leu DO agar medium:0.69g of—Leu DO supplement;
- Trp DO agar medium:0.64g of—Leu/-Leu DO supplementand 0.1g of leucine;
- Leu/Trp DO agar medium:0.64g of —Leu/-Leu DO supplement;
- Trp/His DO agar medium: 0.60g of —Leu/-Trp/-His/-Ade DO supplement and
20mg of adenine hemisulphate salt and 0.1g of leucine;
- Leu/Trp/His DO (triple, TDO) agar medium: 0.60g of —Leu/-Trp/-His/-Ade DO
supplement and 20mg of adenine hemisulphatesalt;
- Leu/Trp/His/Ade DO (quadruple, QDO)liquid medium: 0.60g of —Leu/-Trp/-His/-
Ade DO supplement,
filter sterilised and added to the yeast nitrogen base solution as required. 100 ml of
20% w/v glucose was subsequently added. All media, except of QDO, were
supplemented with 15 ml ofsterile 0.2% w/v adenine hemisulphate.
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—Leu/Ade(low adenine concentration) DO solid medium (1L) (for yIG397 yeast
FASAYscreening)
6.9 g of yeast nitrogen base without amino acids was dissolved in 850 ml of water,
then 20g of agar was added and autoclaved. 0.60g of —Leu/-Trp/-His/-Ade DO was
combined with 4mg of adenine hemisulphate salt, 20mg of histidine, 20mg
tryptophan and dissolved in 50 ml of water followed by filter sterilization. The
amino-acid solution was then added to the autoclaved yeast nitrogen base - agar
solution. 100 ml of 20% w/v glucose, and water was addedto a final volume of IL.
Yeast freezing medium
30g of YEP broth was dissolved in 500 ml of water and autoclaved. 100 ml of 20%
w/v sterile glucose, 15 ml of sterile 0.2% w/v adenine hemisulphate salt, 250ml of
sterile glycerol and water was added to a final volumeof 1L.
Sterile 20% w/v glucose watersolution (1L)
200g of D-(+)-glucose dissolved in |L of water and autoclaved.
2.4 Enzymes
 
 
Enzyme Manufacturer
BamH I NEB
Bgl Il NEB
Cla I NEB
EcoR I NEB
EcoR V NEB    
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HindII] NEB
Neo I NEB
Nhe I NEB
NotI NEB
Sac I NEB
XhoI NEB
Xba | NEB
Taq DNA polymerase Eppendorf
Pfx DNA polymerase Invitrogen
Advantage DNA polymerase Clontech
Lyticase Sigma
MMLV(Moloney Murine Leukemia Virus) Clontech
Reverse Transcriptase
Antarctic phosphatase NEB    
Table 2.2 List of enzymes
2.5 Primers
Nameof the primer Sequence(5’ to 3’)
N=A,G,C, or T; V=A,G,or C
 CDSIII primer ATTCTAGAGGCCGAGGCGGCCGACATG-d(T)30VN,
BD SMARTIll primer AAGCAGTGGTATCAACGCAGAGTGGCCATTATGGCCGGG
cDNA 5'PCR Primer TTCCACCCAAGCAGTGGTATCAACGCAGAGTGG   
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cDNA3' PCR Primer GTATCGATGCCCACCCTCTAGAGGCCGAGGCGGCCGACA
5' AD LD-Insert
Screening Amplimer:
CTATTCGATGATGAAGATACCCCACCAAACCCAAAAAAAG
AG
3' AD LD-Insert
Screening Amplimer
AGTGAACTTGCGGGGTTTTTCAGTATGTACGAT
 NME2for pFLAG- CTCGAATTCCCCGGACCATGGCCAACCTGG
CMV-6b
NME2rev pFLAG- GCTGTTGGATCCACCTCTTATTCATAGACCC
CMV-6b
NMEIfor pFLAG-
CMV-6b
GATGAATTCGGACCATGGTGCTACTGTCTACTTTAG
 NMEIrev pFLAG- GTGGGATCCCCTCCTGTCATTCATAGATCC
rev
CMV-6b
NME2 H118F pCEP GAGCGGCCGCGGACCATGGCCAACCTGGAGCGCACCTTCA
for ,
NME2 H118F pCEP GAGGATCCTTATTCATAGACCCAGTCATGAGCACAAGACC
TIGTAGTCAACCAGTTCTTCAGGCTTAAACCATAGGCTGAT
TICTTTTTCAGCACTTTTTACTGAATCACTGCCAAAATG
 NME2 K12Q pCEPfor GAGCGGCCGCGGACCATGGCCAACCTGGAGCGCACCTTCA
TCGCCATCCAGC
NME2 K12Q pCEPfor GAGCGGCCGCGGACCATGGCCAACCTGGAGCGCACCTTCA
TCGCCATCCAGC
NME2 K12Q pCEPrev GCTGTTGGATCCACCTCTTATTCATAGACCC
P3 FASAY CCTTGCCGTCCCAAGCAATGGATGAT
 P4 FASAY  ACCCTTTTTGGACTTCAGGTGGCTGGAGT
Table 2.3 List of primers
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2.6 Vectors
Nameof the vector Source
pGBKT7 DNA-BDcloning vector ‘Clontech (Matchmakerkit)
pGADT7-Rec ADcloning vector (Smal
linearized)
Clontech (Matchmakerkit)
 pGBT9transformation efficiency control plasmid Clontech (Matchmakerkit)
pGBKT7-p53 control vector Clontech (Matchmakerkit)
pGBKT7-Lam control vector Clontech (Matchmakerkit)
 
pCR.2.1 vector Invitrogen
pFLAG-CMV-6b (NMEI and NME2) Sigma
pCEP4 (NMEI and NME2wt and mutants) Invitrogen
pRDI-22 Obtained from prof. Richard
Iggo, (Waridel etal., 1997)
pCEP4-p53 Obtained from dr Dale Haines
(Boydet al., 2000)
 pCMV-neo-bam-hMDM2  Obtained from prof. BertVogelstein (Olineret al., 1992)
Table 2.4 List of vectors
2.7 Antibodies
 
 
Antibody Manufacturer
Anti-p53 (ab-6) DO-1 mouse monoclonal, primary Calbiochem
Anti-MDM2(ab-1) mouse monoclonal, primary Calbiochem 
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Anti-actin c-2 mouse monoclonal, primary Santa Cruz Biotechnology
Anti-p21"/“4" F-5 mouse monoclonal, primary Santa Cruz Biotechnology
Anti-B Galactosidase mouse monoclonal, primary Calbiochem
NME2L-15 gout polyclonal, primary Santa Cruz Biotechnology
 NME1/2 rabbit polyclonal, primary Abcam
Bax (ab-1), rabbit polyclonal, primary Calbiochem
Anti-mouse antibody, HRP-conjugated, secondary Amersham Biosciences
Anti-mouse antibody, HRP-conjugated, secondary Amersham Biosciences
Anti-goat antibody, HRP-conjugated, secondary  Jackson
Table 2.5 List of antibodies
2.8 Short interfering RNA (siRNA)
Short interring RNA (siRNA) oligonucleotides were designed by Dr Mark T Boyd,
Dharmacon companyor others (wherecited).
Scrambled
Target sequence: 5’- AAGGACGCAUCCUUCUUAAUU-3’
p53 (Martinez et al., 2002)
Target sequence: 5’- AAGCAUGAACCGGAGGCCCAU-3’
MDM2
Target sequence: 5’°- AAGCCACAAAUCUGAUAGUAU-3’
NME2oligo 8
Target sequence: 5’- AAGGCGAGAUCAUCAAGCGCUU-3’
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2.9 Cell culture
Tissue culture was performed in a tissue culture hood using sterile technique. Cells
were grown in humidified incubators at 37°C with 5% CO). Media, providing
nutrients for optimal growth for individualcell lines, are described below.
H1299 cells (non-small cell lung carcinoma cells) were grown in the RPMI 1640
medium supplemented with 10% FBS.
MCEF-7 (breast carcinoma) cell line was maintained in the DMEM Hepes modified
supplement medium, supplemented with 10% FBS and 2mM L-glutamine.
BJ fibroblasts (human dermal fibroblasts) were maintained in MEM Eagles
balanced salt solution supplemented with 10% FBS, 2mM L-glutamine, 1.5g/L
sodium bicarbonate, 0.1mM non-essential amino acids and 1mM sodium pyruvate.
117, ACHN, A498 (RCC)cell lines were maintained in Minimum Essential Medium
Eagle supplemented with 10% FBS, 2mM L-glutamine, 1.5g/L sodium bicarbonate,
0.1mM nonessential amino acids, and 1mM sodium pyruvate.
Caki-2 (RCC) cell line was maintained in the McCoy’s 5a medium supplemented
with 10% FBS, 1.5mM L-glutamine and 2.2g/l sodium bicarbonate.
786-O (RCC) cell line was maintained in the RPMI 1640 medium supplemented
with 10% FBS, 2mM L-glutamine, 10mM HEPES, ImM sodium pyruvate, 4.5g/l
glucose and 1.5g/l sodium bicarbonate.
2.10 RNA extraction, synthesis and amplification of cDNA
Total RNA extraction
Cells were lysed with 15ml of RNA-bee. 0.2 volumes of chloroform was added,
shaken vigorously for 15 seconds and the lysate was put on ice for |5minutes. The
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lysate was then transferred into the screwcap microcentrifuge tube and centrifuged
for 15 minutes at 4°C at 14.200g. The aqueous phase was removed and an equal
volume of isopropanol was added, placed on ice for 15 minutes and centrifuged for
15 minutes at 4°C at 14.200g; isopropanol was removed, the pellet resuspended in
70% v/v ethanol and placed O/N at -20°C. The precipitate was centrifuged for 15
minutes at 4°C at 14.200g, ethanol was removed, the pellet was air-dried and
dissolved in 250ul of water.
The OD at 260 and 280nm was measuredto evaluate purity and yield of RNA.
mRNApurification (RNeasy, Qiagen kit)
mRNA was purified using Qiagen columns following the manufacturer’s
instructions. Typically, 250 ug of total RNA was loaded onto each columneluted
twice with 20ul of OEB buffer followed by measurement of OD at 260 and 280nm to
determine yield and purity of the sample.
Native agarosegel electrophoresis
Typically, 0.5ug of mRNA,lpg of total RNA, and lpg of total control RNA wasrun
on a 1.2% w/v agarose gel containing ethidium bromide (60yg/ml), using 1x TAE
buffer. The gel wasinitially run at 100mA for the first 10 minutes and then at 20mA
for next 7 hours, with buffer circulation in the tank to prevent forming of the pH
gradient across the tank, as basic pH causes auto-degradation of RNA. Following
electrophoresis, the gel was distained for 30 minutes in water to decrease background
fluorescence, RNA wasvisualized using transluminometer and photographed using a
Kodak EDASsystem.
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Denaturing agarosegel electrophoresis (per 100mlgel)
1.2g of agarose and 10ml buffer E were added to 73.3ml of water and boiled in the
microwave machine until agarose was dissolved. Upon cooling to < 55°C, 16.7ml of
37% formaldehyde was added, mixed and the gel was poured into a previously
prepaired tray. RNA samples were heated at 65°C for 5 min. placed on ice for
another 5 minutes and briefly centrifuged. Then, RNA samples were loaded on the
gel and separated at 100m<Aforthe first 10 minutes and at 20mAfor the next 7h. The
Ix E electrophoretic buffer was constantly circulated using a peristaltic pomp in
order to prevent formation of pH gradient across the tank. Subsequently, the gel was
distained for 30 minutes in water and photographed using Kodak Edas system.
cDNAsynthesis
Forthe first strand cDNAsynthesis, I ul of mRNA (lpg/tl) was used, then 2ul of this
was used for cDNA amplification and purification. All procedures were performed
using Matchmaker library construction and screening kit according to the BD
Biosciences Clontech protocol #PT3529-1, version #PR32047.
2.11 The yeast two-hybrid system
The yeast two-hybrid system, used in this study, is based on two domains of the
GAL4transcription factor which can not interact with each other (thus, to
reconstitute the functional Gal4 transcription factor) unless they are connected by the
bait and library proteins (Fields and Song, 1989). pGADT7-Rec plasmid encodes a
fusion of the GAL4 activation domain and the library protein and pGBKT7 produces
the bait protein fused to the DNA binding domain of the GAL4transcription factor.
If the library and bait proteins interact, the reconstituted GAL4 is able to activate
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reporter genes and the yeast will grow on selective media (Figure 2.1). Yeast two-
hybrid screen is a high throughput approach allowing efficient screening of the
library for proteins that interact with the bait. The screen is preceded by numerous
steps of preparation and optimization, which are described below.
Test for the DNA-BD-MDM2fusion toxicity for the Y187 yeast strain
The DNA-BD-bait protein may be toxic to the yeast cells which could affect quality
of the screen or assay by decreasing the rate of cell growth and division. To test for
toxicity of the fusion protein, yeast cells transformed with the bait vector were grown
in the appropriate DO liquid medium and the effect of the fusion in the yeast cells
was determined by measurementof the culture density as described below.
50ml of the -Trp DO liquid medium wasinoculated with one large colony fromthe -
Trp DO agar plate and grown for 16-24h in the shaking incubator at 30°C.If after
24hthe culture does not reach OD¢o0 = 0.8, it means that the fusion protein is toxic
for yeast.
Preparation of competentyeastcells
Preparation of competent yeast cells is a key procedure in achieving high
transformation efficiency which is crucial for construction of a high quality cDNA
library. A large number of individual clones is important as this gives a chance for
less abundant cDNA species to be present in the library. The large number of
individual clones in the library is dependent on high transformation efficiency. To
achieve this, the competent yeast cells must be prepared carefully.
Preparation of competent yeast cells was carried kit according to the BD Biosciences
Clontech protocol #PT3529-1, version #PR32047.
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   Bait | LibraryC] protein
Transcription
GAL UAS Minimal promoter Reporters: ADE2, HIS3, LacZ, MEL1    
Figure 2.1 Principle of the yeast-two-hybrid system. The Diagram illustrates the
molecular mechanism of the yeast two-hybrid-GAL4 system. Interaction between the
bait and the library protein fused to the binding and activation domains, respectively,
lead to activation of reporter genes.
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Library construction
A cDNAlibrary constructed in yeast is a pool of yeast cells transformed with vectors
containing cDNA from defined sources, such as tissues or cell lines. In case of this
work, cDNA for construction of the library was obtained by reverse transcribing
mRNA derived from a cancer cell line. The procedure of cDNA preparation for
construction of the library was described before (2.10.) The procedure of library
construction was performed according to the BD Biosciences Clontech protocol
#PT3529-1, version #PR32047.
The pool of transformed yeast cells constituting the library was mixed thoroughly,
aliquoted (Iml) and stored in -80°C. The following day onelibrary vial was thawed;
dilutions were performed and plated on 15cm —Leu DOagarplates to estimate the
librarytitre.
Mating
Yeast mating is a process based on fusion of two compatible, haploid yeast cells
which subsequently form a diploid cell. This corresponds to fertilization because
haploid yeast cells act as gametes and form a zygote. The process of mating is used
for combining yeast strains transformed with library and bait plasmids growing on
single DO media. After mating, yeast are transferred on multiple DO mediato select
for successfully mated cells (double DO) and yeast bearing plasmids producing
weakly or strongly interacting fusion proteins (triple and quadruple DO media,
respectively). The procedure of yeast mating was carried out according to the
Clontech protocol #PT3529-1, version #PR32047. Following mating, cells were
selected for yeast two-hybrid positives on 15cm —Trp/-Leu/-Ade/-His DO agarplates
and incubated upside down for 8 days at 30°C.Subsequently, yeast colonies were
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then picked and transferred onto fresh —Leu/-Trp/-His/-Ade DO agar plates using
sterile toothpicks and incubated upside down for 3 days at 30°C. Out of these, the
largest clones were picked and inoculated onto —Leu/-Trp/-His/-Ade/X-a-gal DO
agar Petri dishes in order to estimate activation of the MELI reporter gene. The
strongest positives were subjected to PCR for further restriction digest (to
discriminate between identical clones) and sequencing of clones that exhibit unique
fingerprint.
Positive yeast two-hybrid colonies were screened for the presence of inserts by
PCR.
The PCRreaction was composed of 2.5u1 of 10x polymerase buffer, 0.5u1 of 40mM
dNTP mix, ll of 5’, 3’ screening amplimer mix (Spmol/ul each), 0.25ul (1.25U) of
the Taq polymerase and 20.75ul of water to total volume of 25ul. A tiny fraction of
colony waspicked using a sterile toothpick and dipped into the reaction mixture prior
to start of the reaction.
Cycling was programmedasfollows:
Initial denaturation for 3 minutes at 95°C was followed by 30 three-step cycles of
denaturation for 30 seconds at 95°C, 30 seconds of annealing at 68°C and extension
at 72°C for 4 minutes.
2.12 The FASAY(Functional Analysis of Separated Allele in Yeast)
p53 is mutated in at least 50% of human cancers and its inactivation is generally
essential in the process of tumourigenesis (Vousden and Lu, 2002). In some cancers,
mutation of p53 is associated with progression of the disease (reviewed in Boyd,
2008). Therefore, highly sensitive (because some tumour samples are very
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heterogeneous) screening strategies for p53 mutation are important for administration
of the appropriate treatment.
One of such screening techniques is yeast-based FASAY which allowssearching for
relatively rare mutant p53 alleles in heterogeneous samples. The technique is based
on recombination of the p53 cDNA with the vector (pRDI-22 vector used here)
carrying the Leu2 gene which allows the yeast cells to grow on —Leu DO media. Wt
p53, recombined with the pRDI-22 vector, activates expression of the Ade2 gene
encoded by another vector, pLS210, stably integrated with the genome of the y1G397
yeast strain, used for FASAY. Yeast cells, expressing the Ade2 gene are able to form
large white colonies. Mutant p53 is unable to induce expression of the Ade2 gene
and cells that carry the pRDI-22 vector recombined with mt p53, form small and red
colonies (resulting from accumulation of a red pigment, ribosylaminoimidazole
(Smirnovet al., 1967), since there is too little adenine in the medium to allow robust
growth. The distinct morphology of colonies carrying mt p53 allows efficient
screening and straightforward identification of the mutation (Camplejohn and
Rutherford, 2001).
Total RNA was obtained from the tumour sample and 1-5ug of RNA wasreverse
transcribed using oligo-dT and the M-MuLVreversetrascriptase in the total reaction
volume of 20ul incubated for 1h at 42°C. The PCRreaction was then performed with
2ul of cDNA, FASAY P3 and P4 primers and the Phusion polymerase in the total
volume of SOul. The cycling was programmed as follows: 30sec. of initial
denaturation at 98°C was followed by 35 cycles of 10 sec. denaturation at 98°C, 30
sec. annealing at 58°C and 40 sec. extension at 72°C. The PCR product waspurified
from the 1.2% agarose gel. The pRDI-22 was sequentially cut with HindIII and Stul
(digestion of the vector greatly increases recombination efficiency) and 250ng was
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cotransformed with 125ng of the PCR product into the competent yIG397 yeast cells
(prepared and transformed using the Li/Ac method (according to the Clontech
#PT3529-1 manual). Subsequently, yeast were plated on solid FASAY screening
media and incubated up side downat 31°C for 3-4 days and then transferred to 4°C
for the red colour to develop. Red and white colonies were scored and 5 red colonies
for each sample were subject to PCR using the sameprotocol as for amplification of
the p53 cDNA. The PCR products were subsequently separated on the 1% agarose
gel, out of which two to four (for each tumourorcell line) were purified and sent for
sequencing.
2.13 Plasmid production
Small scale plasmid DNAextraction from E.coli
For screening and yeast transformation purposes small scale plasmid DNA extraction
was performed using Quiagen miniprep kit according to the manufacturer’s protocol.
Large scale plasmid DNAextraction from E.coli
For the purpose of transfection experiments, to obtain high quality DNA,large scale
plasmid DNA extraction was performed using Quiagen megaprep kit according to
the manufacturer’s protocol.
2.14 Molecular cloning
Molecular cloning is a process of incorporation of the usually defined fragment of
DNAinto the vector. Various different cDNAs were cloned in this study to obtain
constructs suitable for protein expression in yeast and mammalian systems.
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Cloning of NME2 into pFLAG-CMV-6bvector
NME2 cDNAwasamplified by PCR reaction composed as follows:
Sul of 10X Pf amplification buffer was mixed with 0.5ul of 40mM dNTP mix, I pl
primer mix (NME2 for pFLAG-CMV-6b and NME2 rev pFLAG-CMV-6b, S5pmol/ul
each), lul of placental cDNA, 0.71 Pfx DNA polymerase (2.5U/ul) and 41.8ul of
water up to total volume of 50ul in a 200u1 PCR tube. The sample was subject to
initial denaturation for 2 minutes at 95°C, followed by 10 three-step cycles of
denaturation for 30 seconds at 95°C, 30 seconds of annealing at 60°C and extension
at 68°C for 45 seconds. Then Ipl of Taq polymerase (5U/pl) and 2pl of dATP
(10mM) was addedto the reaction and incubated for 20 minutes at 72°C. The PCR
product wasthen purified using the Geneclean kit and eluted in 20ul and 61 of the
amplified NME2 cDNA was mixed with Il of T4 ligase, Iul of T4 ligase buffer and
2ul (25ng/ul) of the pCR2.1 vector and the ligation reaction was carried out O/N at
14°C.
The following day, the ligation reaction was used to transform the Top-10 E. coli
bacteria according to the manufacturer’s protocol follwed by spreading on the
ampicillin/X-gal/agar 10cm Petri plates and incubation upside down O/N at 37°C to
allow selection of transformants.
The pCR2.1 vector allows blue/white colony screening of transformants. The B-
galactosidase encoded by the lacZ in the pCR2.1 plasmid, digests X-gal present in
the media to the blue product, hence the colony appears blue. The multicloningsite is
present within the lacZ gene; insertion causes inactivation of the gene which is not
expressed in such a case and the colony appears white. Blue colonies are formed by
bacteria carrying a pCR2.1 vector without the insert; these colonies should not be
propagated.
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A white colony waspicked and propagated O/N in 3ml of LB liquid medium at 37°C
followed by Qiagen miniprep plasmid extraction according to the manufacturer’s
protocol. DNA waseluted in 30ul of water, 2g was sent to the MWG companyfor
sequencing and the sequence was subsequently compared with the reference
sequence from the NCBI database using BLAST two sequence alignmentin order to
ensure that no mutations were introduced by means of PCR.
Subsequently, 5ug of the plasmid DNA (pCR2.1-NME2) was digested with EcoRI
and BamHIrestriction enzyme according to the manufacturer’s protocol and Sug of
the plasmid pFLAG-CMV-6b was digested with EcoRI and BamHI restriction
enzyme and dephosphorylated by adding 2ul of Antarctic phosphatase and an
appropriate volume of 10x buffer followed by incubation for 20 minutes at 37°C. The
samples were separated on a 1.5% agarose gel and the band correspondingto the size
of NME2 (~500bp) and the pFLAG-CMV-6b backbone were extracted and purified
using the Geneclean (Qbiogene) reagents and protocol.
An O/N ligation reaction of the NME2 - pFLAG-CMV-6b wassetup using 5Ong of
the vector and as much ofthe insert as possible. The ligation samples were used to
transform XLl-blue E. coli bacterial strain (Stratagene) according to the
manufacturer’s protocol followed by spreading of the bacterial suspension on
ampicillin agar Petri dishes and O/N incubation at 37°C. After 16h, a colony was
picked and propagated O/N in 3ml of LB liquid medium at 37°C and was then
subject to the Qiagen miniprep plasmid DNAextraction . DNA waseluted in 30of
water.. 5ul was digested with of either EcoRI or BamHI enzymesandpresenceofthe
insert confirmed following 1,5% agarose gel electrophoresis.
100.1 of the 3ml O/N culture was used to inoculate a 500ml overnight culture. A
megaprep plasmid preparation protocol was followed to obtain high quality DNA.
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Cloning of NME1 into pFLAG-CMV-6bvector
NME!I wasclonedessentially as described above for NME2. The PCR primers used
for amplification ofNMEI cDNA were:
NMEI for pFLAG-CMV-6b and NME1 rev pFLAG-CMV-6b
Subcloning of NME2 into pCEPvector
Sug of the pFLAG-CMV-6b- NME2and the pCEP-empty vector were digested using
HindIII and BamHI enzymes, the pCEP vector was then dephosphorylated as
described before. The samples were then separated on a 1.5% agarose gel, the pCEP
vector band and the 500bp band of the NME2 cDNA were extracted and purified
using the Geneclean kit according to the manufacturer’s protocol.
An O/N ligation reaction of the NME2 pCEP4,transformation into XL1-blue cells
and a megaprep plasmid preparation were set up, as described previously (2.10).
Subcloning of NME1 into pCEP vector
NMEI was sub-cloned into pCEP4 vector as described above, but the Notl
endonuclease was usedinstead of HindIII for the 5’ end of the NMEI sequence.
Generation of NME1 and NME2chimeric constructs
Both NMEI and NME2 cDNAswere excised from a pCEP vector using NotI and
BamHI (NME1) or HindIII and BamHI (NME2) and were then digested with an
enzyme PflM1 recognising a conservedrestriction site at position 227 (exactly in the
middle of the coding sequence). Subsequently, the N-terminal part of NMEI was
ligated with the C-terminal part of NME2 and the pCEPvector, previously linearized
using NotI and BamHIrestriction endonucleases. Additionally, the C-terminal part of
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NMEI was ligated with the N-terminal part of NME2 and the pCEP vector,
previously linearized using HindIII and BamHI restriction endonucleases. The O/N
ligation reaction mixes were then used for transformation into XL1-blue cells and a
megaprep plasmid preparationwas performed as described previously (2.10).
2.15 DNA sequencing
Sequencing is a technique allowing determination of DNA sequence. In the case of
this project, sequencing of yeast library cDNAs obtained from the yeast two-hybrid
positive clones, was performedas follows.
2ul of the 10x buffer was mixed with 4ul Terminator Ready Reaction Mix, 4ul
primer (1.6 pmoles), 2u! DNA and 8u! H20 in a well of a 96-well PCR plate. The
sample was subject to 25 three-step cycles of denaturation for 10 seconds at 96°C,5
seconds of annealing at 50°C, extension at 60°C for 4 minutes and cooled down to
4°C afterwards until switched off. Then, the precipitation solution, consisting of 31
of 3M Sodium acetate (NAOAc)-pH=4.6, 62.5pl of ethanol and 14.5yl of deionised
water was added to each sample, the plate was vortexed andleft at RT for 15 minutes
to precipitate DNA. The samples were centrifuged at 4,000 rpm for 30 minutes, the
supernatant was discarded, the plate was centrifuged upside down for | minute at 50
x g. 150ul of 70% ethanol was subsequently added; the plate was sealed and inverted
to mix, then centrifuged for 10 minutes at 4,000 rpm. and the supernatant was
discarded. The plate was then inverted and centrifuged upside down for 1 minute at
50 x g to dry the sample. The sample was resuspended in 20u1 of formamide and
vortexed. Formamide was also put into any unused wells to avoid damage to the
sequencer. The samples were then subjected to sequencing on ABI3100.
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2.16 Protein analysis by SDS PAGEandwestern blotting
SDS-PAGE(polyacrylamide gel electrophoresis) is a process of protein separation
according to their molecular mass which is based on the migration of protein
molecules in the electric field. Proteins are evenly denatured by SDS, an anionic
detergent, which also gives the protein a negative charge that correspondsto the size
of the protein.
SDS-PAGE,preceded by protein sample preparation procedure is described below.
Protein samples were preparedas follows:
Cell pellets obtained by centrifugation of trypsinised cells at 300g were lysed with
SLIP buffer containing protease inhibitors (PIs) — aprotinin, leupeptin, pepstatin, STI
(soybeantrypsin inhibitor) from 1,000x concentrated stock and PMSFprepared fresh
as 100x concentrated (0.0174g/ml) in ethanol. Lysis was carried out for 15 minutes
on ice followed by centrifugation for 10 minutesat 4°C at 16.100g.
In the meantime the spectrophotometer wascalibrated for the Bradford protein assay:
serial dilutions (20; 10; 5; 2,5; 1.25; 0.625 and 0.3125mg/ml) of BSA in SLIP+PIs
buffer were performed and 2of each dilution was added to Iml of bio-rad protein
assay reagent, mixed and usedto calibrate the spectrophotometer. Then, 2y11 of each
sample was mixed with Iml of 1x bio-rad protein assay reagent and concentration of
the protein in the sample wasread using the spectrofotometer.
Typically, 50pg of the protein was mixed with 1x, 2x, and 4x sample buffer to obtain
a final concentration of 1x sample buffer and 50g of protein in the sample mix.
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SDSpolyacrylamide separating gel was prepared as follows
 
      
6% 10% 10% 12% 15%
Water 5.8 ml 5.42ml 4.8ml 4.3ml 3.55ml
Acrylamide/bisacrylami 1.5 ml 1.87ml 2.5ml 3ml 3.75ml
de mix
1.5M Tris pH=8.8 2.5ml 2.5ml 2.5ml 2.5ml 2.5ml
10% w/v SDS 0.1ml 0.1ml 0.1ml 0.1ml 0.1ml
10% w/v APS 0.1ml 0.1m] 0.1ml 0.1ml 0.1m]
TEMED 0.008ml 0.008ml 0.008ml 0.008ml 0.008ml  
Table 2.6 List of substrates for a polyacrylamide gel of given percentage.
SDSpolyacrylamide stacking gel
 
   
Water 7.225 ml
Acrylamide/bisacrylamide mix 1.275 ml
1M Tris pH=6.8 1.25ml
10% w/v SDS 0.1ml
10% w/v APS 0.1ml
TEMED 0.01ml  
Table 2.7 List of substrates for stacking a polyacrylamidegel.
A 0.75mmthick separating gel was poured and overlaid with Iml of water. After 30
minutes water was removed,the stacking gel was poured onthe top of the separating
gel and the 10-well comb was immediately inserted between the plates into the
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stacking gel. The gel was allowed to polymerase for one hourprior to use. Typically,
electrophoresis was carried out at 200mV. The plates were subsequently
disassembled and the gel was placed on a Hybond ECL nitrocellulose membrane
(pre-soaked in the transfer buffer), the gel and the membrane were placed between
two 3mm Whatman paper sheets and two sponges; air bubbles were carefully
removed from this “sandwich”. Then the “sandwich”wasplaced into the tank next to
the frozen cooling block, filled with the transfer buffer and transferred for | hourat
100mV. The membrane was removed, stained with ponceau S for Imin, excess dye
washed away with water and the membrane wascut into regular strips according to
the molecular mass marker bands corresponding to the MW ofproteins ofinterest.
The membraneswere distained in PBS/Tweenandtransferred into 5% w/v blocking
milk dissolved in PBS/Tweenfor at least 1 hour to block places on the membrane
that could unspecifically bind antibodies, thus increasing the background.
Immunoblotting
Immunoblotting is a technique based on a specific recognition of the epitope by the
antibody. Antibodies, which allow specific recognition of a given amino acid
sequenceofthe protein of interest, are commercially available and were usedin this
study (Table 2.5). Procedure of protein detection with specific antibodies is described
below. Membranes prepaired as described above, were placed in 5% blocking
solution with primary antibody and agitated for 1 hour at room temperature. The
primary antibody solution was then removed and the membrane washed with
PBS/Tween for three times for every 10 minutes. Secondary antibody diluted
(Amersham Biosciences anti mouse 1:2500, anti rabbit 1:4000, Jackson anti-goat
1:20,000) in 5% blocking solution was added to the membranes and incubated for |
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hour at room temperature. The secondary antibody solution was then removed and
the blot was re-washedas above.
Detection of western blot signals
The secondary antibody is conjugated to an enzyme, peroxidase which is capable of
catalysing reaction resulting in production oflight. It recognizes the Fc fragment of
the primary antibody. The western blot was developed using western lightning
chemiluminescence reagent plus. Equal volumes of the enhanced luminal and
oxidising reagents were combined and vortexed. The solution was subsequently
applied to the membrane and incubated for 1 min. The membrane was then dried
gently on a tissue and placed between two layers of clingfilm. Luminescence was
detected on a Kodak Image Station 4000mmand savedas jpg files.
2.17 Dual luciferase reporter assay (Promega)
p53 activity can be studied using luciferase reporter system. The pp53-TA-Luc
vector, uesd here, contains a firefly (Photuris lucicrescens, a beetle producing
luminescence) luciferase gene. Luciferase is an enzyme, capable of emitting light
which can be detected. Expression of luciferase from the pp53-TA-Luc vector is
controlled by the herpes simplex virus thymidine kinase promoter and a p53 response
element composed of the part of the putative replication origin of the human
ribosomalgene cluster and a p53-binding consensus sequence.
The second reporter vector, pRL-TK, was used in the assay. It encodesa luciferase
gene from Renilla reniformis (a polyp forming anthozoan animalliving in the sea),
controlled by the herpes simplex virus thymidine kinase promoter. Renilla luciferase
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activity is independent of p53 and is detected independently of the firefly luciferase
used in the sameassay, therefore it serves as a internal control.
The assay was performed according to the manufacturer’s manual using the GloMax
20/20 Luminometer.
2.18 Transfection of plasmid DNA intocells
Transient transfection procedure aims at introduction of DNA into cells. For this
purpose the cells were seeded in 6-well plates at density leading to subconfluency
after 48h of incubation at 37°C. 24 hours after seeding the cells were transfected with
Gene juice [ul] : vector DNA [pg] at a ratio of 3: 1 ([2.5:1] in BJ fibroblests)
according to the manufacturer’s protocol. Typically, of 1.2ug of the pp53-TA-Luc
vector expressing luciferase and 0.2ug of the pRL-TK vector expressing renilla
(when transfection was performed for the purpose of a subsequent luciferase assay),
0.3ug of the pSUPER vector expressing GFP as internal controls, 0.02ug pCEP-p53
vector expressing p53 (0.04ug in BJ fibriblasts), 0.06,1g of pCMV-neo-bam-MDM2
vector expressing MDM2 (0.04ug in BJ fibroblasts) and 3pg of pCEP-NME
expressing NME1 or NME2wastransfected per one well of the six well plate. Where
indicated, larger amounts of MDM2 and p53 vectors were used.
2.19 Transfection of siRNA into cells
Introduction of specific siRNAs (small interfering RNAs) into cells results in a
transient “knockdown” of gene expression. siRNAs target mRNAofthe particular
gene for degradation, which results in downregulation of its expression. For this
purpose cells were seeded in 6-well plates or 10cm dishes at density leading to
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subconfluency after 72h of incubation. 24 hours after seeding the cells were
transfected with Lipofectamine 2000 (4p1 per each well). 80 pmoles of siRNA
(40nM concentration) was used for each well of the six-well plate. The procedure
wascarried out according to the manufacturer’s protocol.
6 hours after transfection (depending on the purpose of the experiment and thecell
line), the media were replaced to avoid the cell stress and death caused by toxic
properties of the transfection reagent. 48 hours after transfection the cells were
washed with PBS, three wells of each plate were harvested for further applications
by adding 0.5ml of trypsin-EDTA solution into each well of the 6-well plate. After
cell detachment, trypsin was neutralized using media with 10% FBSandthe cell
suspension was collected. Depending on the subsequent application, the cell were
counted (using the Beckman coulter counter) and seeded or centrifuged for 5 min. at
300g. After centrifugation the pellet was washed with PBS, centrifuged again and
frozen for protein analysis by western blotting.
2.20 Boyden chamber motility assay
Boyden chamber motility assay measurestheintrinsic ability of cells to migrate. The
bottom of the chamber, used in this experiment, contains a porous membrane (pore
size 8um) which serves as barrier for the non-motile cells. Motile cells, however,
actively move through the pores to the other side of the membrane and can be
quantified upon fixing andstaining.
Optimization of seeding density
600ul of media was added to the wells of the 24-well companion plate and the
Boyden chamber inserts were placed into the wells. Cells were harvested as
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described in Section 2.18, and counted. 5,000, 10,000, 15,000 and 50,000 cells was
seeded in the volume of 300ul into the Boyden chambers inserted into the
companion plate and placed immediately in the incubator for 18h. Then, the cells
were carefully wiped of the inner side of the chamber using cotton swabs, washed in
PBS, fixed and stained using the REASTAIN kit according to the manufacturer’s
protocol. Subsequently, the membrane was cut off the chamber, placed on the
microscopic slide on a drop of the DPX mounting solution, overlaid with another
drop of DPX and covered with a coverslip.
The cells were counted on the microscope; a grid was drawn on the coverslip if
necessary. The seeding density yielding approx. 1,000-10,000 cells that migrated
through the membraneofthe chamberwasused in subsequent experiments.
Motility assay
The cells were grown in culture for at least 48h in triplicates, harvested, counted and
the experiment wascarried outessentially as described above.
2.21 Characterization of the cell-based RCC tumour progression
model and cell lines spontaneously over-expressing p53 and
MDM2
Several years ago, members of our research group proposed and attempted to
generate a cellular model of RCC tumour progression. It was based on the
observation, that high levels of p53 correlate with intermediate prognosis and
upregulation of both p53 and MDM2is correlated with poor outcome in RCC
patients (Haitel et al., 2000). Preliminary experiments have shownthatcells failed to
express high levels of wt p53. It has therefore been concluded, that upregulated p53
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in RCC may be mutated. Preliminary results have also confirmed the observation
made by Haitel et al. in a clinical study, that MDM2is rarely upregulated in tumour
samples harbouring low levels of p53; no cell lines overexpressing MDM2alone
have been generated. This finding also suggests that RCC cells do not tolerate high
levels of MDM2.
Totest if cell lines overexpressing mutant p53 (it has been assumedthat the levels of
p53 in RCC are high because of the mutation) tolerate high levels of MDM2,a series
of stabile transfections have been performed. For this experiment, UOK 117 RCC
cell line, expressing low levels of endogenous wt p53 and MDM2proteins has been
selected. Cells have first been transfected with DNp53 (dominant negative mutant of
p53 RI75H), pCEP vector as a control and subsequently selected for stabile
transfectants. Several clones have been obtained andthese cells expressed high levels
of DNp53. Subsequently, to test if expression of the mutated p53 allowsthecells to
over-express MDM2 (which wouldreflect the situation in RCC described by Heitel
et al.) the DNp53, as well as pCEP vector control clones have been subject to second
round oftransfections with either MDM2 or pCMV-neo-bam vector as a control and
selected for stabile transfectants. Clones expressing high levels of MDM2 and
DNp53 have now beenidentified. Interestingly, after second round of cloning, some
clones overexpressing MDM2 could be found on plates where MDM2 has been
transfected in to the pCEP control cells. However, unexpectedly, also some clones
from double empty vector control transfections, spontaneously started to express
MDM2. Most interestingly, these clones also over-expressed p53 which further
supported the notion, that high levels of MDM2are dependent on upregulation of (as
it wasinitially presumed, mutated) p53.
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3 Results
3.1 Identification of MDM2 binding proteins in RCC cells using a
yeast two-hybrid system
3.1.1 Introduction to the yeast-two hybrid system
Over-expression of MDM2in RCCcorrelates with poor outcome (see Section 1.4)
and the basis of the activity of MDM2 which promotes tumour aggressiveness is
unknown. The aim of this project was the elucidation of the MDM2-mediated
mechanism responsible for promoting tumour progression. Since all of the known
functions of MDM2 are mediated via protein-protein interactions, it is likely that
MDM2contributes to poor outcome in RCCpatients by binding to other proteins. It
was hypothesized that MDM2binding resulting in altered function/s of the target
protein/s would contribute to aggressiveness of renal tumours. Therefore, this project
aimed at the identification of proteins interacting with MDM2 in RCCcells. To
achieve this, a cDNAlibrary was constructed from an RCCcell line and transformed
into yeast and a yeast two-hybrid screen for MDM2 interacting proteins was
performed (see Section 3.1.3).
The yeast two-hybrid system allows detection of interactions between two proteins
that are fused to either the DNA binding or activation domain of the Gal4
transcription factor (see Diagram 2.1). Interaction is manifested by activation of
marker genes that enable auxotrophic yeast cells to grow on selective media. The
yeast two-hybrid method, unlike various in vitro techniques, provides the opportunity
of investigating proteins synthesized and folded under natural conditions in a
eukaryotic cell.
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Overview of the strategy for the yeast two hybrid screen
In order to perform the screen for the MDM2 binding proteins, a construct
expressing MDM2asa fusion with the Gal4 DNA binding domain wastransformed
into an appropriate yeast strain (a mating partner for the strain to be used to express
the cDNAlibrary). Then, the cDNAlibrary had to be constructed in the appropriate
yeast cells using mRNA from the 786-0 RCC cell line (for a description of the
reasons for choosing this line see 4.1). Subsequently, the MDM2- and library-
expressing yeast strains were mated and selected for clones expressing the library
protein interacting with MDM2. cDNAsencoding the putative MDM2 interacting
proteins selected in the screen were then identified by sequencing.
3.1.2 The yeast two hybrid screen
3.1.2.1 Construction of the cDNA library
Preparation of mRNA for cDNA synthesis
To construct the cDNA library, total RNA wasextracted from 786-0 cells. Based on
absorbance measurements at 260nm and 280nm,the calculated concentration of the
sample was 6.24ug/ul, the total yield was 1.56mg with an Ad2eo280 =2.00.
Contamination with DNA (A260/280 ratio of pure DNA is expected to be around 1.8),
proteins or phenol decreases the A260/280 ratio of the RNA sampleas these substances
absorb light of longer wavelength than RNA.Therefore, the RNA sample is regarded
as pure, when the A2eogo ratio is between 2 and 2.1. The obtained results then
suggest that the RNA was not contaminated with substantial amounts of protein,
phenol or DNA (Wilfingeret al., 1997 506).
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Subsequently, mRNA was purified from 240ug of total RNA prepared as described
in Section 2.8. The resulting mRNApurification procedure yielded 42.1ug mRNAat
a concentration of 0.134,1g/ul which constitutes 2.7% of the total RNA. The A2¢60/280
ratio of 2.03 again suggested that the mRNA sample was not contaminated with
substantial amounts of protein, phenol or DNA.
This mRNA wasthen used to produce a cDNAlibrary for the yeast 2-hybrid screen.
The presence of mRNAandalso the presence of the 18S and 28S rRNA bands in
total cellular RNA wasverified using native agarose gel electrophoresis (Figure 3.1).
The quality (degree of degradation) of RNA was evaluated by comparison of the
intensities of the 18S and 28S rRNA bands. Since the 28S molecule is nearly 2.4
times longer (4.5kb vs 1.9kb) than 18S rRNA (Sobkiewicz and Twardowski, 1998),
it is approximately 2.4 times more likely that randomly distributed endonuclease
cleavage events would occur within it and would result in decreased intensity of the
28S band compared with 18S rRNA on the agarose gel. Therefore it is generally
accepted that the ratio lower than 2:1 of 28S to 18S rRNA indicates degradation
(Wang, 2005). There is a significant difference of intensity between the 28S and 18S
rRNA bands(at least 2:1) which can be seen on the native agarose gel (lanes 3 and
4), suggesting that RNA was not degraded. mRNA appears as a smear onthe gel.
Note that traces of 28S and 18S rRNA seem to be present in the mRNA sample.
However, the intensity of the rRNA appears to be several times lowerin the purified
mRNAthanin the total RNA suggesting high enrichment of mRNA.
The degree of RNA degradation was further examined using denaturing agarose gel
electrophoresis. An advantage of this approach is that denaturation disrupts the
secondary andtertiary structures formed by rRNA (Streit et al., 2009). Since RNA
forms complex three-dimensional structures which stabilise the folded molecule,
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electrophoresis under native conditions may not reveal degradation of RNA, because
even degraded RNAcanstill retain intact 3D structures due to the presence of weak
bonds. Denaturation leads to linearization of RNA molecules and if degradation is
present, it can be evaluated by comparison of the intensities of the 18S and 28S
rRNA bands. Denaturing agarose gel electrophoresis (Figure 3.2) further confirms
that the RNA is not degraded,as the ratio of 28S to 18S rRNA (lane 3, 5g of total
RNA loaded) wasestimated to be at least 2:1. The mRNA smearis hardly visible on
this denaturing agarose gel. However, under denaturing conditions, formation of
dsRNA and, as a result, intercalation of ethidium bromide into the double stranded
nucleic acids (thus, also fluorescence) is greatly reduced. Therefore, bands and
smears composed of less abundant molecules, unlike bands composed of 18S and
28S rRNA’s (which are very abundant in the cell), may not be readily visualized.
Therefore the absence of a visible smear does not mean that mRNA is degraded or
absent in the sample,it rather suggests that sensitivity of this technique or UV source
used for visualization of RNA, is not sensitive or powerful enough to allow
visualization of mRNA.
cDNAsynthesis and library construction
cDNAsynthesis is the process of generating DNA from an RNA template. Reverse
transcriptase, an enzymeofretroviral origin that possesses an RNA directed DNA
polymeraseactivity is used in this reaction. For the purpose of generating cDNA for
the recombination steps involved in library construction, mRNA extracted from 786-
0 cells was used for the first strand synthesis and was subsequently amplified by LD-
PCR (long distance PCR, performed according to the Matchmaker Library
Construction and Screening Kit manual) using primers specifically designed to allow
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homologous recombination with the yeast vector pGADT7-Rec. The image shown in
Figure 3.3 confirms the presence of amplified cDNA in the sample and the smear
visible on the gel represents molecules of different sizes with an apparent average
length of approximately 0.5-1kb. In the process of transformation, amplified cDNA
and the linearized pGADT7-Recvector are taken up by the competent yeast cells and
recombination is carried out inside the yeast cells by cellular recombinases
(Birnboim and Doly, 1979). Subsequent plating of the cells on —Leu DO agarPetri
dishes allowsselection for clones containing the circularized (circularization usually
occurs by homologous recombination with the library cDNA) vector as shownin the
Figure 3.4.
To evaluate the transformation efficiency (to ensure that the transformation
efficiency wasat least 1 x 10° per 3yg of the vector in order to provide a diverse and
representative source of cDNA for the subsequent yeast 2-hybrid screen), a series of
dilutions of the transformation reaction was performed. The recommended
transformation efficiency had been experimentally determined by the manufacturer
of the kit and the number of 10° appears to provide sufficiently high diversity of
cDNA species in the library. Table 3.1 presents data regarding the actual
transformation efficiency obtained, calculated from three different dilutions of the
transformation reaction. The transformation efficiency thus determined was1-2 x 10°
clones per Iug of pGADT7-Rec vector (in total 3,1g of the vector was used for the
library construction) based on the numberof clones obtained on the —Leu DO agar
medium. The lowest dilution, and therefore the highest number of colonies, is the
least biased, therefore it is likely that the numberof clones in the library per lg of
plasmid DNA wasaround 1.8 x 10°. This constituted an expected numberofatleast
10° independentclonesin thelibrary.
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Figure 3.1
DNAmarker mRNA Total RNA Control
(1kb ladder) 0,5 ppg RP lpg tore RNA
Hg
mRNA
1,6 kb
+— 28S rRNA
1 kb
+— 18SrRNA
0,5 kb
 
Native 1.2%agarose gel electrophoresis of RNA. mRNA appears as a
smearin lane 2, next to the marker. Two strong bands corresponding to the 18S and
28S rRNAcanbe seen in lanes 3 and 4 where the total RNA samples were loaded.
Notethat traces of 28S and 18S rRNAseem to be present in the mRNA sample.
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1kb ladder lug Sug lug totRNA 2ugLoi
 
      
+—— 28S rRNA
2kb———— +«— 18S rRNA
1kb ————>
Figure 3.2 Denaturing 1.2% agarose gel electrophoresis of mRNA and total
RNA. lpg of mRNA,Sug of total RNA, Ipg of total RNA and 21g of a controltotal
RNAwereseparated on the denaturing gel. Bands corresponding to the 18S and 28S
rRNAareindicated.
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DNA marker Amplified cDNAlkb ladder
Amplified
cDNA
1,6kb ———___»
Ikb ———»
0.5 kb —————_»
 
Figure 3.3 Native agarose gel electrophoresis of amplified cDNA for library
construction. 7yl of the LD-PCR (long distance PCR) reaction (performed
according to the Matchmaker Library Construction and Screening Kit manual) was
loaded onto a 1.2% native agarose gel to visualise the products from the PCR
reaction. lug of the DNA ladder marker was loaded on the gel; the 1.6kb band ofthe
marker contains 100ng of DNA.
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Figure 3.4 Construction of the library. The Figure presents several steps leading to
generation of the library: RNA extraction from cells is followed by the first strand
synthesis, long distance PCR which yields amplified cDNA for recombination with
the library vector during the process of transformation into the yeast cells. The yeast
clones which carry the library plasmids are selected on the —Leu DO plates,
harvested, pooled andstored at -80°C.
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 Dilution of the No.of Transformation efficiency
library suspension clones (No.of clones/pg of pGADT7-Rec)
1:100 180 1,.8 x 10°
1:1,000 12 1.2x 10°
1:10,000 1 1.0 x 10°     
Table 3.1 Library transformation efficiency. The Table summarizes a series of
dilutions performed in orderto estimate the efficiency of transformation. The library
suspension (total volume of 30ml) was diluted as shown in the first column and
plated on the -Leu DO media. The third column showstransformation efficiency
presented as a numberofclones per one pg of plasmid DNA (outof 3g ofthe total
amount of the pGADT7-Rec vector used here) calculated based on the number of
colonies (second columns) that grew on —Leu DOagarplates inoculated with the
transformation mixture diluted as indicated in the first column.
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3.1.2.2 Identification of putative MDM2interacting proteins expressed in RCC
cells
cDNAsfrom 722 clones obtained in the yeast two-hybrid screen were amplified by
PCR, 178 of them were sequenced and identified using BLASTn (NCBI website).
Out of 30 different sequencesidentified in the screen, 14 appeared to be presentin a
correct reading frame, 11 were out of frame and 5 corresponded to non-coding
sequences. The screen reconfirmed previously described interactions of MDM2 with:
ribosomal proteins L5, $7, L11, L26 and a transcription factor E2F1 which suggests
that the technique reliably identified MDM2 interacting proteins. Several novel
putative MDM2interacting proteins werealso identified.
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Protein name Numberof
clones identified
Numberof clones in a
correct reading
frame/numberof clones
tested
 
Activating signal cointegrator |
complex subunit 2
Adhesion regulating molecule 1,
transcript variant 2
Cyclophylin G
Cytochromec, somatic
DnaJ(Hsp 40) homolog
E2F1
Generaltranscription factor IIF
H2A histone family, member Z
Hipothetical protein MGCGI1
LI
L3
L11
L12
L26
L27
L31
L36, L36-like, similar to L36a
Lectin, mannose-binding-2
Mitochondrial genomic sequence
NME2   
Non-coding sequence
0/1
0/1
1/1
0/1
2/2
1/1
0/1
3/3
1/1
0/2
2/2
1/1
Ev)
0/2
3/3
10/10
0/1
Non-coding sequence
0/2  
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Peptidase alpha (mitochondrial
processing)
Pseudouridilate synthase-like |
S7
$23
$25
S27a
Small ribonucleoprotein D2
polypeptide transcript variant |
Thioredoxin reductase 2
Ubiquinol-cytochrome c
reductase complex,transcript
variant |
Y box protein  
a7
 
Non-coding sequence
0/1
7/7
2/2
3/3
1/1
Non-coding sequence
0/1
0/1
Non-coding sequence  
Table 3.2 Putative MDM2interacting proteins identified in the yeast two-hybrid
screen. The Table summarizes the screen results with clones listed in alphabetical
order. The middle column shows the numberof clones obtained in the screen and the
right-hand column shows the numberofclones that proved to be in a correct reading
frame with the activation domain of the Gal4 transcription factor expressed as a
fraction of the total number of clones checked for in-frame compatibility with the
pGADT7-Recvector.
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3.1.3 Re-testing of the NME2 interaction with MDM2and the B-galactosidase
assay confirm screen results
Two clones encoding the NME2 protein were identified in the yeast two-hybrid
screen. NME2 was chosen for further analysis because it was independently
identified as an MDM2interacting protein in our laboratory using a proteomic
approach - NME2present in the HEK293cell lysate, appeared to bind to His-tagged
MDM2 coating the nickel-sepharose column (Dr Maria Maguire, unpublished
results). However, at the time whenthis decision was taken, it was not apparentthat
both NME2clones identified in the screen were not recombined with the pGADT7-
Rec vector in a correct reading frame, therefore potentially producing a false positive
result. However, published data suggest that an out of frame construct may produce a
protein of a correct amino acid sequence. This issue will be discussed more
extensively in Section 4.2. To authenticate the screen result, the MDM2 — NME2
interaction was retested in yeast with full length NME2. cDNA of an orthologous,
highly related gene (encoding a protein exhibiting 88% aminoacid identity), NMEJ,
wasalso cloned into the pGADT7vector andtested.
The yeast two-hybrid assay measuresthe ability of two proteins to interact with each
other in the yeast system. A positive result is manifested by yeast growth and
activation of reporter genes; MELI (encoding a-galactosidase degrading the X-
a—gal to a blue product which is detected on the X-a-gal agar plates) and [-
galactosidase (used for quantitative analysis of the strength of the interaction in the
B-galactosidase assay). As Figure 3.5 shows, NME2 interacts with MDM2inthis
system. Although yeast clones expressing the NME2 and MDM2fusions grew much
slower than the p53 and Large T expressing yeast (used as a positive control for
protein-protein interaction), the colonies and adjacent agar medium (supplemented
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with X-a-gal) appeared blue, suggesting that a sufficiently strong interaction
occurred between NME2 and MDM2to activate the MELI reporter gene. Figure 3.5
also shows, that NME1 did not detectably interact with MDM2as no growth could
be observed in yeast expressing these proteins. These results suggest that NME2
interacts with MDM2in yeast, and that this interaction is highly specific, since the
highly homologous NME1I protein (see Figure 4.2) did not give a positive signal in
the yeast two-hybrid assay.
The PB-galactosidase assay, which measures the activity of the second reporter
gene, B-galactosidase (due to its ability to degrade X—B—gal to a product which can
be colorimetrically assayed) revealed that the NME2-MDM2interaction leads to
induction of the B-galactosidase activity by nearly three-fold compared to the yeast
lysate control. However, it does not appear to be as active as the positive control
(Large T - p53) which induced the activity of the B-galactosidase by ten-fold
compared to the yeast lysate control. Thus, the B-galactosidase assay further supports
the results obtained on the plate and showsactivation of an additional, to MELI,
reporter gene as a result of the NME2-MDM2interaction, as well as yielding
quantitative results.
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Figure 3.5 The yeast two-hybrid assay for interactions of MDM2 with NME1
and NME2showsthat NME2,but not NME1interacts with MDM2. TheFigure
shows yeast cells plated on QDO agar media supplemented with X-a-gal. The
interaction between NME2/NMEI and MDM?wastested in this experiment. Growth
and blue colour indicate that there is an interaction between NME2 and MDM2and
the positive control of p53 and LargeT. In contrast, neither the control nor the
NMEI1-MDM2pairs appeared to promote yeast growth andactivate the reporter gene
in this assay.
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Figure 3.6 B-galactosidase assay of the NME2-MDM2interaction. f-galactosidase
assay demonstrates that NME2interacts with MDM2in yeast. The Figure shows B-
galactosidase activity in cell lysates obtained following a yeast two-hybrid assay for
NME2interaction with MDM2and for p53 interaction with Large T antigen for
comparison asa positive control. The lysate from mated AH109 and Y187 yeast was
used as a negative control. 1 unit of B-galactosidase catalyses hydrolysis of 1umol of
ONPG(ortho-Nitrophenyl-f-galactoside) per minute at pH=7.5 at 37°C.
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3.1.4 Functional assays reveal that NME2 regulates the activity of p53
The yeast two-hybrid system is a sensitive technique that allows high throughput
screening. It also serves as a useful tool for testing and analysis of protein-protein
interactions, yielding quantitative results when the f-galactosidase assay is
performed.
There are, however, several drawbacks of this system. Cytoplasmic and trans-
membraneproteins may not adopt a proper conformation in the nuclear environment.
Several post-translational modifications determining conformation and functionality
of proteins in higher eukaryotes may be different in yeast. Hence, false positive and
negative results do occur. Therefore, yeast two-hybrid results should be confirmed
using other methods such as in vitro binding assays, coIP or a mammalian two-
hybrid assay to increase confidence that the interaction detected in yeast is real. A
good wayofverifying the interaction may be a functional assay which depends on
protein-protein interactions. One way to perform a functional assay is co-over-
expression of two or more proteins in cells and subsequent observation if their levels
or functions change in comparison with control samples.
The mostsensitive assay reflecting changesin the activity of MDM2available in our
laboratory, is a luciferase assay which measuresthe activity of p53. This assay, along
with protein analysis by western blotting, was used in the following series of
transfection experiments in order to determine functional consequences ofthe
NME2-MDM2interaction.
NME2, together with p53 and MDM?weretransfected into three differentcell lines:
H1299 (non small cell lung cancer, p53-null cell line), MCF-7 (breast cancer cell
line, p53 wt) and BJ-fibroblasts (human fibroblasts). These cells were chosen for
transfection because they are either p53-null (H1299) and therefore suitable for
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experiments using exogenous p53; or expressing wt p53 (MCF-7 and BJ-fibroblasts)
allowing evaluation of the effects of transfected NME2 onthe levels/activity of the
endogenousprotein. Additionally, this selection allowed use of already optimised
transfection protocols, as these cell lines are commonly used in our laboratory. The
added benefit of using BJ fibroblasts was the possibility of testing of the functional
consequences of the NME2-MDM2interaction in non-cancercells. To evaluate the
influence of NME2 onthe activity of p53 and MDM2, NME2 wasco-transfected
with p53 and MDM2(according to the protocol described in Section 2.17). The
activity of p53 was measured using the luciferase assay and protein levels analysed
by western blotting.
The experiments show that transfection of NME2 leads to a decrease in p53
transcriptional activity in the absence of exogenously expressed MDM2 and
augments the decrease of p53 activity in the presence of exogenously expressed
MDM2inall three tested cell lines (Figures 3.7, 3.8, 3.9). The activity of the
endogenously expressed p53 does not seem to be affected in MCF-7 cells (Figure
3.8), however, NME2 expression appears to reduce theactivity of endogenous p53 in
BJ fibroblasts (Figure 3.9).
Western blot analysis shows that, although the NME2-dependent reduction of the
activity of p53 is not accompanied by reduction in p53 levels, NME2 seemsto have
an effect on the MDM2-dependentpost-translational modification of p53 (intensity
of the ladder of more slowly migrating forms of p53 decreases upon co-transfection
with NME2) in H1299 (Figure 3.7) and MCF-7 (Figure 3.8). The blot for MDM2
indicates that NME2 mayhave an effect on the steady state level of MDM2 which
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seems to be lower in the sample co-transfected with NME2 than for the sample
without NME2.
The results therefore suggest that NME2 mayhave pleiotropic effects on the p53-
MDM2networkas it reduces the activity of p53 in both presence and absence of
exogenously expressed MDM2, changes the MDM2-dependentpost-translational
modifications ofp53 and, potentially, also reduces the level of MDM2.
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Figure 3.7 NME2 decreases the activity of p53 and the intensity of the post-
translational modification of p53. The H1299 cells were seeded into six-well plates
and after 24h transfected with 0.02ug of pCEP-p53, 0.06ug of pCMV-neo-bam-
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MDM2, 3ug of pCEP-NME2 and 0.3ug of pSUPER-GFPper one well of the six-
well plate in triplicates, using Genejuice as a transfection reagent at a ratio of
Genejuice to DNA 3:1 (the procedure described in Section 2.18). Note that small
amounts of the p53 and MDM2plasmid DNA were used compared with the amount
of NME2in order to avoid apoptosis in transfected cells and to guarantee sensitivity
of the system (the effect of NME2 on the activity of p53 could be less obvious if
large amounts of p53 were used; additionally, larger amounts of MDM2 would lead
to significantly more decreased activity of p53 so that further suppression due to the
action of NME2 would not be detectable). 24h after transfection, cells from three
wells (of the 6-well plate) were harvested for protein analysis by western blotting and
cells from the remaining three wells were lysed for the luciferase assay. a) Histogram
shows the results of the dual luciferase reporter assays of the activity of p53
performed in the H1299 cells. The activity of luciferase or renilla was measured in
the cell lysates (method described in Section 2.17) as indicated, normalised to protein
concentration and the mean of three replicates +/- s.e.m is presented on the
histogram as RLU(relative light units). b) Western blot analysis of transfected
samples show main bands of p53 and its modified forms, MDM2 and NME2.Actin
wasused as a loading control and GFPindicates transfection efficiency.
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Figure 3.8 NME2 decreases p53 activity in the MCF-7 cell line. The MCF-7 cells
were seeded into six-well plates and after 24h transfected, harvested and assayed by
western blotting and subject the luciferase assay as described previously (see legend
for the Figure 3.7)
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Figure 3.9 Titration of NME2 in BJ fibroblasts shows the dose-dependent
decrease of p53 activity. In this experiment, NME2 wastitrated in the presence and
absence of exogenously expressed MDM2 andthe activity of both transfected and
endogenous p53 was measured. BJ-fibroblasts were seeded into six-well plates and
after 24h transfected with 0.04ug of pCEP-p53, 0.04ug of pCMV-neo-bam-MDM2
and 0.3ug, lug and 3ug of pCEP-NME2 per one well of the six-well plate in
triplicates, using Genejuice as a transfection reagent at a ratio of Genejuice to DNA
2.5:1 (according to the procedure described in Section 2.18). All subsequent steps
were carried out essentially as described in the legend for the Figure 3.7.
Note that no western blot control was performed,as the transfection efficiency of BJ
fibroblasts is no higher than 1% as determined by the in situ B-galactosidase assay
and thus the endogenous levels of the proteins mask the signal coming from the
transfected protein.
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3.1.5 The ability of NME2to reducethe activity of p53 is not dependentonits
kinase activity
NMEproteins predominantly function as nucleoside diphosphate kinases (reviewed
in Lacombeet al., 2000) and this function could be vital for NME2 to be able to
reduce the activity of p53. To investigate whether reduction of the activity of p53
upon NME2transfection is dependent on the kinase activity of NME2, a HI18F
kinase mutant (described in Postel et al., 1996) was constructed and tested.
Additionally, another mutant, K12Q (K12Q mutation abolishes all known functions
of NME2(Postelet al., 2002), was also constructed andtested in these experiments.
Wtprotein and the kinase mutant (H118F) of NME2decrease the activity of p53 in
the presence and absence of exogenously expressed MDM2 as shownin Figure
3.10a. The ability of the “total loss of function” NME2 mutant (K12Q) to reduce the
activity of transfected p53 appears to be only slightly compromised suggesting that
none of the other previously identified activities of NME2 determine this effect and
this is compatible with a requirementfor direct protein-protein interaction to mediate
the effect of NME2 on p53. The western blot (Figure 3.10b) shows that the
transfection efficiency between the samples and the expression level of MDM2, p53
and NME2proteins are essentially even. Theresult therefore suggests that the kinase
activity ofNME2is dispensable for the ability of NME2to inhibit p53.
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Figure 3.10 The effect of mutant-NME2proteins on the activity of p53. The
experiment was performed andthe data are presented essentially as described in the
legend for the Figure 3.7 and presents the luciferase assay (a) and western blot
analysis (b).
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3.1.6 NME1 and NME2inhibit the activity of p53 but differentially regulate
the levels of MDM2
NME2shares 88% homologyat the protein level with its ortholog, NMEI (Figure
4.1). Since NME2 but not NMEI interacted with MDM2 in yeast, the ability of
NMEI to negatively regulate the activity of p53 was examined in BJ fibroblasts
(Figure 3.1 1a) and in p53/MDM2-double null (Mdm2™, p53”) MEFs(Figure 3.1 1b)
using the luciferase assay. BJ fibroblasts (3.1 1a) proved to be a reliable non-cancer
cell line for studying the effects of NME2 on the activity of p53 (Figure 3.9) and
therefore these have also been used to study the effect of NMEI on the activity of
p53. Additionally, as it was shown that NME2 reducedtheactivity of p53 in absence
of exogenously expressed MDM2 (Section 3.1.4), it was notclear if this effect was
mediated through the action of the endogenously expressed MDM2, or MDM2-
independently. There are detectable levels of endogenously expressed MDM2
present in H1299, MCF-7 and BJ-fibroblastcells and it is possible, that NME2 could
act through them to decrease the activity of p53. Thus a major advantage of using the
double null MEFs wasthe possibility to determine whether the NME2 (and possibly
NME1) mediated suppression ofthe activity of p53 depends on MDM2protein.
The results of the experiment shown in Figure 3.11 demonstrate that NMEI co-
transfected with p53 leads to a reduction of the activity of p53 to a similar extent to
that observed for NME2 (Figure 3.1 1a). Moreover, (as Figure 3.11b illustrates) the
experiment performed in double null MEFs showsthat in absence of MDM2both
NMEI and NME2are capable of reducing the activity of p53. The results therefore
suggest that p53 inhibition is an MDM2-independent property of NMEI and NME2
and that the protein sequence differences between NME1 and NME2 do notaffect
their ability to suppress p53 transcriptionalactivity.
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Previous experiments (see Section 3.1.4, Figures 3.7 and 3.8) suggested a possible
effect of NME2 onthe levels of the MDM2protein. To investigate this issue, NME1,
NME2,and the K12Q mutant ofNME2 were co-transfected with MDM2into H1299
cells. NME2 appears to down-regulate expression of MDM2andthe decrease of
MDM2levels does not occur when NME1is co-expressed with MDM2 (Figure
3.12). The K12Q mutant appears to promote an intermediate level of MDM2protein
and thus it appears that this mutant of NME decreases the level of MDM2less
efficiently than the wt protein. The results suggest that unlike NME1, NME2 could
be involved in regulating MDM2steadystate levels.
115
Results
 
 
 
   
  
  
  
  
 
  
 
 
a)
30000
25000 - ~G@ Luciferase
20000 - @ Renilla
=|Z 15000
10000
5000 +
0 4
S @ N\ ivé < « «& oo s SS
ss 9 S SQrs Q Q
b)
450000
400000
350000
300000 +
3 250000 + B Luciferase
© 200000 + ® Renilla  
150000 ;
100000 ;
50000 + 0-
% wv fs \ wy VveS w W& w w
a wl & we Sog Fw R JW g
¢ ¢
Figure 3.11 Comparison of the ability of NME1 and NME2 to decrease the
activity of p53 in normal cells and in the MDM2-null background. In this
experiment, the ability of NMEI and NME2to reduce the activity of p53 in BJ
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fibroblasts (a) and p53/MDM2-double null (Mdm2”, p53”) MEFs (b) was
compared. The BJ fibroblasts and MEFscells were seeded into six-well plates and
after 24h transfected with 0.02ug of pCEP-p53, 0.06ug of pCMV-neo-bam-MDM2
(b only) and 3ug of pCEP-NME2per one well of the six-well plate in triplicates as
indicated, using Genejuice as a transfection reagent at a ratio of Genejuice to DNA
2.5: 1 (the procedure described in Section 2.18). All subsequent steps were carried
out essentially as described in the legend for the Figure 3.7. Note that no western blot
control was performed,as the transfection efficiency of fibroblasts is no higher than
1% as determined by the in situ B-galactosidase assay and thus the endogenouslevels
of the proteins mask the signal generated by the transfected protein.
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Figure 3.12 NME2 downregulates MDM2. The Figure shows westernblot analysis
of H1299 cells transfected with MDM2 and NMEs. The H1299 cells were seeded
into six-well plates and after 24h transfected with 0.5.1g of pCMV-neo-bam-MDM2,
3ug of pCEP-NME1/2/K12Q and 0.3g of pSUPER-GFP per one well ofthe six-
well plate in triplicates essentially as described in the legend for the Figure 3.7
except, that only western blotting was performed. Note that large amounts of the
MDM2plasmid DNA were used compared with these used previously (see Sections
3.1.4, 3.1.5 and 3.1.6) as it was experimentally defined that higher levels of MDM2
enable better visualization of the NME2-mediated effect than low levels of MDM2.
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3.1.7. The reduction of MDM2 upon co-expression with NME2 is dependent on
the activity of 26S proteasomes, an intact RING-finger of MDM2 and the N-
terminus of NME2
It was previously shown (Figure 3.12) that transfection of NME2led to a decrease in
the MDM2protein levels, however, it remained unclear if this was due to changes in
transcription, translation or stability of MDM2. To determine whether the observed
reduction in MDM2levels was mediated via the proteasomal degradation pathway,
the proteasomeinhibitor MG132 wasusedto inhibit degradation.
As Figure 3.13 shows, NME2-dependent down-regulation of MDM2 appears to be
inhibited by the proteasome inhibitor. Additionally, the K12Q mutation does not
seem to abrogate the ability of NME2 to down-regulate MDM2suggesting that this
is a novel activity of NME2 (as the K12Q mutation has been shownto abrogate all
knownfunctions of NME2 (Postelet al., 2002). Since reduction of the MDM2level
upon co-transfection with NME2 appears to occur via the proteasomal pathway,it
could therefore be hypothesized that this is a result of increased auto-ubiquitylation
of MDM2 (MDM2is known to possess an E3 ubiquitin ligase activity that can
promote auto-ubiquitylation and degradation as described in Section 1.5.4.1.3).
Therefore, a RING-finger mutant of MDM2(whichis unable to auto-ubiquitylate),
or wt MDM2 were co-transfected with NME2 to test if the NME2-dependent
decrease in MDM2 levels is dependent on the activity of the RING domain of
MDM2.Theresults show (Figure 3.14) that the RING-finger mutant of MDM2,
unlike the wt protein, is refractory to both NME2- and NME2-K12Q - induced
down-regulation. NME1 does not appearto influence the level of MDM2suggesting
that reduction of MDM2 levels upon co-expression of NME2 might be a result of
protein-protein interaction dependent on an intact RING-finger domain of MDM2.
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Additionally, as shown on the p53 blot (Figure 3.14), p53 appears to undergo post-
translational modifications which are dependenton the intact RING-finger domain of
MDM2as the RING finger mutant (MDM2-C464A) does not appear to promote, nor
undergo such modifications. The migration pattern of the modified p53 detected on
the western blot suggests poly-modification (attachment of chains of proteins, such
as ubiquitin), or multiple mono-modification (by monomeric modifiers such as
ubiquitin at several different lysine residues) as several different bands of gradually
increasing molecular weight are visible. NME2 orits kinase mutant H118F decrease
the intensity of the fraction of high molecular weight forms of modified p53 (most
likely corresponding to the poly-modified p53) and seem to increase the intensity of
the first few bands of the ladder (which the mostlikely correspond to p53 whichis
mono-modified at a few different residues). This suggests that NME2 could promote
changes in the MDM2-mediated modification of p53 by altering its ability to
promote its poly- or mono-modification. Moreover, the results suggest that the kinase
activity of NME2is dispensable for this process as the H118F mutant of NME2also
leads to changesin the pattern of p53 modification.
In order to establish which part of NME2 is responsible for the NME2-mediated
reduction of the MDM2level, chimeric NME1/2 proteins were generated (Section
2.14) and expressed in H1299 cells. As the majority of differences in the amino acid
sequence between NME1 and NME2are within the N-terminus, the N-terminus of
NME2wassubstituted with the N-terminus of NMEI (1+2). Accordingly, in the
second chimeric protein, the C-teminus of NME2 was substituted with the C-
terminus of NMEI (2+1). The ability of NME2 to decrease the level of MDM2 is
conferred by its N-terminus (Figure 3.15). The chimeric protein 1+2, unlike the 2+]
chimera, does not havethe ability to decrease the level of MDM2.
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Figure 3.13 Inhibition of the 26S proteasome rescues the NME2-mediated
decrease of the levels of MDM2. The Figure shows western blot analysis of H1299
cells transfected with MDM2, NME1, NME2 and NME2-K12Qasindicated. H1299
cells were seeded into six-well plates and after 24h transfected with 0O.5ug of
pCMV-neo-bam-MDM2, 3yug of pCEP-NME1/2/K12Q and 0.3ug of pSUPER-GFP
per one well of the six-well plate essentially as described in the legend for the Figure
3.7. 19h after transfection, cells were treated with the proteasome inhibitor MG132 at
10M concentration for Sh and cells were then harvested for western blotting. Note
that large amounts of the MDM2 plasmid DNA were used for reasons explained in
the legend for the Figure 3.12.
121
Results
 
 
 
 
NME2-H118F = = 7 - fe = + = +
NME2 e
MDM2 C464A o = + © © =o = &
MDM2 - £ «ss w»« « @ © =
MDM2long nulccoccue
|
bem el
MDM2 short
fideSkoa
eh deel
exposure b+from foe omeeert
Actin
GFP aaeeeace
NME?
esse,A
eM
p53 » see
oot
Actin ee  
Figure 3.14 NME2 has noeffect on the RING-finger mutant of MDM2. The
Figure shows western blot analysis of H1299 cells transfected with p53, MDM2,
MDM2-C464A (RING-finger mutant), NME2 and NME2-H118F. The H1299 cells
were seededinto six-well plates and after 24h transfected with 0.083ug of pCEP-p53,
0.5ug of pCMV-neo-bam-MDM2/C464A,3pg of pCEP-NME2/H118F and 0.3pg of
pSUPER-GFP per one well of the six-well plate in triplicates, essentially as
described in the legend for the Figure 3.7 except, that only western blotting was
performed. Note that large amounts of the MDM2 plasmid DNA were used for
reasons explained in the legend for the Figure 3.12.
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Figure 3.15 N-terminus of NME2is responsible for the reduction of the MDM2
expression levels. The figure shows western blot analysis of H1299 cells transfected
with MDM2, NME2 and NME2 chimeric expression constructs 1+2 (N’ of NMEI
fused to C’ of NME2) and 2+1 (N’ ofNME2 fused to C’ of NME1). The H1299cells
were seeded into six-well plates and after 24h transfected with 0.5ug of pCMV-neo-
bam-MDM2,3g of pCEP-NMEconstructs and 0.3ug of psUPER-GFPperone well
of the six-well plate in triplicates, essentially as described in the legend for the Figure
3.7, except that only western blotting was performed. Note that large amounts of the
MDM2plasmid DNA were used for reasons explained in the legend for the Figure
3.12.
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3.2 MDM2andp53increase the motility of RCC cells
The results presented in previous sections clearly suggest pleiotropic involvement of
NME2in the regulation of p53 and MDM2.This mayindicate a role for NME2 in
the fine-tuning of the p53-MDM2 network; however, such data do not explain the
situation present in RCC, where over-expression of both p53 and MDM2results in
poor outcome as it has been shown that NME2is rather down-regulated in high
grade tumours (see Section 4.5). Here, no obvious effects of p53 and MDM2could
be seen on the levels of NME2. Therefore, the next step in this project aimed at
identification of a process or mechanism that engages all three proteins: NME2,
MDM2and p53 and which might better account for the association between p53,
MDM2and outcome in RCC. NME2has been described previously to function as a
motility and metastasis suppressor (see Section 4.3). We therefore investigated
whether p53 and MDM2playa role in the regulation of motility in RCC cells and
moreover, whether any such effect might act via NME2. Cellular motility plays a
crucial role in processes such as development (migration of precursor cells) and in
immunity. On the other hand, increased motility in cancer cells correlates with
cancer progression, since the cells can more actively migrate and colonize distant
tissues (Rinker-Schaeffer et al., 1996). An in vitro model of RCC tumourprogression
(a surrogate of the situation observed in RCC, where cells spontaneously acquire
high levels of wt p53 and MDM2,see Section 2.21) was used in this study. The in
vitro model of RCC tumourprogression is based on derivative clones of the 117 cell
line which naturally express low levels of p53 and MDM2, which werefer to
hereafter as “double low”: 1.1, 1.2, 1.6; clones expressing intermediate levels of p53
and MDM2,“double intermediate”: 1.16, 1.17, 1.20; or clones spontaneously over-
expressing both proteins, “double high” 1.11, 1.21, 1.27. These cell lines were
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examined using Boyden chambers to determine their motility (an in vitro assay that
reflects one aspect of the cells’ metastatic potential) to evaluate and compare their
motility.
The ability of “double low” and “double intermediate” cells to migrate through the
pores of the membrane appears to be unchanged in comparison with the parental 117
cell line. “Double high” cells however, were highly motile in this experiment (Figure
3.16). This suggests a possible involvement of p53 and/or MDM2in induction of
motility in RCC cells.
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Figure 3.16 Basal levels of protein expression and motility of 117 derivative
cells. The 117 parental cell line and derivative cell lines were harvested and subject
to western blotting analysis and motility assay. The panel above (a) presents western
blot analysis of p53 and MDM2expression in 117 RCCcell lines. Actin was used as
a loading control. b) The histogram showsanalysis of the Boyden chamber motility
assay performed essentially as described in Section 2.20. Cells were harvested and
counted, and then 50,000 cells were seeded into each chamber. After 18h the cells
were carefully wiped of the inner side of the porous membranes of Boyden
chambers. Cells were subsequently fixed and stained. The membranes were then
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mounted on the slide, covered with a cover slip and the cells were counted. The
numberofcells that migrated through membranes of Boyden chambers are presented
on the histogram as the mean of three replicates +/- s.e.m. In this experiment, the
parental 117 cell line was compared with three “double low” (1.1, 1.2, 1.6), three
“double intermediate” (1.16, 1.17, 1.20) and three “double high” (1.11, 1.21, 1.27)
117-derivative cell lines (for details regarding 117-derivative cell lines see Section
2.21).
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3.2.1. p53 increases motility by promoting over-expression of MDM2
As shownin the previous experiment, RCC cells over-expressing p53 and MDM2
were characterised by increased motility. We therefore set out to investigate whether
this phenotypic change was a result of up-regulated p53 and/or MDM2.Firstly,
transient reduction of p53 levels was achieved using siRNA in the p53 and MDM2
over-expressing 1.21 and 1.27 RCCcell lines and the Boyden chamber motility assay
was again performed. In both cell lines, transfection of p53-siRNA results in
decreased motility. The western blot shows that the p53 levels were successfully
reduced upon siRNA treatment, as the intensity of p53 bands decreases in p53-
siRNA treated samples compared to the scrambled siRNA control. Interestingly,
intensity of the MDM2bandsin the samples treated with p53-siRNAis also reduced
suggesting that high levels of MDM2 might be promoted by p53 in these cells
(Figure 3.17). It was still not clear, however, whether increased motility in these
“double high” cells was due to over-expression of p53 itself or rather was a result of
p53-promoted MDM2 up-regulation. To address this issue, MDM2 and p53 were
reduced using siRNA individually and simultaneously in five “double high” cell
lines: 117 derivative, A498 and Caki-2. Cell motility was again measured using
Boyden chambers.
These experiments show that depletion of either p53 or MDM2results in decreased
motility, but depletion of MDM2 seemsto generally have a more pronouncedeffect
(Figure 3.18). Interestingly, concomitant knockdown of p53 and MDM2 does not
lead to further decrease of motility in most cases (there is one exception cell line
1.21). Conversely, double knockdown seemsto result in a slight increase of motility
in someof the cell lines (A498), therefore it is likely that MDM2,rather than p53 is
directly involved in promoting cell motility. However, it remains unclear whether
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p53 also promotes motility in an MDM2-independent manner. To addressthis issue,
p53 was knocked downin the 2.26 (117-derivative) cell line. In 2.26 cells, MDM2
expression is driven by the CMV promoter, therefore p53 depletion should notalter
the level of MDM2. Subsequently, Boyden chamber motility assays were performed
to determine whether reduction of the p53 level has any impact on motility while the
levels of MDM2remain intact. Western blotting was also performed to ensure that
knockdown of p53 has no impact on the levels of MDM2in this system.
This experiment showsthat an efficient reduction of the level of p53 leads to neither
reduction of motility nor reduction of the levels of ectopically expressed MDM2
which suggests that p53 on its own may not have any influence on cell motility in
RCC asFigure 3.19 illustrates.
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Figure 3.17 siRNA mediated reduction of the p53 levels in “double high”, highly
motile RCC cells results in decreased MDM2 levels and motility. The Figure
shows data from a Boyden chamber motility assay together with western blot
analysis to determine knockdown efficiency in 117 derivative cell lines 1.21 and
1.27. Cells which were transfected with 40nM scrambled siRNA or p53 siRNA using
Lipofectamine 2000 as a transfection reagent and the motility assay was performed
essentially as described in the legend for the Figure 3.16.
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Figure 3.18 Depletion of p53 and MDM2in “double high” RCC cells. The Figure
shows the Boyden chamber motility assay, on the p53/MDM2-siRNA treated
samples (as indicated) along with western blot analysis of 1.11 (a), 1.21 (4), 1.27 (c),
A498 (d) and Caki-2 (e). Histograms show analysis of Boyden chamber motility
assays performed essentially as described in the legend for the Figure 3.17 except,
that 15,000 of A498 and Caki-2 cells was seeded into chambers.
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Figure 3.19 Reduction of the p53 levels in 2.26 cells using siRNA. The Figure
shows the Boyden chamber motility assay and western blots control of the 117
derivative cell lines 1.21 and 1.27 performed essentially as described in the legend
for the Figure 3.17.
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3.3 p53 in RCCis wild type, functional and regulated by MDM2
Data presented in previous Section 3.2 strongly suggested that p53 is wt and
functional in 117 derivative cell lines that have spontaneously acquired high levels of
both p53 and MDM2 (A498 and Caki-2 were already known to harbour wt p53, data
available from IARC database) as reducing p53 expression with siRNA led to
reduction of the levels of MDM2. However, based on already published evidence,it
was not clear, whether up-regulated p53 in RCC is usually wt or mutated (see
Section 4.7), therefore, the status of p53 was examined in a set of tumour samples.
The tumour samples were selected based on the expression of p53 and MDM2. 9
specimens which were positively stained (based on IHC performed by the members
of our group) for both p53 and MDM2 were chosen to study the status of p53 in
double high RCC tumours. Additionally, as it was suspected that specimens
positively stained for only p53 might carry mutation in the p53 gene (as mutated p53
would not be unable to contribute to over-expression of MDM2), 3 samples over-
expressing only p53 were chosen. Since the IHC analysis identified also tumours in
which only MDM2 is up-regulated, also 3 specimens positively stained for only
MDM2were added to the experiment. The FASAY technique (described in section
2.12), which is a yeast based technique allowing detection of mutated p53 alleles
even from very heterogeneous samples (cancer cells may sometimes constitute a
relatively small percentage ofall cells in the biopsy), was used for analysis of these
tumour samples. Out of these 15 tumour samples, only two samples carried missense
mutations of p53 and both of these were present in the p53 and MDM2 over-
expressing group. In one sample a G733T mutation was present, resulting in a
G245C aminoacid substitution. The second p53 mutated sample contained a C406G
nucleotide substitution resulting in a Q136E substitution in the amino acid sequence.
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All other samples were p53 wt which was confirmed by sequencing of 2-4 red
colonies for each sample (for sequencing results see the Appendix 1). As a large
number of PCR cycles were performed to amplify cDNA for recombination during
FASAY,polymerase errors occur and contribute to the background of about 5% (5%
red colonies in p53 wt samples). Considering a very low ratio of red to white
colonies which in these samples did not exceed 5% (for comparison, the two samples
in which mutations have been identified, contained nearly exclusively red colonies),
and that the PCR errors are very unlikely to be introduced in the samesite, it was
assumedthat the p53 status is wt unless the same mutation occurs in more than one
clone.
The 117 derivative cell lines (see 2.21) were also tested using FASAY. No p53
mutations were detected in the 117 derivative cell lines. The analysis of the p53
status performed in both tumourtissue andcell lines suggest, that p53 is generally wt
in RCC.
Totest if wt p53 is functional in RCCcell lines (some evidence was already provided
in experiments 3.2.1 and 3.2.2 which show that expression of MDM2is p53-
dependent) and responds to genotoxic stress; 117 and 1.27 cells were exposed to
AJ/m’, 10J/m?, or 20J/m? of UV-C light. As shown in Figure 3.20, UV treatment
leads to stabilization of p53 in 117 cells which is in contrast with 1.27 cell line where
no further stabilization of p53 can be observed, perhaps, becauseit is already stabile.
Expression of p53 downstream genes appears to be variable; although induction of
MDM2and Bax in response to UV appears to be stronger in 117 than in 1.27
compared tothebasal protein levels in these cell lines, highly induced levels of Bax
and MDM2in 117 cells seem to be comparable with the levels of non-induced
proteins in 1.27 cells. p21 also becomes induced in 117 cells, contrasting with its
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decrease in 1.27 in response to UV radiation. It can therefore generally be concluded,
that p53 is functional and respondsto stress (DNA damage) in bothcell lines.
Since it was not clear what causes stabilization of p53 (it could be assumed that high
levels of p53 could result from an inability of MDM2 to regulate p53 levels), the
ability of MDM2 to regulate the levels of p53 in RCC cells was examined. To
accomplishthis, nutlin-3 (a small molecule that inhibits p53-MDM2interaction) was
titrated onto 117 and 1.27 cell lines in order to determine to what extent is p53
regulated by MDM2in these cells. The experiment revealed that nutlin-3 treatment,
and therefore inhibition of the p53-MDM2 interaction, results in a subtle
accumulation of p53 in both 117 and 1.27 cells (Figure 3.21). On the other hand,
MDM2becomesstrongly induced in both cell lines, and in 1.27 cells this process
seems to occur even moreefficiently. p21 also becomes induced in both 117 and
1.27, but to a muchlesser extent. The results suggests, that increased levels of p53
and MDM2in 1.27 cells can not be simply explained by the inability of MDM2 to
degrade/inhibit p53, as MDM2still appears to play a role in regulation of the p53
level and activity.
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Figure 3.20 DNA damageinducesthe p53 response in RCCcell lines. 117 cells
expressing low levels of p53 and MDM2 and 1.27 cells over-expressing p53 and
MDM?weretreated with increasing doses of UV-C radiation as indicated. 24h after
exposure to UV, the cells were harvested, and the protein extracts were subject to
western blotting which shows expression of p53 and various p53-responsive genes:
MDM2, BAXand p21. Actin was used as a loading control.
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Figure 3.21 Response of 117 and 1.27cell lines to nutlin-3 treatment. 117 cells
expressing low levels of p53 and MDM2and 1.27 cells over-expressing p53 and
MDM2were seeded and after 24h treated with increasing doses of nutlin-3 as
indicated. After 24h cells were harvested, and the protein extracts were subject to
western blotting which shows expression of p53 its responsive genes: MDM2 and
p21. Actin was used as a loading control.
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3.4 Comparison of growth rate of 117 derivative cell lines
Since, as shownin previoussections, there is an obvious difference in the levels and
activity of p53 between the “double high” and “double low” cells it could be
assumed that p53 and/or MDM2 mayalterproliferation in these cells. We therefore
set out to investigate whether the difference in the p53 and MDM2levels
correspondsto any difference in proliferation. To addressthis issue, cell proliferation
was measured.
The plotted growth curves show that high levels of p53 and MDM2do not seem to
have any obviouseffect on cell proliferation, as shownin the Figure 3.22. This result
also suggests that increased motility of “double high” cells obtained in the Boyden
chamber motility assay cannot be due to any increased proliferation rate of these
cells.
138
Results
 
 
    
2500000
2000000 4_ +117
$ 11
© 4 1,21500000 4
5 = 116
oO5 Cm 4,17
5 1000000 1,20£ 111
—2 1,21
500000 - whet
0 T T T T 1
Oh 24h 48h 72h 96h 
Figure 3.22 Over-expression p53 and MDM2 in RCC cells does not affect
proliferation. 150,000 cells of each cell line was seeded per one well of the 6-well
plate. Subsequently, cells growing in well (for each cell line) were harvested every
24h and counted. The numbersofcells counted at each time point for each cell line
are presented on the histogram as the mean of three replicates +/- s.e.m. The red
colour represents growth curves of “double low” cells, green represents “double
intermediate” and blue represents “double high”. The growth curve of the parental
117 cell line is presented in black.
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3.5 High levels of MDM2 abrogate NME2-dependent motility
suppression in RCCcells
NME2 proteins have a well-documented involvement in motility/metastasis
suppression as mentioned before in Section 3.4 (this will be more extensively
described and discussed in Section 4). Since MDM2 appeared to play a role in
promoting motility of RCC cells (see Section 3.2), the functional aspects of NME2-
MDM2interplay with respect to motility were investigated. Expression of NME2,
MDM2andboth proteins together were reduced using siRNA in 117 and 1.27 cells
and cell motility was studied using the Boyden chamberassay.
The results revealed that NME2 functions in different ways in 117 and 1.27 cells.
Although depletion of NME2 expression in 117 cells leads to increased motility,
reduction of the MDM2expression levels using RNAi, does notresult in reduction of
motility suggesting that low levels of MDM2 do not play a major role in the
regulation of motility in these cells. On the other hand, treatment of highly motile
1.27 cells with NME2 siRNA doesnotresult in increased motility, unless the levels
of MDM2are reduced with siRNA (Figure 3.23). This suggests that NME2 and
MDM2haveopposite functions in regulation of motility and, perhaps, high levels of
MDM2blockthe motility-suppressive activity of NME2.
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Figure 3.23 MDM12has an opposing effect on the NME2-dependent motility
suppression. The Figure shows the Boyden chamber motility assay performed on the
siRNA-treated cells (as indicated) and western blots performed essentially as
described in the legend for the Figure 3.17. The panel (a) represents the parental 117,
and the panel(b) the 1.27 cell line.
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4 Discussion
4.1 Introduction
Over-expression of MDM2is associated with poor outcome in RCC (Haitel et al.,
2000). Because this phenomenon is not a result of MDM2-dependent p53
degradation (p53 is usually also upregulated in MDM2 positive renal tumours), it
suggests the existence of some alternative, MDM2-associated mechanism
responsible for an aggressive phenotype of kidney cancers which express high levels
of MDM2.Theaim ofthis study was to identify MDM2interacting proteins which
could be involved in mediating poor outcome in RCCpatients.
The yeast two-hybrid system allows detection of interactions between two proteins
that are fused to either the DNA binding or activation domain of the Gal4
transcription factor (Fields and Song, 1989). Interaction is manifested by activation
of marker genes that enable the auxotrophic yeast cells to grow on selective media
and reporter genes which allow evaluation of the strength of the interaction. The
yeast two-hybrid method, unlike various in vitro techniques gives a chance of
investigating proteins synthesized and folded in natural conditions of the eukaryotic
cell.
In this study, the yeast two-hybrid system was used to look for novel MDM2
interacting proteins expressed in RCCcells. For this purpose, a cDNA library was
constructed using mRNAextracted from the RCC 786-0 cell line. This particular cell
line was chosen as a source of mRNA becauseit was expected to reflect the situation
present in a subset of in RCC tumours, which are characterised by highly aggressive
phenotype associated with over-expression of both MDM2and(supposedly) mutated
p53. The use of mRNAfrom this cell line was intended to increase the chance of
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finding the relevant MDM?2-interacting proteins (the hypothetical interaction most
likely takes place in such cells as they presumably manifest the phenotype common
to the most aggressive RCCs. Subsequently, following transformation into yeast the
library was then screened for interaction with MDM2. The screen reconfirmed
previously described interactions of MDM2 with: ribosomal proteins L5, $7, L11,
L26 and transcription factor E2F1 (Elenbaaset al., 1996, Chenet al., 2007, Zhang
et al., 2003, Ofir-Rosenfeld et al., 2008, Zhang et al., 2005). Several new potential
targets were also identified. Of these, the candidates for MDM2 binding proteins
which would be further investigated had to be selected. The NME2protein appeared
to be a good candidate for further study for a numberof reasons.Firstly, it was also
identified in our laboratory as a MDM?2-interacting protein using a proteomic
approach and thus two independent approaches provided evidence of an interaction.
Secondly, NME2 has been identified as the PuF transcription factor and has been
shownto contribute to expression of c-Myc (Postelet al., 1993), thus playing role
in regulation of expression of a potent proto-oncogene and, potentially also other
genes involved in tumourigenesis. Finally, NME2 has been shown to function as a
metastasis suppressor and therefore, hypothetically, its inhibition by MDM2could
explain how high levels of MDM2 increase aggressiveness of RCC. Therefore,
NME2protein becamea subject to further analysis.
4.2 Authenticity and specificity of the NME2-MDM2interaction
At the time, when the putative MDM2interacting proteins identified in the screen
were selected for further investigation, it was not obvious that both NME2 clones
were not recombined with the pGADT7-Rec vector in a correct reading frame (as
subsequently revealed by sequencing) and were thus potentially unable to produce
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mRNAencoding the NME2protein. Severallines of evidence support the conclusion
that this out of frame fusion nevertheless produced NME2protein fused in frame
with the Gal4 AD and thus gave rise to yeast growth through interaction with
MDM2.Firstly, the apparent interaction depended upon the presence of the cDNA
since no interaction wasdetectable in the absence of this (when the vector expressing
the AD only was used). Secondly, examination of this cDNA demonstrated that read-
through from the Gal4 AD would produce a peptide of only 2 amino acids. It seems
unlikely that such a small peptide expressed at the carboxy-terminus of a muchlarger
fusion partner (Gal4 AD) could mediate the interaction that we detected. Thirdly,
subsequent analysis of the full length NME2 cDNA expressed in-frame with the
Gal4 AD confirmed that NME2 interacts with MDM2 in this system. In addition,
several lines of evidence suggest that such an out of frame construct may still
produce a protein of a correct amino acid sequence. It may occurat the level of
transcription, when the RNA polymerase slips over a poly-adenine tract adding or
losing 1 adenine nucleotide at a frequency that may reach 10% in mammalian cells
(Linton et al., 1997, Bensonet al., 2004). This mechanism appears to be conserved as
a similar phenomenon has also been described in bacteria (Baranov et al., 2005).
Interestingly, various studies show, that some viruses use polymeraseslippage over
homo-nucleotide tracts, to generate alternative reading frames from the same
nucleotide sequence (Ratinier et al., 2008). A heptameric stretch of adenineis present
in the pGADT7-Recvectorat the end of the Gal4 activation domain. Slippage at this
site, resulting in the addition of one adenine, would lead to mutation of 2-3 codons
(depending onthe site of slippage) of the 3’ terminus of the activation domain of
Gal4 and synchronisation with a reading frame of downstream NME2 (see Figure
4.1). In this case, however, three STOP codons would appearin the 80bp-long spacer
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between the Gal4 and NME2 ORF. Although several reports suggest that the STOP
codon read-through events occur in yeast with frequency up to 3% (Williams etal.,
2004, Namyet al., 2001, Mottagui-Tabaret al., 1998), the likelihood of successful
read-through all three STOP codonspresent in the spacer between the Gal4AD and
NME2 ORF is low. However, frameshift mutations may also occur at the
translational levels. If such mutations occurred within the sequence of the vector
between the last of the three STOP codonspresent in the sequence ofthe vector (see
Figure 4.1) and NME2 ORF,then expression of NME2 would bepossible. Although
this event is extremely rare and appears with frequency ofless than once in 100,000
codons (Farabaugh and Bjork, 1999), shortages of aminoacyl-tRNA may promote
frameshifting by near-cognate decoding (O'Connor, 1998). As there is a shortage of
amino acids present during selection of mated yeast on the plates, it is therefore
possible, that this process might also contribute to the expression of NME2in this
study. This would result in the Gal4AD-NME2fusion being less abundant; however,
this could provide a growth advantage to the yeast cells, as studies of full length
NME2that was cloned in a correct reading frame into the pGADT7-Rec vector,
showed that this protein appeared to be toxic to the cells. This toxicity was
manifested by substantial inhibition of growth and irregularities in shape of the yeast
colonies which contrasted with the original NME2clonesidentified in the screen (the
colonies grew robustly and were round).
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Figure 4.1 Nucleotide sequence of the recombination site of the 5’ end of the
NME2 cDNA and the pGADT7-Rec vector. The figure shows the nucleotide
sequence of the pGADT7-Rec vector recombined with the incomplete cDNA
(missing the 5’ part) encoding the NME2 protein. The sequence is divided into
codingtriplets as indicated. Insertion of an additional adenosine (red colour font) due
to polymerase slippage results in a shift of the reading frame (as indicated by red
lines) and accordance with the reading frame of NME2. Green stars indicate STOP
codonscreated as a result of the polymerase slippage and the blue star indicates the
STOP codon terminating expression of the peptide encoded by the out of frame
NME2 cDNA(whennoslippage occurs).
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Whenit became apparent that NME2 clonesidentified in the yeast two-hybrid screen
were not recombined with the expression vector in a correct reading frame, the
cDNAencoding the full length NME2 was cloned into the pGADT7 vector and the
interaction wasretested with a positive result (see 3.1.4 for details). However NME1,
which shares 88% of amino acid identity and a very high degree of homology across
the remaining sequence with NME2(see Figure 4.2), did not detectably interact with
MDM2in yeast. This suggests a very high specificity of the interaction and as will
be discussed later in this section, this difference may determine the ability of NME
proteins to regulate the levels of MDM2.
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NME1 N’MANCERTFIAIKPDGVORGLVGEIIKRFEQKGFRLVGLKFMQASEDLLKEHYVDLKDRPFFAGLVKYMHSGPVVAMV
NME2 N’MANLERTFIAIKPDGVQRGLVGEI IKRFEQKGFRLVAMKFLRASEEHLKQHYIDLKDRPFFPGLVKYMNSGPVVAMV
eK k KKRKKORokkk
NME1 WEGLNVVKTGRVMLGETNPADSKPGTIRGDFCIQVGRNIIHGSDSVESAEKEIGLWFHPEELVDYTSCAQNWIYE C’
NME2 WEGLNVVKTGRVMLGETNPADSKPGTIRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHDWVYE C’
KK KK KR KK KKK KO KKKKKKKKKORkRk kk kk KR KR RR KKK aK KKK KKK KKK KKK
Figure 4.2 Clustal W (1.83) alignment of NME1 and NME2 amino acid
sequences. The Figure shows a comparison of the amino acid sequences of NME1
(gil49457226) and NME2(gi|49456397). “*” refers to amino acidsthat are identical
66 99in given positions, “:” indicates conservative substitutions, indicates semi-
conservative substitutions and gaps refer to non-conservative substitutions.
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4.3 NMEproteins have a variety of different functions
Proteins from the NME family, also called NM23 (non-metastatic 23) or NDPK
(nucleoside diphosphate kinase) are well known for their nucleoside diphosphate
kinase activity. However, several lines of evidence suggest that in addition to their
nucleoside diphosphate kinase activity ((EC 2.7.4.6, which is responsible for the
generation of nucleoside triphosphates from nucleoside diphosphates (Otero, 2000),
NMEproteins havealso different properties and indeed,the list of other functions of
the NMEproteins is a long one. NME2 has been identified as the PuF transcription
factor which has been shownto contribute to expression of c-MYC(Postelet al.,
1993). In addition, it has been demonstrated that an ancestral form of human NME
proteins (called AWD in Drosophila which has only one homologue)is essential for
drosophila development, since null mutations causedlarval lethality, suggesting that
the activity of NMEproteins mayalso be essential for developmentin higher animals
(Xu et al., 1996). There are 8 NME orthologs in mouse and human and Nme/is the
only member of the Nme gene family that has been knocked out in higher animals.
Analysis of Nme/-null mice has demonstrated that Nmel protein is not essential for
life. Mice lacking Nmel displayed growth retardation and a lactation disorder,
nevertheless, NmeJ-null animals otherwise develop normally (Arnaud-Dabernat et
al., 2003), most likely due to high functional redundancy between the members of
the NMEprotein family. However, analysis of a hepatocellular carcinoma model on
an Nmel KO background mice revealed that the animals suffered from a higher
incidence of pulmonary metastasis, thus suggesting (along with other evidence
described in Section 4.5) a role for Nme/ in metastasis suppression (Boissanetal.,
2005). Interestingly, tumour cells from the Nme] KO mice expressed higherlevels of
Nme2, compared to matched normal tissues. This suggests the existence of a
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feedback mechanism leading to compensation of Nmel function by the Nme2
protein. However, it also showsthat at least some anti-metastatic functions of Nmel
and Nme2 are not redundant as Nmel KO mice develop more metastases despite the
potential compensation provided by up-regulation ofNme2 (Boissanet al., 2005).
As described above, NMEproteins play various roles in cells. In the present study,
additional activities of NME2 were identified. NME2 was shown to regulate the
transcriptional activity of p53 and also to regulate the steady state levels of MDM2.
The data also suggest, that NME2 mayplay a role in regulation of the post-
translational modifications of p53, thus, further expanding the potential functional
repertoire of NMEproteins.
4.4 NME2 and NMEIsuppressthe activity of p53
Considering the pleiotropic nature of NMEproteins (see above), it was difficult to
predict what would be the consequence of the interaction between MDM2 and
NME2.First, it was decided to investigate if NME2 has any influence on MDM2,
because the appropriate techniques were well optimised and routinely used in our
laboratory. The most sensitive method of detecting changes in the activity of MDM2,
and which was available in our laboratory, was to perform a luciferase assay to
measure the activity of p53. The assay was therefore used to test if the NME2-
MDM2interaction had any effect on the activity of MDM2 towards p53 (which
would be reflected by changes in the activity of p53). Experiments performed in
tissue culture as shown in Section 3.1.4, revealed an activity of NME2 that could
regulate p53 activity. Over-expression of NME2 in human cancercell lines H1299
and MCF-7,led to a reductionin the activity of the ectopically expressed p53 protein
(Figures 3.7, 3.8). Moreover, the kinase activity of NME2 appears to be dispensable
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for this effect (Figure 3.10) and the observed reduction of p53 activity was not
accompanied by a reduction in the p53 protein level. This latter suggests that the
effect is on the intrinsic activity of p53 and not on the steady state levels of the
protein. The experiments performed in normalcells, BJ fibroblasts (Figure 3.9, 3.11)
further supported the data from cancercell lines and provided evidence, that NME1
also reduces the activity of p53 in a similar way to NME2. Moreover, transfection
experiments using double null (Mdm2™, p53") MEFs revealed that NME2 and
NMEI inhibit the activity of p53 independently of MDM2. These results do not
accord with some data that were published while this project was being carried out
(Jung et al., 2007). On the basis of similar experimental procedures to these used in
the present study, these authors cameto the conclusion that NME1 interacts with p53
and inducesits activity. The panels ofcell lines used by Junget al., overlaps with the
ones used here (MCF-7 and H1299), however, the authors did not use any non-
cancer cells (such as BJ fibroblasts used in the present study) or cells providing an
Mam2-null background (double-null MEFs) to validate their results. Thus the results
presented in the current study are morereliable.
4.5 NME2alters the MDM2 dependent modification of p53 and
decreasesthe levels of MDM2
Analysis of western blotting (Figures 3.7, 3.8) suggested that not only the activity,
but also the MDM2-dependent post-translational modifications of p53 might be
regulated by NME2. MDM2is known to promote post-translational modifications
such as ubiquitylation, sumoylation or neddylation of several target proteins
including itself and p53 (Honda and Yasuda, 2000, Xirodimasetal., 2004, Meek and
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Knippschild, 2003, Melchior and Hengst, 2002), often with profound effects on
stability and activity of the target protein. The results presented in this thesis show
that the ladder of high molecular weight forms of p53 visible above the main un-
modified form of the protein, present in samples transfected with p53 and MDM2,
seems to disappear after co-transfection with NME2. The molecular weight of the
second p53 immunoreactive band has an apparent MW of 60kDa which corresponds
to the expected apparent MW of mono-ubiquitylated p53 (Figures 3.7, 3.8 and 3.14).
Moreinterestingly, co-transfection of NME2 appears to change the profile of the
ladder and seems to promote enrichment of the mono-ubiquitylated fraction (Figure
3.14). A RING finger mutant of MDM2 C464A does not promote any detectable
modification of p53 which suggests that the p53 ladder, present in the samples co-
transfected with MDM2,is produced byanactivity of the RING-domain of MDM2
(Figure 3.14). Since the RING-domain of MDM2carries the E3 ubiquitin ligase
activity, one could speculate that the ladder is composed of mono- and poly-
ubiquitylated p53 molecules (as it has been shown that the RING finger of MDM2
promotes NEDDylation of p53 (Xirodimaset al., 2004). In such a scenario one could
hypothesize that the NME2 protein mayalso take part in regulation of p53 levels (if
the ladder is composed of poly-ubiquitylated forms of p53) independently ofits
ability to regulate the activity of p53. Figure 3.14 supports this notion as
coexpression of NME2 with p53 and MDM2 seemsto increase the intensity of the
band corresponding to the main (un-modified form) of p53. This does not appear to
happen in experiments where much smaller amounts (for details see Section 2.18)
and a higher ratio of p53 to MDM2 plasmid DNA were used (see Figures 3.7 and
3.8). This could be explained by the fact that the amount of p53 present in the ladder
in these latter experiments (Figures 3.7 and 3.8) is relatively insignificant compared
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with the amount of unmodified p53 present in the main band, mostlikely due to low
levels of transfected MDM2 which do not promote efficient modification of p53 (the
ratio of transfected p53 to MDM2vectors was 1:3 in these experiments). Hence the
effect of NME2 on the unmodified fraction of p53 is masked by the high basal level
of p53. On the other hand, large amounts of plasmid DNA and a lowerratio of
transfected p53 to MDM2(1 : 6) as used in the experiment described in Section 3.1.7
(Figure 3.14) significantly increased the amount of p53 presentin the ladder fraction,
but also decreased the relative intensity of the main p53 band. This allows detection
of the NME2-mediated changes of the intensity the main band of p53 (as well as the
ladder) in this experiment.
Western blot analyses of MDM2levels after co-transfection with NME2 suggest the
possibility that NME2 is involved in the regulation of MDM2levels as the MDM2
band appears less intense in samples that were co-transfected with NME2 (Figures
3.7 and 3.8). The effect seems to be much more pronounced with larger amounts of
the plasmid encoding MDM2used for transfection and is independent of any other
known function of NME2,as either the H118F or K12Q mutants appear to function
similarly with respect to MDM2 (Figures 3.12, 3.13, 3.14). Interestingly, co-
overexpressed NME1 doesnotlead to reduction of the MDM2levels (Figure 3.13),
suggesting a high specificity of the NME2-mediated effect on MDM2. Further
investigation of this phenomenonrevealed that the NME2-dependent downregulation
of MDM?can be blocked using the proteasome inhibitor MG132, indicating that 26S
proteasomesare essential for this process (Figure 3.13). Even moreinterestingly, the
C464A RING-finger mutant of MDM2 appeared to be refractory to NME2-
dependent downregulation, which suggests that the effect is dependent on an intact
RING-domain of MDM2. Moreover, this effect appeared to be mediated by the N-
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terminus of NME2, as the chimeric protein in which the N-terminus of NME2 was
replaced with the N-terminus of NME1, failed to reduce the level of MDM2 (Figure
3.15). One can therefore hypothesise that NME2 increases auto-ubiquitylation and,
as a consequence, proteasomal degradation of MDM2. The ability of NME2 to
decrease the levels of MDM2 could also explain why the intensity of the MDM2-
mediated post-translational modification of p53 decreases in samples co-transfected
with NME2, since it has been shown that low levels of MDM2 promote mono-
ubiquitylation of p53 rather than poly-ubiquitylation (Li et al., 2003). This is
consistent with a decrease of the intensity of the ladder in the fraction corresponding
to poly-ubiquitylated p53 and enrichment of the mono-ubiquitylated forms of p53 in
observed in samples co-transfected with NME2.
4.6 MDM2promotes motility in RCC cells and opposes the ability
of NME2to suppress cell motility
Apart from involvement of NME2in regulation of MDM2levels, another potential
connection between NME2 and MDM2- regulation of motility was proposed andis
going to be discussed later in this Section. It will, however, be preceded by
discussion overthe ability of MDM2 to promote motility of RCC cells (a feature that
strongly links MDM2 with aggressive phenotype of cancer cells), which was also
discovered in the present study.
One of the main goals of this project was to identify phenotypic changesthat result
from upregulation of MDM2. This would help the initial selection of potential
MDM2bindingproteins for further investigation from those identified in the screen,
with respect to their putative involvement in mediating the aggressive phenotype of
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RCC. For this purpose, the isogenic clones of the UOK117 RCC cell line were
obtained (see Section 2.21) and a panel ofcell lines expressing high levels of both
p53 and MDM2(double high), low levels of both p53 and MDM2 (double low) or
clones expressing intermediate (double intermediate) levels of p53 and MDM2 was
selected (Figure 3.16a) and characterised with respect to motility and p53 status. As
the cells that have spontaneously acquired expression of high levels of p53 and
MDM2have been obtained by selection and not by forced, ectopic expression of
proteins, it was suggested, that this process could be a surrogate of the natural
selection occurring in progressing RCC tumours and therefore serve as a model of
RCCprogression.
Subsequent analysis revealed dramatic changes in cell behaviour. Double high cells
appeared to be about 10-fold more motile than the parental 117, double low and
intermediate clones (Figure 3.16b). Moreover, siRNA-mediated reduction of the
MDM2expression levels resulted in inhibition of motility in highly motile double
high cells. It has previously been suggested by others, that MDM2 mayregulatecell
motility via ubiquitylation and degradation of E-cadherin (Yanget al., 2006). It has
been shown, that MDM2upregulation correlates with decreased levels of E-cadherin
in high grade breast tumourclinical samples. These results do not accord with ours as
the experiments performed in our lab show that the RING-finger mutant of MDM2
(unable to promote ubiquitylation of E-cadherin), over-expressed in H1299 cells also
promoted motility (Polanski et al. manuscript in preparation) suggesting that
ubiquitylation and degradation of E-cadherin may not be the only way in which
MDM2influences motility.
Interestingly, depletion of p53 also led to decreased motility and this was associated
with reduction of MDM2levels (Figure 3.17). Importantly, reduction of the levels of
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both p53 and MDM2,performed on a numberofoccasions in five individual double
high cell lines did not lead to further reduction of motility (with only one exception,
Figure 3.18). To exclude the MDM2-independent role of p53 in regulation of
motility, an experiment involving the 2.26 cell line which expresses high levels of
endogenous p53 and exogenous MDM2 was performed (Figure 3.19). The
expression of MDM2 in 2.26 cells is driven by the CMV promoter; hence, is
independent of p53. Although the experiment did not demonstrate that exogenously
expressed MDM2contributes to increased motility in these cells (which is two fold
higher than in parental 117 or double low cells), it shows that depletion of p53 using
siRNAtransfection in the 2.26 cell line does not result in reduction of MDM2levels
and cell motility. This suggests that the reduction of motility in the p53/MDM2
siRNA experiments (see Section 3.2) was not caused by inhibition of MDM2-
independentactivity of p53.
Oncethe role of p53 and MDM2as motility promoting agents in RCCcell lines was
identified, the functional consequences of NME2 - MDM2relationship with respect
to cell motility were studied in RCCcelllines.
It has been demonstrated by others that NME1 and NME2 suppresscell motility and
it has been suggested that both proteins function as metastasis suppressors (Rayneret
al., 2008, Jung et al., 2006). NME2 has beenreported to be expressedat higherlevels
in non-metastatic versus metastatic cells, for example oral squamouscarcinomacells.
In addition, transfection of cells with NME2 has been shown to reduce their
metastatic potential, which suggests a role of NME2 in metastasis suppression
(Miyazakietal., 1999). Similarly to NME2, NMEI hasalso been shownto be down-
regulated in numerous metastatic types of cancers such as: melanoma,
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neuroblastoma, breast, colorectal, liver, gastric, ovarian, prostate, cervical, thyroid,
lung and pancreatic suggesting its function in metastasis suppression (reviewed in
(de la Rosaet al., 1995).
Two mechanisms for NME1-mediated metastasis suppression have been proposed so
far. Studies of a number of different carcinoma and cell lines have suggested the
inverse correlation between the expression levels of NMEI and the lysophosphatidic
acid receptor EDG2. Transfection experiments revealed, that NME1 downregulates
EDG2expression, thus reduces the EDG2-dependent motility and overexpression of
EDGz2has been shownto rescuethis effect (Horak et al., 2007a). A subsequent study
has shownthat restitution of EDG2 expression in NME1-overexpressing cell lines
markedly increased their metastatic properties in nude mice (Horak et al., 2007b),
further supporting the in vitro data.
It has also been demonstrated, that NME1 regulates the Racl-dependentcell motility
through binding and inhibition of Tiam1 (Racl-specific nucleotide exchangefactor)
which leads to inhibition of the Racl-GTP complex formation. Interestingly, this
effect appears to be independent on the kinase activity of NMEI suggesting that,
perhaps, the protein-protein interaction of NME1 with Tiam1 inhibits activation of
Racl and the downstream JNK pathway (Otsuki etal., 2001).
No molecular mechanism for NME2-mediated motility/metastasis suppression has
been proposed so far. It reflects the general tendency for NME2 being less studied
than NME1. However, considering high homology between the two and reported
involvement in regulation of the same processes (motility/metastasis suppression) it
is not unreasonable to assume, that NME2acts in a similar way to NMEI.
In the present work, it was observed, that reduction of the levels of NME2, MDM2
and both proteins simultaneously using siRNA, appeared to have different
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consequences in the parental 117 cells and double high 1.27 cells. In 117 cells,
depletion of NME2 leads to induction of motility (consistently with previously
published data) both in the presence and absence (siRNA treatment) of endogenous
MDM2(Figure 3.23a). However, in 1.27 cells which express high levels of MDM2,
NME2depletion does not lead to further induction of motility. Consistent with data
presented previously (Figure 3.18), reduction of MDM2levels, results in decreased
motility. This could to be due to the action of NME2 (which now functions in
absence of MDM2), since a double NME2+MDM2 siRNA-mediated reduction of
protein expression partially rescues the decrease of motility caused by MDM2
depletion (Figure 3.23b). It can therefore be suggested that MDM2 and NME2 have
opposing effect on motility, yet regulate different pathways modulating cell motility.
Alternatively, the results could be interpreted as follows: high levels of MDM2
directly block the ability of NME2 to suppress cell motility (this could be a result of
the protein-protein interaction) and either constitutively expressed low MDM2levels
or its high levels reduced using siRNA (in cell overexpressing MDM2) allows
functioning of NME2.
The finding suggests a potential therapeutic strategy, which could be based on either
reduction of MDM2levels (if decreased levels of MDM2 allow NME2to function)
or prevention of the MDM2-mediated effect on NME2 (preventing the protein-
protein interaction if this interaction results in inhibition of the NME2-mediated
motility suppression) and potentially lead to inhibition of metastatic spread.
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4.7 p53 is wt, functional and drives overexpression of MDM2 in
RCCcells
Several additional issues were raised in this study as a consequenceof investigating
the p53 status and its relationship with MDM2 in RCC.It has previously been
demonstrated, that p53 overexpression in various types of cancers such as
oesophageal, breast, colorectal, lung or ovary usually indicates its mutation (Shi et
al., 1999, Davidoff et al., 1991, Yang et al., 1999, Westra et al., 1993, Marksetal.,
1991). Although some studies report that p53 mutations are very rare in RCC
(Suzuki et al., 1992), the others present data suggesting that p53 is mutated at high
frequency in sarcomatoid RCC (sarcomatoid RCC is a highly aggressive form of
RCC characterised by the presence of tumour cells with morphology resembling
various types of mesenchymalcells, such as miofibroblasts (Delahunt, 1999), (Odaet
al., 1995).
Mutation of p53 in the p53-MDM2 overexpressing tumours was one of the
assumptions leading to construction of the RCC tumour progression model based in
117-derivative cell lines (see Section 2.21). It was hypothesized that cells harbouring
mutated and stabile (and therefore overexpressed) p53, somehow acquire high levels
of MDM2. Also based on this hypothesis, the 786-0 RCC cell line, expressing
mutated p53, was used for construction of the library (subsequently screened for the
MDM2binding proteins). The results described in the present study clarify the issue
of the p53 status in RCC. To contradict the founding assumptions and the data from
other carcinomas mentioned above, the results suggest that p53 is usually wt in p53
over-expressing RCC tumours, as only 2 samples out of 12 (p53 over-expressing)
tested by FASAY,carried p53 mutation. Moreover, no 117-derivative cell line over-
expressing both MDM2and endogenousp53, harboured p53 mutation. Additionally,
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direct sequencing of the genomic DNA sequence of the 786-0 cell line did not
confirm presence of the expected 832C>G missense mutation resulting in the P>A
aminoacid substitution in the codon 278 (IARC TP53 mutation database).
This also suggests that the function of wt p53 must be compromised in RCC to allow
cell growth and survival. It has been proposed before, that p53 is not functional in
RCCcell lines (which express wt p53) and that the p53 pathway is repressed by an
unidentified dominant mechanism (Gurovaet al., 2004). The results obtained in our
lab show, however, that p53 is functional in RCC cell lines and its levels are
significantly regulated by MDM2 (Warburton et al., 2005). It would therefore be
expected, that increased levels of MDM2 lead to reduction of p53 as a result of the
MDM2-dependent ubiquitylation and degradation of p53 (Honda et al., 1997).
However, it is shown here that although MDM2still plays a role in regulation of the
stability and activity of p53 (see Section 3.2), yet it is unable to reduce the level of
p53 in double high cell lines. The results presented in this thesis suggest repression
of the p53 pathway downstream from p53 rather than repression of p53 itself. It was
demonstrated that p53 is functional and, although the “double high” cells have
greatly increased levels and activity of p53, they neither die nor proliferate slower as
a result of p53-dependentactivation of genes such as BAX and p21.
The first evidence that p53 is functional in the cell lines used in this project, was
provided in the Figure 3.18, where depletion of p53 using siRNA in the double high
cells resulted in markedly decreased expression of MDM2 which did not happen
when MDM2wasexpressedectopically from the CMV promoter (Figure 3.19). This
suggests that high levels of MDM2are promotedby high levels of p53 in cells which
spontaneously acquired high levels of both proteins.
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Additionally, the p53 functionality, as well as the ability of MDM2to regulate the
levels and activity of p53 was tested in the double high 1.27 and a parental 117 cell
line. The UV-induced DNA damageled to strong stabilization of p53 in 117 and,
even though further p53 stabilization did not occur in 1.27 cells, a significant
induction of MDM2could be seen in both cell lines (Figure 3.20). The inability of
1.27 cells to increase the p53 level upon DNA damage could be due to the presence
of already stabile p53. However, elevated expression of MDM2,and to a muchlesser
extent also BAX, suggests that p53 could be further activated by UV in the 1.27cell
line. Moreover, the steady-state level of p21 is much higher in 1.27 than in parental
117 cells (Figures 3.20 and 3.21) suggesting, that elevated levels of p53 increase
transactivation of the p21 gene. Interestingly, the Figure 3.20 shows that the p21
levels decrease in response to UV in 1.27 cells; this could be explained by general
suppression of gene expression caused by UV. However, downregulation of p21
could potentially act as an element of apoptotic response of the cells (or an attempt),
since it has been shown that downregulation or deletion of p21 markedly increases
apoptotic rate in various types of cells (Yu et al., 2003, Park et al., 2008). This can
further be supported by the fact, that no suppression of the p21 expression can be
seen in parental 117 cells suggesting that this change may be specific and not caused
by general suppression of gene expression after UV treatment.
It is unclear, to what extent is the p53-MDM2negative feedback loop functional in
RCCcells, but clearly MDM2does not promote efficient degradation of p53. It was
shownthat titration of a small compound which blocks binding of MDM2 to p53,
nutlin-3 (Vassilev et al., 2004), led to stabilization of p53 in 117 cells. No further
stabilization could be seen in 1.27 cells, perhaps (as suggested previously), because
p53 was already stabile in this cell line. This was accompanied by significant
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induction of MDM2and to a lesser extent also p21 in both 117 and 1.27 cell lines.
These results suggest that, even though the p53 levels are elevated in some RCCcells
(such as 1.27), p53 is still regulated by MDM2in these cells as a specific inhibition
of MDM2results in activation of p53 and leads to increased expression of p53-
downstream genes (Figure 3.21). These results clearly indicate that high levels of
MDM2are driven by elevated levels (and, perhapsalso) activity of p53 in RCCcells
given that the siRNA-mediated decrease of the level of p53 reduces both the MDM2
level and motility (which is a result of upregulation of MDM2). One could speculate
that in RCC cells which over-express wt p53 and MDM2,p53 acts as an oncogeneas
it neither induces apoptosis nor decreasesthe cell proliferation rate (Figure 3.22). On
the other hand, however, it drives overexpression of MDM2 whichis responsible for
increased motility and, perhaps, also other features contributing to poor outcome in
RCC patients. It could therefore be speculated, that anticancer therapies relying on
further activation of p53 (for instance commonly used chemotherapeutic drugs such
as cysplatin) in RCC tumours harbouring high levels of p53 and MDM2, could not
be effective as they would simultaneously result in further induction of MDM2(see
3.21) and, perhaps, contribute to even worse outcome. Therefore, further studies
addressing this issue are needed.
4.8 Future plans
As mentioned several times in this document, elevated levels of p53 and MDM2
increase tumour aggressiveness, for reasons which have not been explained to date.
Previously published evidence described in the introduction,is restricted to analysis
of the phenotype of the disease, based on clinical data. Results presented in this
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thesis strongly suggest a role of MDM2 in promoting an aggressive phenotype of
RCCcells. The study, however, raises several questions:
1. Is blocking of the motility suppressive effect of NME2 by MDM2increasing
aggressiveness of RCCcells in the real tumour?
2. Would it be the only way MDM2functions to promote poor outcome?
3. Whyare high levels of active p53 not mediating apoptosis orthe cell cycle arrest?
Is the ability of p53 to mediate apoptosis counterbalanced by high levels of
MDM2?
4. Would further activation of p53 accompanied by downregulation of MDM2be a
good therapeutic strategy to target RCC overexpressing p53 and MDM2?
There are no definitive answers to these questions. The points 1 and 2 will be
addressed in future studies using mouse xenograft experiments and further hunting
for MDM2interacting proteins. Questions 3 and 4 will also soon be investigated in
our lab. Since RCC cells accumulate high levels of active p53, then, why do high
levels of wild type and active p53 not induce apoptosis in RCC (it doesn’t also
appearto inducecell cycle arrest or senescence), like they would do in other types of
cancers? On one hand, it has been suggested that this could be due to a natural
propensity of renal cells to not respond by apoptosis to increased levels of p53
(MacCallum et al., 1996). The study has demonstrated that unlike other epithelia,
such as the gut lining, tubular epithelial cells do not apoptose in response to IR
despite increased levels of p53. However, this conclusion was drawn based on
studies of cells exposed to ionising radiation which induces the DNA damage
response (mice were treated with whole-body irradiation) which maynotreflect the
situation present in the tumour where the number of stresses that could potentially
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activate p53, may be both higher and of different kinds. Interestingly, others have
reported p53-dependent apoptosis of renal tubular epithelial cells (these cells give
rise to RCC) in response to stimuli other than IR (Li et al., 2007, Choiet al., 2001,
Kelly et al., 2003).
The results presented in this thesis suggest that blocking the MDM2 mediated
inhibition of p53 using nutlin-3 does not appear to effectively induce apoptosis (data
not shown), despite increased expression of p53 responsive genes. Perhapsthis is due
to the counterbalancing action of MDM2 which becomesvery strongly induced upon
nutlin-3 treatment (see Figure 3.21). Our unpublished (not presented here)
observations suggest that reduction of MDM2 protein levels using siRNA, decreases
the number of cells in culture. Therefore one could hypothesize that a therapeutic
agent decreasing the level of MDM2 (and therefore, potentially inhibiting also
survival or aggressiveness-promoting features of MDM2), applied together with
chemotherapy (p53-inducing genotoxic agents such as cisplatin), would be a good
way of targeting RCC overexpressing p53 and MDM2.
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5 Conclusions
High levels of p53 and MDM2 in RCC tumours correlate with increased
aggressiveness resulting in poor outcome in patients. The nature of the p53-MDM2
relationship was investigated and the mechanism leading to upregulation of MDM2,
and potentially also aggressiveness of RCC, was proposed based on the results
obtained in this study. It was shownhere that upregulated p53 is usually wt in RCC
and that this p53 drives expression of MDM2 which was subsequently shownto
inducecell motility in RCC cell lines. Since increased motility is a common feature
of metastatic cells, it can therefore be suggested that p53 acquires oncogenic
potential in this particular setting, as it indirectly increases motility and potentially
also metastatic expansivenessofthese cells.
The ultimate purpose of this study was to identify novel MDM2-binding proteins
whose normal function would be altered by high levels of MDM2resulting in an
aggressive phenotype of RCC cells. To accomplish this, the yeast two-hybrid screen
of the cDNAlibrary constructed from the RCCcell line overexpressing high levels
of p53 and MDM2, was performed. Several novel, putative MDM2interacting
proteins were identified. One of them, NME2, was thoroughly studied. It was
demonstrated, that NME2 reducesactivity of p53, leads to reduction of the MDM2
levels and influences the MDM2 mediated post-translational modifications of p53 in
transfection experiments. Moreover, high levels of MDM2 in RCCcell lines were
shown to oppose the NME2-mediated motility suppression, whereas NME2 wasable
to act as a motility suppressor in the RCCcell lines naturally expressing low levels of
MDM2orcell lines in which the high level of MDM2 wasreduced using siRNA.
These results suggest a possible mechanism of p53-promoted-MDM2-mediated
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action which, by opposing (or directly blocking) the NME2 mediated suppression of
motility (thus inducing cell motility), could potentially increase aggressiveness of
RCC cells. This issue will be addressed in future experiments using mouse xenograft
experiments in order to evaluate significance of this mechanism in tumour
progression.
Tumour progression and metastasis is a complex process which is not dependent
only on increased motility. Therefore, there is a need for identification of other
MDM2interacting proteins which could be involved in promoting other features of
aggressive RCC: resistance to therapies, formation of micro- and macrometastases
and could potentially constitute targets for drug design. It is also vital to investigate
the reason for which the levels of p53 are elevated in RCC and why do they not
trigger apoptosis.
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7 Appendices
7.1 Appendix 1. Sequenceanalysis of p53 in RCC tumour samples
 
 
 
 
  
Sample Mutation
1-1 Wt
1-2 Poor quality sequence
1-3 Wt
2-1 Wt
2-2 Wt
2-3 T633 deletion
3-1 Wt
3-2 Wt
3-3 C509Tsubstitution
4-] Wt
4-2 Wt
4-3 Wt
4-4 Wt
5-1 Wt
5-2 C785T mismatch
5-3 Wt
6-1 Wt
6-2 T853 deletion
6-3 G734Asubstitution
7-1 G733T substitution (G245C)
7-2 G733T substitution (G245C)
8-1 Wt
8-2 T852 deletion
8-3 Wt
9-] T635 deletion
9-2 T605 deletion
9-3 Wt  
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10-1 C406Gsubstitution (Q136E)
10-2 C406Gsubstitution (Q136E)
11-1 Wt
11-2 C916T substitution
11-3 G725Asubstitution
12-1 C530Tsubstitution
12-2 T821 deletion
12-3 G596Asubstitution
13-1 C497A substitution
13-2 Wt
13-3 G848A substitution
14-1 Wt
14-2 Wt
14-3 Wt
15-1 Wt
15-2 Wt
15-3 Wt   
Table 7.1 Sequencing results of red yeast colonies obtained in FASAY.Theleft
column shows a sample number (tumours 1-15 and two to four clones for each
tumour sample) and identified mutations of p53 are shown in the right column.
Mutations that were identified and confirmed by direct sequencing of at least two
independentclones are showninred.
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Tumour 7 |
 
 
 
    
Clone 1 3
G733Tnucleotide hESSEe
substitution
(G245C aminoacid
substitution) Ava
530Clone2 gerecatGaaccGs
Wild type NNN,
GULUGGLAIL_ GCAAGC LSE
Tumour10 f |
Clone 1
C406G nucleotide TITTSe Gas te ees
substitution
(Q136E aminoacid
substitution)
Clone2 = =
TYITTGOGAACTGGCE
Wild type 20
TTTTECCAACTGGCE
Figure 7.1 Mutations identified in tumour samples nr 7 and 10. The figure
presents chromatograms from direct sequencing (performed by Eurofins company) of
wt and mutated p53 from RCC tumour samples identified using FASAY.
206
Appendices
 
7.2 Appendix 2. Abstracts of manuscripts submitted for
publications that have arisen as a result of this study.
Manuscript 1
MDM2and NME2?interact and have opposing effects on cell motility
Maria Maguire}, Radostaw Polanski}, Paul Nield, *Rosalind Jenkins, *B. Kevin
Park, Karolina Krawezynska, Timothy Devling, Arpita Ray-Sinha, Nikolina
Vlatkovié and Mark T. Boyd
Division of Surgery and Oncology, University of Liverpool, L69 3GA, UK and
*Department of Pharmacology and Therapeutics, University of Liverpool, L69 3GE,
UK
*contributed equally to this study
Abstract
Up-regulation of MDM2, combined with high levels of p53, are associated with poor
overall survival in renal cell carcinoma. We therefore set out to identify MDM2
interacting proteins that could act as mediators of MDM2oncogeniceffects in renal
cells. Using affinity chromatography and MS/MSweidentified the non-metastatic
cells 2, protein; NME2, a nucleoside diphosphate kinase, as an MDM2interacting
protein in HEK293 cell extracts. NME2 wasalsoidentified in parallel studies using a
yeast two-hybrid screen for MDM2interacting proteins expressed in renal cancer
cells. The interaction is highly specific, as the closely related protein NME1 (87.5%
amino acid identity) does not interact with MDM2in yeast. Using measurements of
p53 transcriptional activity as surrogates for MDM2activity, we find that NME2
inhibits p53 activity in both normal and tumourcells. However, studies using Mdm2
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-/- MEFs demonstrate that this occurs independently of MDM2. It is also
independent of NME2 kinase activity. Specific NME proteins possess a well
documented ability to suppress cell motility and metastasis and we show that NME2
suppresses motility under conditions where normal physiological levels of MDM2
are expressed. However, when higher levels of MDM2 are present, NME2 can no
longer inhibit motility. This is not due to MDM2 promoting degradation of NME2
and is p53-independent. Our studies link MDM2 (andindirectly p53) with a key
suppressor of motility and metastasis and may provide a mechanism to explain the
association between MDM2expression and poorpatient survival.
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Manuscript 2
MDM2links poorsurvival and increased invasivenessin renalcell carcinoma
Radostaw Polanski’, Aidan P. Noon’, Ashraf Y. El-Fert’, Hazel E. Warburton’,
Timothy Devling’, Arpita Ray-Sinha’, Carlos P. Rubbi', Helen Kalirai”, Howida
Shawki*, Fiona Campbell”, Andy Dodson’, Richard M Eccles*, Bryony H. Lloyd’,
David R. Sibson?, Sarah Lake*, Sarah Coupland’, Keith Parsons”, Nikolina
Vlatkovié! and Mark T. Boyd’
From the 'p53/MDM2Research Group, ‘Clatterbridge Cancer Research Group and
the "Division of Pathology, School of Cancer Studies, University of Liverpool, L69
3GA, UK, and from the “Departments of Pathology, and “Urology, Royal Liverpool
University Hospital, Liverpool, L7 8XP, UK
Abstract
Purpose
Renal cell carcinomas (RCC) display an unusualpattern of co-upregulated p53 and
MDM2expression associated with disease progression and we find that the up-
regulated p53 in RCC is frequently wild-type and is responsible for the co-up-
regulation of MDM2. Wealso investigated the cellular mechanism by which
p53/MDM2 up-regulation promotes disease progression and propose a novel
consequence of MDM2expression in RCCcells in promoting increased motility and
invasiveness.
Patients and Methods
90 patients diagnosed with RCC were examined by IHC, with FASAY and genetic
analysis of p53 IHC positive cases. Motility and invasion assays were performed on
RCCcells with modulated p53/MDM2levels.
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Results
p53 mutations are rare amongst p53 positive RCCs. Up-regulation of wild-type p53
in RCC promotes MDM2up-regulation in vivo (P=0.000012) and in vitro (P=0.01).
Co-upregulation of p53 and MDM2identifies patients with significantly reduced
disease specific survival (DSS) by univariate (P=0.036) and Cox multiple regression
analysis (P=0.027, RR=3.20). p53 dependent MDM2 up-regulation in RCC cells
promotes increased motility and invasion.
Conclusions
p53/MDM2expression identifies RCC patients with reduced DSS and we show for
the first time that MDM2is critical regulator of probable determinants of this; cell
motility and invasion in cells. The capacity of MDM2to promote increased motility
is independent of both p53 and ofits intrinsic E3 ubiquitin ligase activity. Our
studies thus identify MDM2as an important subject for further investigation in RCC
whichlikely acts via protein-protein interactions which potentially constitute a novel
drug target.
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